

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	265.17	273.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-14.97	-14.97

STN INTERNATIONAL LOGOFF AT 13:41:38 ON 25 NOV 2003

AN 1994:528898 CAPLUS
 DN 121:128898
 TI Synthesis of [11C]dapoxetine.cntdot.HCl, a serotonin re-uptake inhibitor:
 Biodistribution in rat and preliminary PET imaging in the monkey
 AU Livni, E.; Satterlee, Winston; Robey, Roger L.; Alt, Charles A.; Van
 Meter, Elden E.; Babich, John W.; Wheeler, William J.; O'Bannon, Douglas
 D.; Thrall, James H.; et al.
 CS Harv. Med. Sch., Mass. Gen. Hosp., Boston, MA, 02114, USA
 SO Nuclear Medicine and Biology (1994), 21(4), 669-75
 CODEN: NMBIEO; ISSN: 0883-2897
 DT Journal
 LA English
 CC 8-9 (Radiation Biochemistry)
 Section cross-reference(s): 1
 AB [11C]Dapoxetine.cntdot.HCl, S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl]benzenemethanamine hydrochloride, a potent serotonin re-uptake inhibitor was prepd. from its mono-Me precursor, S-(+)-N-methyl-a-[2-(naphthalenyloxy)ethyl]benzene methanamine hydrochloride. Biodistribution was detd. in rats at 5, 30 and 60 min after injection and preliminary PET studies were performed in a Rhesus monkey. 11CH3I was bubbled into a soln. of S-(+)-N-methyl-.alpha.-[2-(naphthalenyloxy)ethyl]benzene methanamine hydrochloride (3.0 mg in DMSO) and the mixt. was heated at 110.degree.C for 8 min. [11C]Dapoxetine.cntdot.HCl was purified by HPLC on a C18 cartridge eluted with MeOH:phosphate buffer, pH 7.2(75:25) with a 10% yield (end of synthesis). The time required for the synthesis was 40 min from the end of bombardment. Radiochem. purity of the final product was >99% and specific activity was routinely >400 mCi/.mu.mol [EOS]. In the biodistribution studies the highest concn. (%ID/g) of dapoxetine.cntdot.HCl was detected in lung: 4.56 (5 min), 1.28 (30 min) and 0.67 (60 min). Brain accumulation was 0.76 (5 min), 0.46 (30 min) and 0.27 (60 min). Preliminary PET studies demonstrated significant displaceable binding in the cerebral cortex and subcortical gray matter. These results demonstrate that [11C]dapoxetine.cntdot.HCl can be prepd. in high purity and may be useful for the in vivo evaluation of serotonin re-uptake mechanisms.
 ST carbon 11 dapoxetine brain PET
 IT Brain, metabolism
 (dapoxetine metab. by, PET of, using carbon-11-dapoxetine)
 IT Tomography
 (positron-emission, of dapoxetine metab. in brain, using carbgon-11-dapoxetine)
 IT 157166-72-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and biodistribution of and PET with, of dapoxetine metab. in brain)
 IT 156453-53-1P 157166-71-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and conversion to dapoxetine)
 IT **119356-77-3P**, Dapoxetine
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (prepn. and metab. of, PET of, with carbon-11-dapoxetine)

=>

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 10 SEP 22 DIPPR file reloaded
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded
NEWS 12 SEP 29 DISSABS now available on STN
NEWS 13 OCT 10 PCTFULL: Two new display fields added
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16 NOV 24 MSDS-CCOHS file reloaded

NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:20:03 ON 25 NOV 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:20:14 ON 25 NOV 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 NOV 2003 HIGHEST RN 620531-14-8
DICTIONARY FILE UPDATES: 24 NOV 2003 HIGHEST RN 620531-14-8

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e dapoxetine

E1	2	DAPOTUM/BI
E2	5	DAPOX/BI
E3	2 -->	DAPOXETINE/BI
E4	4	DAPOXYL/BI
E5	1	DAPP/BI
E6	4	DAPP1/BI
E7	1	DAPPB/BI
E8	3	DAPPER/BI
E9	2	DAPPER1/BI
E10	2	DAPPER2/BI
E11	1	DAPPI/BI
E12	1	DAPPLE/BI


=> s e3

L1 2 DAPOXETINE/BI

=> d l1 1-2

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2003 ACS on STN
RN 129938-20-1 REGISTRY
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
hydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
hydrochloride, (S)-
OTHER NAMES:
CN **Dapoxetine hydrochloride**
CN LY 210448 hydrochloride
FS STEREOSEARCH
MF C21 H23 N O . Cl H
SR US Adopted Names Council
LC STN Files: CA, CAPLUS, IPA, SYNTHLINE, USAN, USPATFULL
Other Sources: WHO
CRN (119356-77-3)

Absolute stereochemistry.




● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS on STN
RN 119356-77-3 REGISTRY
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
(.alpha.S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
(S)-
OTHER NAMES:
CN **Dapoxetine**
CN LY 210448
FS STEREOSEARCH
MF C21 H23 N O
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB,
CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, PHAR, PROMT,
RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST

ENTRY SESSION
7.98 8.19

FILE 'CAPLUS' ENTERED AT 12:21:05 ON 25 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Nov 2003 VOL 139 ISS 22
FILE LAST UPDATED: 24 Nov 2003 (20031124/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11

L2 14 L1

=> d 12 1-14

L2 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:494560 CAPLUS
DN 137:226186
TI Studies on the three dimensional quantitative structure-activity relationship of serotonin reuptake inhibitors
AU Shi, Yu; Wang, Xiao-fang; Yang, Guang-zhong
CS Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, 100050, Peop. Rep. China
SO Jisuanji Yu Yingyong Huaxue (2002), 19(1/2), 35-40
 CODEN: JYYHE6; ISSN: 1001-4160
PB Jisuanji Yu Yingyong Huaxue Bianjibu
DT Journal
LA Chinese

L2 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:241329 CAPLUS
DN 136:284433
TI Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
IN Wilson, Leland F.; Doherty, Paul C.; Place, Virgil A.; Smith, William L.; Abdel-Hamid, Abdou Ali Ibrahim Aboubakr
PA USA
SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 467,094.
 CODEN: USXXCO
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2002037828	A1	20020328	US 2001-888250	20010621
	US 6403597	B2	20020611		

US 6037346 A 20000314 US 1998-181070 19981027
 US 6548490 B1 20030415 US 1999-467094 19991210
 WO 2003000343 A2 20030103 WO 2002-US9415 20020325

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 1997-958816 B2 19971028
 US 1998-181070 A2 19981027
 US 1999-467094 A2 19991210
 US 2001-888250 A 20010621

L2 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:90620 CAPLUS
 DN 136:112659
 TI Methods of inhibiting platelet activation with selective serotonin
 reuptake inhibitors and treatment of cardiovascular disease
 IN Serebruany, Victor L.; Gurbel, Paul A.; O'Connor, Christopher M.
 PA Heartdrug Research, LLC, USA
 SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. 6,245,782.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002013343	A1	20020131	US 2001-804689	20010312
	US 6552014	B2	20030422		
	US 6245782	B1	20010612	US 1999-312987	19990517
	ZA 2001009994	A	20020826	ZA 2001-9994	20011205
PRAI	US 1999-312987	A2	19990517		

L2 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:434867 CAPLUS
 DN 135:29158
 TI The combination of a serotonin reuptake inhibitor and irindalone for the
 treatment of depression and other affective disorders
 IN Bogeso, Klaus Peter; Cremers, Thomas Ivo Franciscus Hubert
 PA H. Lundbeck A/S, Den.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041766	A1	20010614	WO 2000-DK667	20001204
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 2002103249 A1 20020801 US 2000-731411 20001206
PRAI US 1999-169245P P 19991206
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:434808 CAPLUS
DN 135:41033
TI The combination of a serotonin reuptake inhibitor and a 5-HT_{2C} antagonist,
inverse agonist or partial agonist
IN Cremers, Thomas Ivo Franciscus Hubert; Wikstroem, Hakan Wilhelm; Den Boer,
Johan Antonie; Bosker, Fokko Jan; Westerink, Bernard Hendrik Cornelis;
Bogeso, Klaus Peter; Hogg, Sandra; Mork, Arne
PA H. Lundbeck A/s, Den.
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041701	A2	20010614	WO 2000-DK671	20001206
	WO 2001041701	A3	20011213		
	W:	AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001018511	A5	20010618	AU 2001-18511	20001206
	US 2002103249	A1	20020801	US 2000-731411	20001206
	EP 1237553	A2	20020911	EP 2000-981174	20001206
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	BR 2000016385	A	20030218	BR 2000-16385	20001206
	JP 2003516326	T2	20030513	JP 2001-542871	20001206
	NO 2002002657	A	20020726	NO 2002-2657	20020605
	US 2003032636	A1	20030213	US 2002-165196	20020606
	BG 106895	A	20030430	BG 2002-106895	20020702
PRAI	US 1999-169245P	P	19991206		
	WO 2000-DK671	W	20001206		

L2 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:185565 CAPLUS
DN 134:217211
TI Methods of using rapid-onset selective serotonin reuptake inhibitors for
treating sexual dysfunction
IN Thor, Karl Bruce
PA Eli Lilly and Co., USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017521	A1	20010315	WO 2000-US20788	20000822
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,			

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 BR 2000014166 A 20020514 BR 2000-14166 20000822
 EP 1225881 A1 20020731 EP 2000-957264 20000822
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 EE 200200107 A 20030415 EE 2002-107 20000822
 NZ 517038 A 20030429 NZ 2000-517038 20000822
 AU 762934 B2 20030710 AU 2000-68911 20000822
 JP 2001089394 A2 20010403 JP 2000-259000 20000829
 JP 3194734 B2 20010806
 BG 106461 A 20021229 BG 2002-106461 20020228
 NO 2002001035 A 20020502 NO 2002-1035 20020301
 PRAI US 1999-152435P P 19990903
 WO 2000-US20788 W 20000822
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:98327 CAPLUS
 DN 132:146650
 TI Treating depression with a combination of a serotonin uptake inhibitor, a
 5-HT1A presynaptic antagonist, and a 5-HT1A agonist
 IN Depoortere, Henri
 PA Sanofi-Synthelabo, Fr.
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006160	A1	20000210	WO 1999-FR1825	19990726
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2781671	A1	20000204	FR 1998-9603	19980728
	AU 9949167	A1	20000221	AU 1999-49167	19990726
PRAI	FR 1998-9603	A	19980728		
	WO 1999-FR1825	W	19990726		
RE.CNT	11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L2 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:733398 CAPLUS
 DN 123:102797
 TI Treatment of tobacco withdrawal symptoms
 IN Johnson, Kristine Hagen
 PA Lilly, Eli, and Co., USA
 SO S. African, 60 pp.

CODEN: JCBADL; ISSN: 0378-4347

DT Journal
LA English

L2 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:255284 CAPLUS
DN 116:255284

TI A chiral synthesis of dapoxetine hydrochloride, a serotonin reuptake inhibitor, and its 14C isotopomer

AU Wheeler, William J.; O'Bannon, Douglas D.

CS Lilly Corp. Cent., Eli Lilly and Co., Indianapolis, IN, 46285, USA

SO Journal of Labelled Compounds and Radiopharmaceuticals (1992), 31(4), 305-15

CODEN: JLCRD4; ISSN: 0362-4803

DT Journal
LA English

OS CASREACT 116:255284

L2 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:114467 CAPLUS
DN 110:114467

TI Preparation of 1-phenyl-3-(naphthalenyloxy)propanamines as serotonin inhibitors

IN Robertson, David Wayne; Thompson, Dennis Charles; Wong, David Taiwai

PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 38 pp.

CODEN: EPXXDW

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	----	-----	-----
PI	EP 288188	A1	19881026	EP 1988-303177	19880408
	EP 288188	B1	19911016		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 85988	A1	19920818	IL 1988-85988	19880406
	CA 1329937	A1	19940531	CA 1988-563374	19880406
	AU 8814335	A1	19881013	AU 1988-14335	19880407
	AU 602971	B2	19901101		
	JP 63258837	A2	19881026	JP 1988-88025	19880407
	JP 06037443	B4	19940518		
	DK 8801882	A	19890112	DK 1988-1882	19880407
	DK 170637	B1	19951120		
	ZA 8802418	A	19891227	ZA 1988-2418	19880407
	CN 88102018	A	19881026	CN 1988-102018	19880408
	CN 1020093	B	19930317		
	HU 50316	A2	19900129	HU 1988-1790	19880408
	HU 204767	B	19920228		
	SU 1568886	A3	19900530	SU 1988-4355511	19880408
	AT 68473	E	19911115	AT 1988-303177	19880408
	ES 2045109	T3	19940116	ES 1988-303177	19880408
	US 5135947	A	19920804	US 1990-561492	19900801
PRAI	US 1987-36534		19870409		
	EP 1988-303177		19880408		
	US 1988-191465		19880509		
	US 1989-372149		19890626		
OS	MARPAT 110:114467				

=> s selective serotonin reuptake inhibitor
342211 SELECTIVE
143 SEROTININ

6406 REUPTAKE
427374 INHIBITOR
L3 0 SELECTIVE SEROTININ REUPTAKE INHIBITOR
(SELECTIVE(W) SEROTININ(W) REUPTAKE(W) INHIBITOR)

=> s selective serotonin reuptake inhibitor
342211 SELECTIVE
62015 SEROTONIN
6406 REUPTAKE
427374 INHIBITOR
L4 697 SELECTIVE SEROTONIN REUPTAKE INHIBITOR
(SELECTIVE(W) SEROTONIN(W) REUPTAKE(W) INHIBITOR)

=> e ejaculation
E1 53 EJACULATING/BI
E2 1 EJACULATIO/BI
E3 1387 --> EJACULATION/BI
E4 236 EJACULATIONS/BI
E5 1 EJACULATON/BI
E6 3 EJACULATOR/BI
E7 1 EJACULATORII/BI
E8 13 EJACULATORIUS/BI
E9 5 EJACULATORS/BI
E10 507 EJACULATORY/BI
E11 1 EJACULATUS/BI
E12 1 EJACULTE/BI

=> s e1-e10
53 EJACULATING/BI
1 EJACULATIO/BI
1387 EJACULATION/BI
236 EJACULATIONS/BI
1 EJACULATON/BI
3 EJACULATOR/BI
1 EJACULATORII/BI
13 EJACULATORIUS/BI
5 EJACULATORS/BI
507 EJACULATORY/BI
L5 1881 (EJACULATING/BI OR EJACULATIO/BI OR EJACULATION/BI OR EJACULATIO
NS/BI OR EJACULATON/BI OR EJACULATOR/BI OR EJACULATORII/BI OR
EJACULATORIUS/BI OR EJACULATORS/BI OR EJACULATORY/BI)

=> s 14 and 15
L6 18 L4 AND L5

=> d 16 1-18

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:769978 CAPLUS
TI Antidepressants and **Ejaculation**: A Double-Blind, Randomized,
Fixed-Dose Study With Mirtazapine and Paroxetine
AU Waldinger, Marcel D.; Zwinderman, Aeilko H.; Olivier, Berend
CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, The Hague,
Neth.
SO Journal of Clinical Psychopharmacology (2003), 23(5), 467-470
CODEN: JCPYDR; ISSN: 0271-0749
PB Lippincott Williams & Wilkins
DT Journal
LA English

L6 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:569775 CAPLUS

DN 139:224310
 TI High-dose sildenafil citrate for **selective serotonin reuptake inhibitor**-associated **ejaculatory** delay: open clinical trial
 AU Seidman, Stuart N.; Pesce, Vanessa C.; Roose, Steven P.
 CS Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA
 SO Journal of Clinical Psychiatry (2003), 64(6), 721-725
 CODEN: JCLPDE; ISSN: 0160-6689
 PB Physicians Postgraduate Press, Inc.
 DT Journal
 LA English
 RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:245616 CAPLUS
 DN 138:379122
 TI Serum leptin levels in patients with premature **ejaculation** before and after citalopram treatment
 AU Atmaca, M.; Kuloglu, M.; Tezcan, E.; Ustundag, B.; Semercioz, A.
 CS Department of Psychiatry, Firat University, School of Medicine, Elazig, Turk.
 SO BJU International (2003), 91(3), 252-254
 CODEN: BJINFO; ISSN: 1464-4096
 PB Blackwell Publishing Ltd.
 DT Journal
 LA English
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:777890 CAPLUS
 DN 137:294879
 TI Preparation of cyclopropylindoles as selective serotonin reuptake inhibitors
 IN Mattson, Ronald; Denhart, Derek; Deskus, Jeffrey; Ditta, Jonathan; Marcin, Lawrence; Epperson, James; Catt, John; King, Dalton; Higgins, Mendi
 PA Bristol-Myers Squibb Company, USA
 SO PCT Int. Appl., 161 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002079152	A1	20021010	WO 2002-US6627	20020305
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003073849	A1	20030417	US 2002-91232	20020305
PRAI	US 2001-279888P	P	20010329		
	US 2001-293122P	P	20010523		
	US 2001-327804P	P	20011009		
OS	MARPAT 137:294879				

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:184345 CAPLUS
DN 137:210798
TI Chronic oral administration of clomipramine decreases sexual behavior in
the male Syrian hamster (Mesocricetus auratus)
AU Boscarino, Brent T.; Parfitt, David B.
CS Department of Biology and Neuroscience Program, Middlebury College,
Middlebury, VT, 05753, USA
SO Physiology & Behavior (2002), 75(3), 361-366
CODEN: PHBHA4; ISSN: 0031-9384
PB Elsevier Science Inc.
DT Journal
LA English

L6 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:51254 CAPLUS
DN 136:107530
TI Combinations of serotonin reuptake inhibitor and estrogenic agents
IN Jenkins, Simon Nicholas
PA American Home Products Corporation, USA
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 2002003975	A2	20020117	WO 2001-US20738	20010629
	WO 2002003975	A3	20020926		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6369051	B1	20020409	US 2001-896361	20010629
	US 2002042432	A1	20020411		
	EP 1311293	A2	20030521	EP 2001-952310	20010629
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-216408P	P	20000706		
	WO 2001-US20738	W	20010629		
OS	MARPAT 136:107530				

L6 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:185565 CAPLUS
DN 134:217211
TI Methods of using rapid-onset selective serotonin reuptake inhibitors for
treating sexual dysfunction
IN Thor, Karl Bruce
PA Eli Lilly and Co., USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017521	A1	20010315	WO 2000-US20788	20000822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000014166	A	20020514	BR 2000-14166	20000822
	EP 1225881	A1	20020731	EP 2000-957264	20000822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	EE 200200107	A	20030415	EE 2002-107	20000822
	NZ 517038	A	20030429	NZ 2000-517038	20000822
	AU 762934	B2	20030710	AU 2000-68911	20000822
	JP 2001089394	A2	20010403	JP 2000-259000	20000829
	JP 3194734	B2	20010806		
	BG 106461	A	20021229	BG 2002-106461	20020228
	NO 2002001035	A	20020502	NO 2002-1035	20020301
PRAI	US 1999-152435P	P	19990903		
	WO 2000-US20788	W	20000822		
RE.CNT	8	THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L6 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:623767 CAPLUS
 DN 132:117578
 TI Hormone-neurotransmitter interactions in the control of sexual behavior
 AU Hull, E. M.; Lorrain, D. S.; Du, J.; Matuszewich, L.; Lumley, L. A.;
 Putnam, S. K.; Moses, J.
 CS Department of Psychology, State University of New York at Buffalo,
 Buffalo, NY, USA
 SO Behavioural Brain Research (1999), 105(1), 105-116
 CODEN: BBREDI; ISSN: 0166-4328
 PB Elsevier Science Ireland Ltd.
 DT Journal; General Review
 LA English
 RE.CNT 113 THERE ARE 113 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:362458 CAPLUS
 DN 131:13920
 TI Effect of buspirone on sexual dysfunction in depressed patients treated
 with selective serotonin reuptake inhibitors
 AU Landen, Mikael; Eriksson, Elias; Agren, Hans; Fahlen, Tom
 CS Institute of Clinical Neuroscience, Departments of Psychiatry and
 Neurochemistry, Goteborg University, Goteborg, Swed.
 SO Journal of Clinical Psychopharmacology (1999), 19(3), 268-271
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:62618 CAPLUS

DN 130:262483
TI Facilitation and inhibition of male rat **ejaculatory** behavior by
the respective 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and
anpirtoline, as evidenced by use of the corresponding new and selective
receptor antagonists NAD-299 and NAS-181
AU Hillegaart, Viveka; Ahlenius, Sven
CS Department of Pharmacology, Astra Arcus AB, Soedertaelje, SE-151 85, Swed.
SO British Journal of Pharmacology (1998), 125(8), 1733-1743
CODEN: BJPCBM; ISSN: 0007-1188
PB Stockton Press
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:45466 CAPLUS
DN 130:306414
TI A comparison of the effects of different serotonin reuptake blockers on
sexual behavior of the male rat
AU Mos, Jan; Mollet, Ian; Tolboom, Jeroen T. B. M.; Waldinger, Marcel D.;
Olivier, Berend
CS Solvay Pharmaceuticals, Department of Pharmacology, Weesp, 1380 DA, Neth.
SO European Neuropsychopharmacology (1999), 9(1-2), 123-135
CODEN: EURNE8; ISSN: 0924-977X
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:419621 CAPLUS
DN 129:156848
TI An open-label pilot study of fluvoxamine for mixed anxiety-depression
AU Houck, Carl
CS Department of Psychiatry and Behavioral Neurobiology, University of
Alabama at Birmingham, Birmingham, AL, 35205, USA
SO Psychopharmacology Bulletin (1998), 34(2), 225-227
CODEN: PSYBB9; ISSN: 0048-5764
PB National Institute of Mental Health
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:349246 CAPLUS
DN 129:90380
TI The **selective serotonin reuptake**
inhibitor fluoxetine reduces sexual motivation in male rats
AU Matuszcyk, Josefa Vega; Larsson, Knut; Eriksson, Elias
CS Department of Psychology, University of Goteborg, Goteborg, S-413 14,
Swed.
SO Pharmacology, Biochemistry and Behavior (1998), 60(2), 527-532
CODEN: PBBHAU; ISSN: 0091-3057
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:751744 CAPLUS
 DN 128:57654
 TI Extracellular serotonin in the lateral hypothalamic area is increased during the postejaculatory interval and impairs copulation in male rats
 AU Lorrain, Daniel S.; Matuszewich, Leslie; Friedman, Ross D.; Hull, Elaine M.
 CS Department of Psychology, State University of New York at Buffalo, Buffalo, NY, 14260, USA
 SO Journal of Neuroscience (1997), 17(23), 9361-9366
 CODEN: JNRSDS; ISSN: 0270-6474
 PB Society for Neuroscience
 DT Journal
 LA English
 RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:702829 CAPLUS
 DN 127:341724
 TI Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients
 AU Claghorn, James L.; Earl, Craig Q.; Walczak, Donna D.; Stoner, Kim A.; Wong, Lung Fai; Kanter, Donald; Houser, Vincent P.
 CS Clin. Res. Assocs., Houston, TX, USA
 SO Journal of Clinical Psychopharmacology (1996), 16(2), 113-120
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Williams & Wilkins
 DT Journal
 LA English

L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:702827 CAPLUS
 DN 128:10222
 TI An open clinical trial of fluoxetine in the treatment of premature **ejaculation**
 AU Lee, Hong Shick; Song, Dong Ho; Kim, Chan-Hyung; Choi, Hyoung Kee
 CS Department Psychiatry, College Medicine, Yonsei University, Seoul, S. Korea
 SO Journal of Clinical Psychopharmacology (1996), 16(5), 379-382
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:634304 CAPLUS
 DN 127:287476
 TI A critical review of **selective serotonin reuptake inhibitor**-related sexual dysfunction; incidence, possible etiology and implications for management
 AU Lane, R. M.
 CS Pfizer Inc., New York, NY, 10017, USA
 SO Journal of Psychopharmacology (London) (1997), 11(1), 72-82
 CODEN: JOPSEQ; ISSN: 0269-8811
 PB SAGE Publications
 DT Journal; General Review
 LA English

L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:79863 CAPLUS
 DN 126:180636
 TI Tolerability and safety of citalopram
 AU Baldwin, David; Johnson, F. Neil
 CS Royal South Hants Hospital, University Department of Psychiatry,
 Southampton, SO14 0YG, UK
 SO Reviews in Contemporary Pharmacotherapy (1995), 6(6), 315-325
 CODEN: RCPHFW; ISSN: 0954-8602
 PB Marius Press
 DT Journal; General Review
 LA English

=> d 16 9 all

L6 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:362458 CAPLUS
 DN 131:13920
 TI Effect of buspirone on sexual dysfunction in depressed patients treated
 with selective serotonin reuptake inhibitors
 AU Landen, Mikael; Eriksson, Elias; Agren, Hans; Fahlen, Tom
 CS Institute of Clinical Neuroscience, Departments of Psychiatry and
 Neurochemistry, Goteborg University, Goteborg, Swed.
 SO Journal of Clinical Psychopharmacology (1999), 19(3), 268-271
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB To evaluate the possible influence of buspirone on sexual dysfunction in
 depressed patients treated with a **selective serotonin
 reuptake inhibitor** (SSRI; citalopram or paroxetine),
 data were analyzed from a placebo-controlled trial designed to explore the
 efficacy of buspirone as add-on treatment for patients not responding to
 an SSRI alone. All the patients met the criteria for a major depressive
 episode according to DSM-IV and had received citalopram or paroxetine
 during a min. of 4 wk without responding to the treatment. Buspirone
 (20-60 mg/day) or placebo was added to the SSRI for 4 wk; the mean daily
 dose of buspirone at endpoint was 48.5 mg/day. Before starting medication
 with buspirone or placebo, 40% (47 of 117 patients) reported at least one
 kind of sexual dysfunction (decreased libido, **ejaculatory**
 dysfunction, orgasmic dysfunction). During the 4 wk of treatment, approx.
 58% of the subjects treated with buspirone reported an improvement with
 respect to sexual function; in the placebo group, the response rate was
 30%. The difference between placebo and active drug treatment was more
 pronounced in women than in men. The response was obvious during the 1st
 week, with no further improvement during the course of the study. It is
 suggested that the effect of buspirone on sexual dysfunction is a result
 of a reversal of SSRI-induced sexual side effects rather than of an
 antidepressant effect of the drug.
 ST buspirone serotonin reuptake inhibitor sex dysfunction; antidepressant sex
 dysfunction buspirone; citalopram paroxetine depression sex dysfunction
 buspirone
 IT Antidepressants
 (buspirone effect on sexual dysfunction in depressed humans treated
 with selective serotonin reuptake inhibitors)
 IT Mental disorder
 (depression; buspirone effect on sexual dysfunction in depressed humans
 treated with selective serotonin reuptake inhibitors)
 IT Sexual behavior
 (disorder; buspirone effect on sexual dysfunction in depressed humans
 treated with selective serotonin reuptake inhibitors)

IT 59729-33-8, Citalopram 61869-08-7
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (buspirone effect on sexual dysfunction in depressed humans treated with selective serotonin reuptake inhibitors)

IT 36505-84-7, Buspirone
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (buspirone effect on sexual dysfunction in depressed humans treated with selective serotonin reuptake inhibitors)

IT 50-67-9, Serotonin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (reuptake inhibitors; buspirone effect on sexual dysfunction in depressed humans treated with selective serotonin reuptake inhibitors)

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ahlenius, S; Pharmacol Biochem Behav 1989, V33, P691 CAPLUS
- (2) Aizenberg, D; Clin Neuropharmacol 1997, V20, P210 CAPLUS
- (3) Balogh, S; J Clin Psychiatry 1992, V53, P212 MEDLINE
- (4) Balon, R; JAMA 1995, V273, P1489 MEDLINE
- (5) Bartlik, B; J Sex Marital Ther 1995, V21, P264 MEDLINE
- (6) Blier, P; Neuropharmacology 1991, V30, P692
- (7) Eison, A; Am J Med 1986, V80, P1 CAPLUS
- (8) Elmore, J; Pharmacotherapy 1997, V17, P612 MEDLINE
- (9) Eriksson, E; Neuropsychopharmacology 1995, V12, P167 MEDLINE
- (10) Feiger, A; J Clin Psychiatry 1996, V57(suppl 2), P53
- (11) Guy, W; ECDEU assessment manual for psychopharmacology 1976, P534
- (12) Herman, J; J Clin Psychiatry 1990, V51, P25 MEDLINE
- (13) Hollander, E; J Clin Psychiatry 1992, V53, P207 MEDLINE
- (14) Jacobsen, F; J Clin Psychiatry 1992, V53, P119 MEDLINE
- (15) Kara, H; J Urol 1996, V156, P1631 CAPLUS
- (16) Landen, M; J Clin Psychiatry 1998, V59, P664 CAPLUS
- (17) Lingjaerde, O; Acta Psychiatr Scand Suppl 1987, V334, P1 MEDLINE
- (18) Modell, J; Clin Pharmacol Ther 1997, V61, P476 CAPLUS
- (19) Monteiro, W; Br J Psychiatry 1987, V151, P107 MEDLINE
- (20) Norden, M; Depression 1994, V2, P109
- (21) Othmer, E; J Clin Psychiatry 1987, V48, P201 MEDLINE
- (22) Segraves, R; American Psychiatric Press review of psychiatry 1995, V14, P697
- (23) Shen, W; Int J Psychiatry Med 1995, V25, P239 MEDLINE
- (24) Stein, D; CNS Drugs 1994, V2, P78
- (25) Sundblad, C; Eur Neuropsychopharmacol 1997, V7, P201 CAPLUS
- (26) Tallentire, D; Br J Pharmacol 1996, V118, P63 CAPLUS
- (27) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (28) Zajecka, J; J Clin Psychiatry 1991, V52, P66 MEDLINE

=> d 16 10 all

L6 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:62618 CAPLUS
 DN 130:262483
 TI Facilitation and inhibition of male rat **ejaculatory** behavior by the respective 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline, as evidenced by use of the corresponding new and selective receptor antagonists NAD-299 and NAS-181
 AU Hillegaart, Viveka; Ahlenius, Sven
 CS Department of Pharmacology, Astra Arcus AB, Soedertaelje, SE-151 85, Swed.
 SO British Journal of Pharmacology (1998), 125(8), 1733-1743
 CODEN: BJPCBM; ISSN: 0007-1188

PB Stockton Press
DT Journal
LA English
CC 2-8 (Mammalian Hormones)
Section cross-reference(s): 1
AB **Ejaculatory** problems and anorgasmia are well-known side-effects of the SSRI (**selective serotonin reuptake inhibitor**) antidepressants, and a pharmacol. induced increase in serotonergic neurotransmission inhibits **ejaculatory** behavior in the rat. In the present study the role of 5-HT1A and 5-HT1B receptors in the mediation of male rat **ejaculatory** behavior was examd. by use of selective agonists and antagonists acting at these 5-HT receptor subtypes. The 5-HT1A receptor agonist 8-OH-DPAT (0.25-4.00 .mu.mol kg-1 s.c.) produced an expected facilitation of the male rat **ejaculatory** behavior, and this effect was fully antagonized by pretreatment with the new selective 5-HT1A receptor antagonist (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R) tartrate monohydrate (NAD-299) (1.0 .mu.mol kg-1 s.c.). NAD-299 by itself (0.75-3.00 .mu.mol kg-1 s.c.) did not affect the male rat **ejaculatory** behavior. The 5-HT1B receptor agonist anpirtoline (0.25-4.00 .mu.mol kg-1 s.c.) produced a dose-dependent inhibition of the male rat **ejaculatory** behavior, and this effect was fully antagonized by pretreatment with the 5-HT1B receptor antagonist isamoltane (16 .mu.mol kg-1 s.c.) as well as by the new and selective antagonist (R)-(+)-2-(3-morpholinomethyl-2H-chromene-8-yl)oxymethylmorpholino methanesulfonate (NAS-181) (16 .mu.mol kg-1 s.c.). Isamoltane (1.0-16.0 .mu.mol kg-1 s.c.) and NAS-181 (1.0-16.0 .mu.mol kg-1 s.c.) had no, or weakly facilitatory effects on the male rat **ejaculatory** behavior. The non-selective 5-HT1 receptor antagonist (-)-pindolol (8 .mu.mol kg-1 s.c.), did not antagonize the inhibition produced by anpirtoline. The present results demonstrate opposite effects, facilitation and inhibition, of male rat **ejaculatory** behavior by stimulation of 5-HT1A and 5-HT1B receptors, resp., suggesting that the SSRI-induced inhibition of male **ejaculatory** dysfunction is due to 5-HT1B receptor stimulation.

ST **ejaculatory** behavior serotonergic receptor agonist antagonist
IT 5-HT agonists
(5-HT1; facilitation and inhibition of male rat **ejaculatory** behavior by 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline as evidenced by use of receptor antagonists NAD-299 and NAS-181)

IT 5-HT receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-HT1A; facilitation and inhibition of male rat **ejaculatory** behavior by 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline as evidenced by use of receptor antagonists NAD-299 and NAS-181)

IT 5-HT receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-HT1B; facilitation and inhibition of male rat **ejaculatory** behavior by 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline as evidenced by use of receptor antagonists NAD-299 and NAS-181)

IT Sexual behavior
(**ejaculation**; facilitation and inhibition of male rat **ejaculatory** behavior by 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline as evidenced by use of receptor antagonists NAD-299 and NAS-181)

IT 5-HT antagonists
(facilitation and inhibition of male rat **ejaculatory** behavior

by 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline as evidenced by use of receptor antagonists NAD-299 and NAS-181)

IT 26328-11-0, (-)-Pindolol 55050-95-8, Isamoltane 78950-78-4, 8-OH-DPAT 98330-05-3, Anpirtoline 205242-62-2, NAS 181 208516-87-4, NAD-299

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(facilitation and inhibition of male rat **ejaculatory** behavior by 5-HT1A and 5-HT1B receptor agonists 8-OH-DPAT and anpirtoline as evidenced by use of receptor antagonists NAD-299 and NAS-181)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aghajanian, G; Psychopharmacology:The Fourth Generation of Progress 1995, P451
- (2) Ahlenius, S; 5-HT1A Agonists, 5-HT3 Antagonists and Benzodiazepines:Their Comparative Behavioural Pharmacology 1991, P281 CAPLUS
- (3) Ahlenius, S; Eur Neuropsychopharmacol 1999, V9, P000 CAPLUS
- (4) Ahlenius, S; J Neural Transm 1988, V77, P163
- (5) Ahlenius, S; Pharmacol Biochem Behav 1991, V38, P201 CAPLUS
- (6) Ahlenius, S; Psychopharmacol 1980, V68, P217 CAPLUS
- (7) Ahlenius, S; Psychopharmacol 1998, V137, P374 CAPLUS
- (8) Arvidsson, L; J Med Chem 1981, V24, P921 CAPLUS
- (9) Barnes, T; Sexual Pharmacology 1993, P176
- (10) Berendsen, H; Eur J Pharmacol 1987, V135, P279 CAPLUS
- (11) Berendsen, H; Psychopharmacol 1990, V101, P57 CAPLUS
- (12) Berg, S; J Med Chem 1998, V41, P1934 CAPLUS
- (13) Bos, M; J Med Chem 1997, V40, P2762 MEDLINE
- (14) Engel, J; Drugs Future 1989, V14, P614
- (15) Fernandez-Guasti, A; Eur J Pharmacol 1992, V210, P121 CAPLUS
- (16) Fernandez-Guasti, A; Pharmacol Biochem Behav 1992, V42, P529 CAPLUS
- (17) Finberg, J; Br J Pharmacol 1990, V101, P698 CAPLUS
- (18) Hillegaart, V; Behav Brain Res 1989, V33, P279 CAPLUS
- (19) Hillegaart, V; Behav Brain Res 1991, V42, P169 CAPLUS
- (20) Hillegaart, V; Eur J Pharmacol 1996, V295, P155 CAPLUS
- (21) Hillegaart, V; J Neural Transm [GenSect] 1990, V81, P131 CAPLUS
- (22) Hjorth, S; J Neural Transm 1982, V55, P169 CAPLUS
- (23) Hoyer, D; Pharmacol Rev 1994, V46, P157 CAPLUS
- (24) Hutson, P; Neurosci Lett 1989, V100, P276 CAPLUS
- (25) Johansson, C; Eur J Pharmacol 1991, V202, P81 CAPLUS
- (26) Johansson, L; J Pharmacol Exp Ther 1997, V283, P216 CAPLUS
- (27) Klint, T; Eur J Pharmacol 1992, V212, P241 CAPLUS
- (28) Li, C; Introduction to Experimental Statistics 1964
- (29) Lucas, J; Trends Pharmacol Sci 1995, V16, P246 CAPLUS
- (30) Malmnas, C; Acta Physiol Scand 1973, VS395, P69
- (31) Mathes, C; Pharmacol Biochem Behav 1990, V36, P63 CAPLUS
- (32) Millan, M; Eur J Pharmacol 1997, V321, PR11 CAPLUS
- (33) Modell, J; Clin Pharmacol Ther 1997, V61, P476 CAPLUS
- (34) O'Neill, M; Psychopharmacol 1997, V132, P255 CAPLUS
- (35) Renyi, L; Naunyn-Schmiedeberg's Arch Pharmacol 1991, V343, P1 CAPLUS
- (36) Schlicker, E; Br J Pharmacol 1992, V105, P732 CAPLUS
- (37) Sharp, T; Br J Pharmacol 1989, V96, P283 CAPLUS
- (38) Siegel, S; Nonparametric Statistics for the Behavioral Sciences 1956
- (39) Stancampiano, R; Eur J Pharmacol 1994, V261, P149 CAPLUS
- (40) Swedberg, M; J Pharmacol Exp Ther 1992, V263, P1015 CAPLUS
- (41) Watson, N; Pharmacol Biochem Behav 1991, V39, P605 CAPLUS
- (42) Zajecka, J; Psychopharmacol Bull 1997, V33, P755 CAPLUS

=> d 16 11 all

L6 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:45466 CAPLUS

DN 130:306414

TI A comparison of the effects of different serotonin reuptake blockers on sexual behavior of the male rat
 AU Mos, Jan; Mollet, Ian; Tolboom, Jeroen T. B. M.; Waldinger, Marcel D.; Olivier, Berend
 CS Solvay Pharmaceuticals, Department of Pharmacology, Weesp, 1380 DA, Neth.
 SO European Neuropsychopharmacology (1999), 9(1-2), 123-135
 CODEN: EURNE8; ISSN: 0924-977X
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB In human males, SSRIs differentially affect (premature) **ejaculation**; paroxetine and fluoxetine markedly and sertraline, moderately inhibited **ejaculation** latency, whereas fluvoxamine did not inhibit this parameter (Waldinger, M.D., Hengeveld, M.W., Zwinderman, A.H., Olivier, B., The effect of SSRI antidepressants on **ejaculation**: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J. Clin. Psychopharmacol. (in press)). The present studies tried to investigate, using sexual behavior in male rats, whether such differences could also be found in animal paradigms of sexual behavior. In a series of three expts. we compared various specific serotonin reuptake inhibitors (SSRIs) for their ability to suppress sexual behavior in male rats. In the first expt. sexually experienced rats were tested 60 min after oral administration of clomipramine, fluvoxamine, fluoxetine (all in a range of 0, 3, 10 and 30 mg/kg p.o.), sertraline or paroxetine (both in a range of 0, 1, 3 and 10 mg/kg p.o.). Clomipramine, paroxetine and fluvoxamine did not significantly inhibit male sexual behavior, although some trends were obsd. Sertraline inhibited sexual behavior at 3 and 10 mg/kg p.o., the effects being stronger at 3 mg/kg p.o. Fluoxetine (3 mg/kg p.o.) facilitated sexual behavior, while at 30 mg/kg p.o. a modest increase in the postejaculatory interval was noted. In the second expt., sexual behavior of sexually naive male rats was slightly inhibited by paroxetine 10 mg/kg p.o., but sertraline (range 1-10 mg/kg p.o.), fluvoxamine and fluoxetine (both in a range of 3-30 mg/kg p.o.) were ineffective. In the last expt. the effects of paroxetine (0-10 mg/kg p.o.), fluvoxamine and fluoxetine (both 0-30 mg/kg p.o.) were studied during an exhaustion design in sexually experienced male rats. As rats get more 'sluggish' when they have had multiple **ejaculations**, we hoped to see stronger inhibitory effects in the last cycle prior to exhaustion. None of the drugs dose-dependently inhibited the pattern of sexual behavior during the first sexual cycle. In the last cycle the patterning of sexual behavior differed, but only paroxetine (10 mg/kg p.o.) inhibited sexual behavior significantly. The total no. of **ejaculations** during the test was not reduced by any of the SSRIs tested. Contrary to human findings, we did not find major inhibitory effects of SSRIs on male rat sexual behavior at non-sedative doses. The only differentiation that could be made is that paroxetine and sertraline had slightly stronger effects than the other 5-HT reuptake inhibitors. Masculine sexual behavior in rats does not constitute a suitable model to investigate the differential mechanism of sexual inhibition of SSRIs that have been described in human males.
 ST serotonin reuptake clomipramine paroxetine fluvoxamine sertraline
 IT Antidepressants
 Sexual behavior
 (a comparison of effects of different serotonin reuptake blockers on sexual behavior of male rat)
 IT 303-49-1, Clomipramine 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7, Paroxetine 79617-96-2, Sertraline
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU

(Therapeutic use); BIOL (Biological study); USES (Uses)
(a comparison of effects of different serotonin reuptake blockers on sexual behavior of male rat)

IT 50-67-9, Serotonin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**selective serotonin reuptake inhibitor**; a comparison of effects of different serotonin reuptake blockers on sexual behavior of male rat)

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Agmo, A; J Neural Transm 1989, V77, P21 MEDLINE
- (2) Agmo, A; Pharmacol Biochem Behav 1990, V35, P327 CAPLUS
- (3) Ahlenius, S; Eur J Pharmacol 1984, V99, P279 CAPLUS
- (4) Ahlenius, S; Psychopharmacologia 1971, V20, P383 CAPLUS
- (5) Ahlenius, S; Psychopharmacology 1979, V65, P137 CAPLUS
- (6) Ahlenius, S; Psychopharmacology 1980, V68, P217 CAPLUS
- (7) Aizenberg, D; Clin Neuropharmacol 1995, V18, P320 CAPLUS
- (8) Althof, S; J Clin Psychiatry 1995, V56, P402 MEDLINE
- (9) Assalian, P; J Sex Res 1988, V24, P213
- (10) Baldwin, D; Int Rev Psychiatry 1995, V7, P261
- (11) Baum, M; Pharmacol Biochem Behav 1980, V13, P57 CAPLUS
- (12) Beach, F; Q J Exp Psychol 1956, V8, P121
- (13) Benazzi, F; Pharmacopsychiatry 1994, V27, P246 MEDLINE
- (14) Bitran, D; Neurosci Biobehav Rev 1987, V11, P365 CAPLUS
- (15) Collet, D; Modelling Survival Data in Medical Research Chapman and Hall 1994
- (16) Devane, C; Hum Psychopharmacol 1995, V10(S3), P185
- (17) Dorevitch, A; Ann Pharmacother 1994, V28, P872 MEDLINE
- (18) Eaton, H; J Int Med Res 1973, V1, P432
- (19) Forster, P; Am J Psychiatry 1994, V151, P1523 MEDLINE
- (20) Haensel, S; J Urol 1996, V156, P1310 CAPLUS
- (21) Haensel, S; Pharmacol Biochem Behav 1991, V40, P221 CAPLUS
- (22) Hamburger-Bar, R; Life Sci 1978, V22, P1827 CAPLUS
- (23) Hillegaart, V; Behav Brain Res 1989, V33, P279 CAPLUS
- (24) Hyttel, J; Int Clin Psychopharmacol 1994, V9(S1), P19
- (25) Lane, R; J Psychopharmacol 1995, V9, P163 CAPLUS
- (26) Machale, S; Br J Psychiatry 1994, V164, P854 MEDLINE
- (27) Maritz, J; J Am Stat Assoc 1978, V73, P194
- (28) Meston, C; J Psychoact Drugs 1992, V24, P1 MEDLINE
- (29) Monteiro, W; Br J Psychiatry 1987, V151, P107 MEDLINE
- (30) Mos, J; The Netherlands 1990, P221
- (31) Murdoch, D; Drugs 1992, V44, P604 CAPLUS
- (32) Olivier, B; Depression, Anxiety and Aggression-Preclinical and Clinical Interfaces Medidact 1988, P121
- (33) Patterson, W; J Clin Psychiatry 1993, V54, P71 MEDLINE
- (34) Power-Smith, P; Br J Psychiatry 1994, V164, P249 MEDLINE
- (35) Rothchild, A; Am J Psychiatry 1995, V152, P1514
- (36) Salis, P; Nature 1971, V232, P400 CAPLUS
- (37) Sanchez, C; Eur J Pharmacol 1994, V264, P241 CAPLUS
- (38) Sanchez, C; Psychopharmacology 1997, V129, P197 CAPLUS
- (39) Segraves, R; J Sex Marital Ther 1995, V21, P192 MEDLINE
- (40) Shen, W; Int J Psychiatry Med 1995, V25, P239 MEDLINE
- (41) Sodersten, P; Pharmacol Biochem Behav 1976, V5, P310
- (42) Taylor, G; Physiol Behav 1996, V59, P479 CAPLUS
- (43) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (44) Waldinger, M; J Clin Psychopharmacol (in press)
- (45) Walker, P; J Clin Psychiatry 1993, V54, P459 MEDLINE
- (46) Wise, T; J Clin Psychiatry 1994, V55, P417 MEDLINE
- (47) Yells, D; Pharmacol Biochem Behav 1994, V49, P121 CAPLUS
- (48) Zajacka, J; J Clin Psychiatry 1991, V52, P66 MEDLINE

=> d 16 15 all

L6 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:702829 CAPLUS
DN 127:341724
TI Fluvoxamine maleate in the treatment of depression: a single-center,
double-blind, placebo-controlled comparison with imipramine in outpatients
AU Claghorn, James L.; Earl, Craig Q.; Walczak, Donna D.; Stoner, Kim A.;
Wong, Lung Fai; Kanter, Donald; Houser, Vincent P.
CS Clin. Res. Assocs., Houston, TX, USA
SO Journal of Clinical Psychopharmacology (1996), 16(2), 113-120
CODEN: JCPYDR; ISSN: 0271-0749
PB Williams & Wilkins
DT Journal
LA English
CC 1-11 (Pharmacology)
AB The efficacy and safety of fluvoxamine maleate, a **selective
serotonin reuptake inhibitor**, was compared
with placebo and imipramine in patients with major depression disorder.
Previous literature has cited a dose range of 100 to 300 mg/day of
fluvoxamine maleate for the treatment of major depression; however, this
study demonstrates that a dose range of 50 to 150 mg/day is as effective
as imipramine (80-240 mg/day). After a 1- to 2-wk, single-blind, placebo
washout phase, 150 depressed outpatients were randomized to double-blind
treatment with fluvoxamine maleate (50-150 mg/day), imipramine (80-240
mg/day), or placebo for 6 wk. Fluvoxamine produced a significant
therapeutic benefit over placebo (p < 0.05) as assessed by the
total score on the Hamilton Rating Scale for Depression; imipramine
(80-240 mg/day) produced similar results. The secondary outcome variables
(i.e., Clin. Global Impression severity of illness item of 56-Item Hopkins
Symptom Checklist depression factor) also showed significant differences
between fluvoxamine maleate and placebo during three of the four final
weeks of the study. Both fluvoxamine maleate and imipramine appeared to
be safe and well tolerated by the majority of patients. As expected from
the pharmacol. of these agents, the imipramine groups reported more
anticholinergic effects (dry mouth, dizziness, and urinary retention) and
electrocardiogr. effects, whereas the fluvoxamine group reported more
nausea, somnolence, and abnormal **ejaculation**. The majority of
these adverse events were mild to moderate and, with the exception of dry
mouth (imipramine) and abnormal **ejaculation** (fluvoxamine), were
transient. The data clearly demonstrate the antidepressant activity and
tolerability of fluvoxamine maleate (50-150 mg/day) was compared with
placebo; it is also as effective as the tricyclic antidepressant
imipramine (80-240 mg/day) in patients with major depressive disorder.
ST fluvoxamine imipramine antidepressant
IT Antidepressants
(selective serotonin reuptake inhibitors; Comparison of fluvoxamine and
imipramine in treatment of depression in humans)
IT 54739-18-3, Fluvoxamine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
effector, except adverse); BSU (Biological study, unclassified); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(Comparison of fluvoxamine and imipramine in treatment of depression in
humans)
IT 50-49-7, Imipramine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Comparison of fluvoxamine and imipramine in treatment of depression in
humans)

=> d 16 16 all

L6 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:702827 CAPLUS
 DN 128:10222
 TI An open clinical trial of fluoxetine in the treatment of premature
ejaculation
 AU Lee, Hong Shick; Song, Dong Ho; Kim, Chan-Hyung; Choi, Hyoung Kee
 CS Department Psychiatry, College Medicine, Yonsei University, Seoul, S.
 Korea
 SO Journal of Clinical Psychopharmacology (1996), 16(5), 379-382
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB There have been an increased no. of recent reports on orgasm-related
 sexual dysfunction coincident with **selective serotonin**
reuptake inhibitor (SSRI) treatment. In contrast, it
 has also been reported that SSRIs improve sexual dysfunction. Low doses
 of clomipramine and paroxetine, potent 5-hydroxytryptamine reuptake
 blockers, have been found to retard **ejaculation** time. We
 hypothesized that the SSRI fluoxetine might be effective in treating
 premature **ejaculation**. In an 8-wk open-label clin. study, 11
 male patients with premature **ejaculation** were treated with
 fluoxetine. After a washout period of 2 wk, each patient was assigned to
 receive fluoxetine, 20 mg/day for 2 wk, and then titrated to 60 mg/day,
 depending on the patient's tolerability and clin. response. A
 within-subjects comparison of pre- and posttreatment intravaginal
ejaculation latency ime revealed a significant improvement.
 Fluoxetine treatment produced significant improvements in self-visual
 analog scale scores for sexual desire, anxiety for rapid
ejaculation, and partner's satisfaction with **ejaculation**
 and overall sexual function. These data suggest that serotonergic
 antidepressants may be effective in treating rapid **ejaculation**
 in men and underline the need to carry out a double-blind,
 placebo-controlled trial to confirm these results.
 ST fluoxetine premature **ejaculation** sexual dysfunction
 IT Sexual behavior
 (disorder; fluoxetine treatment of premature **ejaculation**)
 IT Sexual behavior
 (**ejaculation**, premature; fluoxetine treatment of premature
ejaculation)
 IT Biological transport
 (reuptake; fluoxetine treatment of premature **ejaculation**)
 IT Antidepressants
 (selective serotonin reuptake inhibitors; fluoxetine treatment of
 premature **ejaculation**)
 IT 54910-89-3, Fluoxetine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (fluoxetine treatment of premature **ejaculation**)
 IT 50-67-9, Serotonin, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (fluoxetine treatment of premature **ejaculation**)
 RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Althof, S; J Clin Psychiatry 1995, V56, P402 MEDLINE
 (2) Chouinard, G; J Clin Psychiatry 1985, V46, P32 MEDLINE
 (3) Cooper, A; Br J Psychiatry 1986, V114, P719
 (4) Decastros, R; Am J Psychiatry 1985, V142, P783
 (5) Eaton, H; J Int Med Res 1973, V1, P432

- (6) Fisch, C; J Clin Psychiatry 1985, V46, P42 MEDLINE
- (7) Goodman, R; J Int Med Res 1980, V3, P53
- (8) Grenier, G; Arch Sex Behav 1995, V24, P447 MEDLINE
- (9) Herman, J; J Clin Psychiatry 1990, V51, P25 MEDLINE
- (10) Johnson, A; Acta Psychiatrica Scand 1989, V80(suppl 350), P14
- (11) Kline, M; Am J Psychiatry 1989, V146, P804 MEDLINE
- (12) Lydiard, R; South Med J 1989, V82, P933 MEDLINE
- (13) Modell, J; J Clin Psychopharmacol 1989, V9, P63 MEDLINE
- (14) Monteiro, W; Br J Psychiatry 1987, V151, P107 MEDLINE
- (15) Rickels, K; J Clin Psychiatry 1990, V51(12, suppl B), P9
- (16) Schwartz, D; Programs and abstracts of the 89th annual meeting of the American Urological Association [abstract 471] 1994, P345A
- (17) Segraves, R; Arch Gen Psychiatry 1989, V46, P275 CAPLUS
- (18) Segraves, R; J Sex Marital Ther 1993, V19, P198 MEDLINE
- (19) Sovner, R; BMJ 1984, V1, P697
- (20) Thomas, D; Psychopharmacology 1987, V93, P193 CAPLUS
- (21) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE

=> d 116 17 all

L16 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 116 17 all

L16 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 16 17 all

L6 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:634304 CAPLUS

DN 127:287476

TI A critical review of **selective serotonin reuptake inhibitor**-related sexual dysfunction; incidence, possible etiology and implications for management

AU Lane, R. M.

CS Pfizer Inc., New York, NY, 10017, USA

SO Journal of Psychopharmacology (London) (1997), 11(1), 72-82

CODEN: JOPSEQ; ISSN: 0269-8811

PB SAGE Publications

DT Journal; General Review

LA English

CC 1-0 (Pharmacology)

AB A review with 92 refs. There is a high incidence of sexual dysfunction in the general population and sexual dysfunction is often an integral symptom of a depressive disorder. In addn., all antidepressants have effects on sexual functioning as the result of side-effects of these medications and as a reflection of therapeutic success. The selective serotonin reuptake inhibitors (SSRIs) are clearly assocd. with delayed **ejaculation**, inability to ejaculate and absent or delayed orgasm. Furthermore, the incidence of sexual dysfunction obtained by patient self-report does not appear to reflect the true incidence of sexual dysfunction assocd. with antidepressant therapy and systematic inquiry is needed as sexual dysfunction may be an unrecognized caused of non-compliance. The SSRIs may have advantageous effects on sexual functioning and these may also be under-reported due to the same factors resulting in an under-reporting of sexual side-effects in general. In addn., studies have suggested a role for the SSRIs i the management of premature **ejaculation**. The

effects of SSRIs on sexual functioning are clearly dose-related and may vary amongst the group due to their relative effects on the serotonin and dopamine systems and the extent to which plasma levels of these drugs accumulate in the body over time. A variety of strategies have been found useful in the management of SSRI-induced sexual dysfunction including waiting for tolerance to develop, dosage redn., drug holidays, switching to a different antidepressant and various augmentation strategies with 5-HT₂, .alpha.₂ adrenergic receptor antagonists and dopamine receptor agonists.

ST serotonin antagonist antidepressant sexual dysfunction review
IT Sexual behavior
(disorder; incidence, possible etiol. and implications for management of **selective serotonin reuptake inhibitor**-related sexual dysfunction)
IT 5-HT antagonists
Antidepressants
(incidence, possible etiol. and implications for management of **selective serotonin reuptake inhibitor**-related sexual dysfunction)

=> d 16 18 all

L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:79863 CAPLUS
DN 126:180636
TI Tolerability and safety of citalopram
AU Baldwin, David; Johnson, F. Neil
CS Royal South Hants Hospital, University Department of Psychiatry, Southampton, SO14 0YG, UK
SO Reviews in Contemporary Pharmacotherapy (1995), 6(6), 315-325
CODEN: RCPHFW; ISSN: 0954-8602
PB Marius Press
DT Journal; General Review
LA English
CC 1-0 (Pharmacology)
AB A review with .apprx.45 refs. The **selective serotonin reuptake inhibitor** citalopram has proven efficacy in the treatment of acute episodes of depression, and in continuation treatment following symptomatic resoln. The tolerability profile of citalopram is markedly different from that seen with older tricyclic antidepressant drugs, and is similar to that of the other SSRIs. Adverse events which occur more frequently with citalopram than with placebo in controlled trials are nausea, dry mouth, somnolence, increased sweating, tremor, diarrhea, and **ejaculation** failure. When compared with a range of tricyclic and related drugs in controlled trials, citalopram showed more nausea and **ejaculation** failure events than the comparator drugs, but on ten other categories of adverse event the tricyclics and related drugs were significantly worse than citalopram. The tolerability profile among elderly patients was broadly similar to that seen amongst younger patients. When compared with established drugs citalopram may have certain advantages in the treatment of elderly patients if the daily dosage is adjusted appropriately. Citalopram was, on the evidence currently available, well tolerated in chronic use. It appears to be relatively safe in overdose when taken alone, and may be esp. useful in depressed patients with suicidal thoughts or a history of suicidal behavior.
ST review citalopram antidepressant
IT Antidepressants
(tolerability and safety of citalopram in humans)
IT 59729-33-8, Citalopram
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(tolerability and safety of citalopram in humans)

=>
=> d his]
'HIS]' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes. For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO. You may specify the format fields in any order and the

information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):bib

L6 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:769978 CAPLUS
TI Antidepressants and **Ejaculation**: A Double-Blind, Randomized, Fixed-Dose Study With Mirtazapine and Paroxetine
AU Waldinger, Marcel D.; Zwinderman, Aeilko H.; Olivier, Berend
CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, The Hague, Neth.
SO Journal of Clinical Psychopharmacology (2003), 23(5), 467-470
CODEN: JCPYDR; ISSN: 0271-0749
PB Lippincott Williams & Wilkins
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 12:20:03 ON 25 NOV 2003)

FILE 'REGISTRY' ENTERED AT 12:20:14 ON 25 NOV 2003

E DAPOXETINE

L1 2 S E3

FILE 'CAPLUS' ENTERED AT 12:21:05 ON 25 NOV 2003

L2 14 S L1

L3 0 S SELECTIVE SEROTININ REUPTAKE INHIBITOR

L4 697 S SELECTIVE SEROTONIN REUPTAKE INHIBITOR

E EJACULATION

L5 1881 S E1-E10

L6 18 S L4 AND L5

=> d 12

L2 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:494560 CAPLUS

DN 137:226186

TI Studies on the three dimensional quantitative structure-activity relationship of serotonin reuptake inhibitors

AU Shi, Yu; Wang, Xiao-fang; Yang, Guang-zhong

CS Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, 100050, Peop. Rep. China

SO Jisuanji Yu Yingyong Huaxue (2002), 19(1/2), 35-40

CODEN: JYYHE6; ISSN: 1001-4160

PB Jisuanji Yu Yingyong Huaxue Bianjibu

DT Journal

LA Chinese

=> d 12 1-14

L2 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:494560 CAPLUS

DN 137:226186

TI Studies on the three dimensional quantitative structure-activity relationship of serotonin reuptake inhibitors

AU Shi, Yu; Wang, Xiao-fang; Yang, Guang-zhong
 CS Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing,
 100050, Peop. Rep. China
 SO Jisuanji Yu Yingyong Huaxue (2002), 19(1/2), 35-40
 CODEN: JYYHE6; ISSN: 1001-4160
 PB Jisuanji Yu Yingyong Huaxue Bianjibu
 DT Journal
 LA Chinese

L2 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:241329 CAPLUS
 DN 136:284433
 TI Administration of phosphodiesterase inhibitors for the treatment of
 premature ejaculation
 IN Wilson, Leland F.; Doherty, Paul C.; Place, Virgil A.; Smith, William L.;
 Abdel-Hamid, Abdou Ali Ibrahim Aboubakr
 PA USA
 SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 467,094.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002037828	A1	20020328	US 2001-888250	20010621
	US 6403597	B2	20020611		
	US 6037346	A	20000314	US 1998-181070	19981027
	US 6548490	B1	20030415	US 1999-467094	19991210
	WO 2003000343	A2	20030103	WO 2002-US9415	20020325
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 1997-958816	B2	19971028		
	US 1998-181070	A2	19981027		
	US 1999-467094	A2	19991210		
	US 2001-888250	A	20010621		

L2 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:90620 CAPLUS
 DN 136:112659
 TI Methods of inhibiting platelet activation with selective serotonin
 reuptake inhibitors and treatment of cardiovascular disease
 IN Serebruany, Victor L.; Gurbel, Paul A.; O'Connor, Christopher M.
 PA Heartdrug Research, LLC, USA
 SO U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. 6,245,782.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002013343	A1	20020131	US 2001-804689	20010312
	US 6552014	B2	20030422		
	US 6245782	B1	20010612	US 1999-312987	19990517
	ZA 2001009994	A	20020826	ZA 2001-9994	20011205
PRAI	US 1999-312987	A2	19990517		

L2 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:434867 CAPLUS
 DN 135:29158
 TI The combination of a serotonin reuptake inhibitor and irindalone for the
 treatment of depression and other affective disorders
 IN Bogeso, Klaus Peter; Cremers, Thomas Ivo Franciscus Hubert
 PA H. Lundbeck A/S, Den.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041766	A1	20010614	WO 2000-DK667	20001204
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,				
	CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, FI,				
	GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,				
	KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,				
	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR,				
	TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,				
	RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002103249	A1	20020801	US 2000-731411	20001206
PRAI	US 1999-169245P	P	19991206		
RE.CNT	4				
	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD				
	ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L2 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:434808 CAPLUS
 DN 135:41033
 TI The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist,
 inverse agonist or partial agonist
 IN Cremers, Thomas Ivo Franciscus Hubert; Wikstroem, Hakan Wilhelm; Den Boer,
 Johan Antonie; Bosker, Fokko Jan; Westerink, Bernard Hendrik Cornelis;
 Bogeso, Klaus Peter; Hogg, Sandra; Mork, Arne
 PA H. Lundbeck A/s, Den.
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001041701	A2	20010614	WO 2000-DK671	20001206
	WO 2001041701	A3	20011213		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,				
	CN, CR, CU, CZ, DE, DK, DM, DZ, EE, EE, ES, FI, FI,				
	GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,				
	KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,				
	NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR,				
	TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,				
	RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001018511	A5	20010618	AU 2001-18511	20001206
	US 2002103249	A1	20020801	US 2000-731411	20001206
	EP 1237553	A2	20020911	EP 2000-981174	20001206

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR	2000016385	A	20030218	BR	2000-16385	20001206
JP	2003516326	T2	20030513	JP	2001-542871	20001206
NO	2002002657	A	20020726	NO	2002-2657	20020605
US	2003032636	A1	20030213	US	2002-165196	20020606
BG	106895	A	20030430	BG	2002-106895	20020702
PRAI	US 1999-169245P	P	19991206			
WO	2000-DK671	W	20001206			

L2 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:185565 CAPLUS
DN 134:217211
TI Methods of using rapid-onset selective serotonin reuptake inhibitors for
treating sexual dysfunction
IN Thor, Karl Bruce
PA Eli Lilly and Co., USA
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001017521	A1	20010315	WO 2000-US20788	20000822
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
	BR 2000014166	A	20020514	BR 2000-14166	20000822
	EP 1225881	A1	20020731	EP 2000-957264	20000822
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
	EE 200200107	A	20030415	EE 2002-107	20000822
	NZ 517038	A	20030429	NZ 2000-517038	20000822
	AU 762934	B2	20030710	AU 2000-68911	20000822
	JP 2001089394	A2	20010403	JP 2000-259000	20000829
	JP 3194734	B2	20010806		
	BG 106461	A	20021229	BG 2002-106461	20020228
	NO 2002001035	A	20020502	NO 2002-1035	20020301
PRAI	US 1999-152435P	P	19990903		
WO	2000-US20788	W	20000822		

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:98327 CAPLUS
DN 132:146650
TI Treating depression with a combination of a serotonin uptake inhibitor, a
5-HT1A presynaptic antagonist, and a 5-HT1A agonist
IN Depoortere, Henri
PA Sanofi-Synthelabo, Fr.
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006160	A1	20000210	WO 1999-FR1825	19990726
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2781671	A1	20000204	FR 1998-9603	19980728
	AU 9949167	A1	20000221	AU 1999-49167	19990726
PRAI	FR 1998-9603	A	19980728		
	WO 1999-FR1825	W	19990726		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:733398 CAPLUS
 DN 123:102797
 TI Treatment of tobacco withdrawal symptoms
 IN Johnson, Kristine Hagen
 PA Lilly, Eli, and Co., USA
 SO S. African, 60 pp.
 CODEN: SFXAB
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 9300694	A	19930603	ZA 1993-694	19930201
PRAI	ZA 1993-694		19930201		

L2 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:528898 CAPLUS
 DN 121:128898
 TI Synthesis of [11C]dapoxetine.cntdot.HCl, a serotonin re-uptake inhibitor:
 Biodistribution in rat and preliminary PET imaging in the monkey
 AU Livni, E.; Satterlee, Winston; Robey, Roger L.; Alt, Charles A.; Van
 Meter, Elden E.; Babich, John W.; Wheeler, William J.; O'Bannon, Douglas
 D.; Thrall, James H.; et al.
 CS Harv. Med. Sch., Mass. Gen. Hosp., Boston, MA, 02114, USA
 SO Nuclear Medicine and Biology (1994), 21(4), 669-75
 CODEN: NMBIEO; ISSN: 0883-2897
 DT Journal
 LA English

L2 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:482740 CAPLUS
 DN 121:82740
 TI Preparation of intermediates to 1-phenyl-3-(naphthalenyloxy)propanamines
 IN Alt, Charles A.; Robey, Roger L.; Van, Meter Eldon E.
 PA Lilly, Eli, and Co., USA
 SO U.S., 5 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 5292962 A 19940308 US 1992-989291 19921211
PRAI US 1992-989291 19921211
OS CASREACT 121:82740; MARPAT 121:82740

L2 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:235345 CAPLUS
DN 120:235345
TI Disposition of 14C-dapoxetine in rats: complementary experiments with whole-body autoradiographic and tissue dissection techniques
AU Bernstein, J. R.; Manzione, B. M.; Pohland, R. C.; Franklin, R. B.
CS Lilly Res. Lab., Dep. Drug Metab. and Disposition, Indianapolis, IN, 46285, USA
SO Biopharmaceutics & Drug Disposition (1994), 15(2), 137-50
CODEN: BDDID8; ISSN: 0142-2782
DT Journal
LA English

L2 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:204601 CAPLUS
DN 118:204601
TI Determination of dapoxetine, an investigational agent with the potential for treating depression, and its mono- and di-desmethyl metabolites in human plasma using column-switching high-performance liquid chromatography
AU Hamilton, Cristi L.; Cornpropst, J. David
CS Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SO Journal of Chromatography, Biomedical Applications (1993), 612(2), 253-61
CODEN: JCBADL; ISSN: 0378-4347
DT Journal
LA English

L2 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:255284 CAPLUS
DN 116:255284
TI A chiral synthesis of dapoxetine hydrochloride, a serotonin reuptake inhibitor, and its 14C isotopomer
AU Wheeler, William J.; O'Bannon, Douglas D.
CS Lilly Corp. Cent., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SO Journal of Labelled Compounds and Radiopharmaceuticals (1992), 31(4), 305-15
CODEN: JLCRD4; ISSN: 0362-4803
DT Journal
LA English
OS CASREACT 116:255284

L2 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:114467 CAPLUS
DN 110:114467
TI Preparation of 1-phenyl-3-(naphthalenyloxy)propanamines as serotonin inhibitors
IN Robertson, David Wayne; Thompson, Dennis Charles; Wong, David Taiwai
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 288188	A1	19881026	EP 1988-303177	19880408
	EP 288188	B1	19911016		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
IL	85988	A1	19920818	IL 1988-85988	19880406

CA 1329937	A1	19940531	CA 1988-563374	19880406
AU 8814335	A1	19881013	AU 1988-14335	19880407
AU 602971	B2	19901101		
JP 63258837	A2	19881026	JP 1988-88025	19880407
JP 06037443	B4	19940518		
DK 8801882	A	19890112	DK 1988-1882	19880407
DK 170637	B1	19951120		
ZA 8802418	A	19891227	ZA 1988-2418	19880407
CN 88102018	A	19881026	CN 1988-102018	19880408
CN 1020093	B	19930317		
HU 50316	A2	19900129	HU 1988-1790	19880408
HU 204767	B	19920228		
SU 1568886	A3	19900530	SU 1988-4355511	19880408
AT 68473	E	19911115	AT 1988-303177	19880408
ES 2045109	T3	19940116	ES 1988-303177	19880408
US 5135947	A	19920804	US 1990-561492	19900801
PRAI US 1987-36534		19870409		
EP 1988-303177		19880408		
US 1988-191465		19880509		
US 1989-372149		19890626		
OS MARPAT 110:114467				

=> d 12 9 all

L2 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:528898 CAPLUS
 DN 121:128898
 TI Synthesis of [11C]dapoxetine.cntdot.HCl, a serotonin re-uptake inhibitor: Biodistribution in rat and preliminary PET imaging in the monkey
 AU Livni, E.; Satterlee, Winston; Robey, Roger L.; Alt, Charles A.; Van Meter, Elden E.; Babich, John W.; Wheeler, William J.; O'Bannon, Douglas D.; Thrall, James H.; et al.
 CS Harv. Med. Sch., Mass. Gen. Hosp., Boston, MA, 02114, USA
 SO Nuclear Medicine and Biology (1994), 21(4), 669-75
 CODEN: NMBIEO; ISSN: 0883-2897
 DT Journal
 LA English
 CC 8-9 (Radiation Biochemistry)
 Section cross-reference(s): 1
 AB [11C]Dapoxetine.cntdot.HCl, S-(+)-N,N-dimethyl-a-[2-(naphthalenyloxy)ethyl]benzenemethanamine hydrochloride, a potent serotonin re-uptake inhibitor was prepd. from its mono-Me precursor, S-(+)-N-methyl-a-[2-(naphthalenyloxy)ethyl]benzene methanamine hydrochloride. Biodistribution was detd. in rats at 5, 30 and 60 min after injection and preliminary PET studies were performed in a Rhesus monkey. 11CH3I was bubbled into a soln. of S-(+)-N-methyl-.alpha.-[2-(naphthalenyloxy)ethyl]benzene methanamine hydrochloride (3.0 mg in DMSO) and the mixt. was heated at 110.degree.C for 8 min. [11C]Dapoxetine.cntdot.HCl was purified by HPLC on a C18 cartridge eluted with MeOH:phosphate buffer, pH 7.2(75:25) with a 10% yield (end of synthesis). The time required for the synthesis was 40 min from the end of bombardment. Radiochem. purity of the final product was >99% and specific activity was routinely >400 mCi/.mu.mol [EOS]. In the biodistribution studies the highest concn. (%ID/g) of dapoxetine.cntdot.HCl was detected in lung: 4.56 (5 min), 1.28 (30 min) and 0.67 (60 min). Brain accumulation was 0.76 (5 min), 0.46 (30 min) and 0.27 (60 min). Preliminary PET studies demonstrated significant displaceable binding in the cerebral cortex and subcortical gray matter. These results demonstrate that [11C]dapoxetine.cntdot.HCl can be prepd. in high purity and may be useful for the in vivo evaluation of serotonin re-uptake mechanisms.

ST carbon 11 dapoxetine brain PET
 IT Brain, metabolism
 (dapoxetine metab. by, PET of, using carbon-11-dapoxetine)
 IT Tomography
 (positron-emission, of dapoxetine metab. in brain, using
 carbgon-11-dapoxetine)
 IT 157166-72-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and biodistribution of and PET with, of dapoxetine metab. in
 brain)
 IT 156453-53-1P 157166-71-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and conversion to dapoxetine)
 IT **119356-77-3P**, Dapoxetine
 RL: BPR (Biological process); BSU (Biological study, unclassified); SPN
 (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC
 (Process)
 (prepn. and metab. of, PET of, with carbon-11-dapoxetine)

=> d 12 7 all

L2 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:98327 CAPLUS
 DN 132:146650
 TI Treating depression with a combination of a serotonin uptake inhibitor, a
 5-HT1A presynaptic antagonist, and a 5-HT1A agonist
 IN Depoortere, Henri
 PA Sanofi-Synthelabo, Fr.
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 IC ICM A61K031-40
 ICS A61K031-135; A61K031-505; A61K031-135; A61K031-505
 CC 1-11 (Pharmacology)
 Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006160	A1	20000210	WO 1999-FR1825	19990726
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2781671	A1	20000204	FR 1998-9603	19980728
	AU 9949167	A1	20000221	AU 1999-49167	19990726
PRAI	FR 1998-9603	A	19980728		
	WO 1999-FR1825	W	19990726		
AB	Pharmaceutical compns. are provided which contain a serotonin uptake inhibitor (e.g. fluoxetine), a 5-HT1A presynaptic antagonist (e.g. pindolol), and a 5-HT1A agonist (e.g. buspirone) as a combination product for simultaneous, sep., or prolonged use for treating various forms of depression.				
ST	depression fluoxetine pindolol buspirone combination; serotoninergic 5HT1A presynaptic antagonist combination depression; 5HT1A serotoninergic agonist combination depression				

IT 5-HT agonists
5-HT antagonists
(5-HT1A; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT Mental disorder
(depression, major; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT Mental disorder
(depression, neurotic; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT Sleep
(disorder; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT Mental disorder
(manic bipolar disorder; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT Mental disorder
(obsession-compulsion; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT Drug delivery systems
(oral; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A
agonist combination for treatment of depression)

IT Anxiety
(panic; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A
agonist combination for treatment of depression)

IT Mental disorder
(phobia, social; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT Antidepressants
Antipsychotics
Anxiolytics
Cognition enhancers
Drug delivery systems
Drug interactions
(serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A
agonist combination for treatment of depression)

IT Drug interactions
(synergistic; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT 50-67-9, Serotonin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(reuptake inhibitors; serotonin uptake inhibitor-5-HT1A presynaptic
antagonist-5-HT1A agonist combination for treatment of depression)

IT 13523-86-9, Pindolol 36505-84-7, Buspirone 54739-18-3, Fluvoxamine
54910-89-3, Fluoxetine 59729-33-8, Citalopram 61869-08-7, Paroxetine
71827-56-0, Clemeprol 79617-96-2, Sertraline 83366-66-9, Nefazodone
83455-48-5, Bromerguride 83928-76-1, Gepirone 87760-53-0, Tansospirone
90494-76-1, SR 57746 92623-85-3, Milnacipran 93413-69-5, Venlafaxine
95847-70-4, Ipsapirone 98206-10-1, Flesinoxan 99487-26-0, MCI 225
102908-59-8, Binospirone 112922-55-1, Cericlamine 114298-18-9,
Zalospirone **119356-77-3**, Dapoxetine 127266-56-2, WY 50324
132449-45-7, E4414 132449-46-8, Lesopitron 132501-12-3, WY 48723
132873-35-9, LY 274600 133109-86-1, EMD 56551 135722-27-9, S 14671
138298-79-0, Alnespirone 141318-62-9, LY 293284 142348-14-9,
Pyricapirone 144340-02-3, CP 119333 144980-77-8, BAYx 3702
145969-30-8, OPC 14523 146479-45-0, BMS 181101 146998-34-7, S 15535
149494-37-1, Ebalzotan 149654-41-1, U 92016A 150019-94-6, BMS 184111
150527-35-8, FG 5865 150710-80-8, HT 90B 156896-33-2, LY 301317
161178-10-5, YM 35992 161312-09-0 162408-66-4, GR 103691
162581-80-8, LY 297996 163521-12-8, EMD 68843 167933-07-5, Flibanserin
177975-08-5, EMD 77697 179756-58-2, F 11440 208516-87-4, NAD 299

214686-27-8, F 12439 221452-76-2, EF 7412 257614-79-2 257863-96-0,
NS 2389 257863-98-2, EMD 80084 257864-13-4, AP 521 257864-15-6, AZ
16596 257864-30-5, DDR 203901 257864-31-6, DDR 205852 257864-33-8,
DDR 208978 257864-35-0, DDR 211278 257864-36-1, DDR 212219
257864-37-2, FCE 23892 257864-38-3, LY 315535 257864-39-4, S 215521
257864-41-8, WAY 100802 257864-47-4, EMD 67478
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A
agonist combination for treatment of depression)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Cadieux, R; AMERICAN FAMILY PHYSICIAN 1998, P1
- (2) Devane, C; HTTP://MBLCOMMUNICATIONS COM/PP998_DEVANE P10
- (3) Devane, C; PRIMARY PSYCHIATRY 1998, V5(9)
- (4) Eli, L; EP 0687472 A 1995 CAPLUS
- (5) Eli, L; EP 0792649 A 1997 CAPLUS
- (6) Majeroni, B; JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE,
<http://www.medscape.com/ABFP/JABFP/1998/v11.n02/fp1102.05.maje/fp1102.05.maje.html> abrege 1998, V11(2), P127 MEDLINE
- (7) Nemeroff, C; DEPRESSION AND ANXIETY 1996, P169
- (8) Perez, M; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1998, V8(23), P3423
CAPLUS
- (9) Puzantian, T; PHARMACOTHERAPY 1999, P205 CAPLUS
- (10) Redrobe, J; CNS SPECTRUMS 1999, V4/4, P73
- (11) Schweitzer, I; AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY 1997,
V31(3) MEDLINE

=> d 12 12 all

L2 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:204601 CAPLUS
DN 118:204601
TI Determination of dapoxetine, an investigational agent with the potential
for treating depression, and its mono- and di-desmethyl metabolites in
human plasma using column-switching high-performance liquid chromatography
AU Hamilton, Cristi L.; Cornpropst, J. David
CS Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA
SO Journal of Chromatography, Biomedical Applications (1993), 612(2), 253-61
CODEN: JCBADL; ISSN: 0378-4347
DT Journal
LA English
CC 1-1 (Pharmacology)
AB A column-switching high-performance liq. chromatog. (HPLC) method is
described for the detn. of dapoxetine and its mono- and di-desmethyl
metabolites in human plasma. The analytes, including an internal std.,
were extd. from plasma at basic pH with hexane-Et acetate. The org. ext.
was evapd. to dryness and the residue reconstituted with acetonitrile.
The analytes were sepd. from late-eluting endogenous substances on a
Zorbax RX-C8 pre-column. The front-cut fraction contg. the analytes was
further sepd. on a second RX-C8 column. The analytes were detected by
their native fluorescence, using excitation and emission wavelengths of
230 and 330 nm, resp. The limit of quantitation was detd. to be 20 ng/mL,
and the response was linear from 20 to 200 ng/mL. The method has been
successfully applied to human plasma samples in a Phase I study.
ST dapoxetine metabolite detn blood HPLC; liq chromatog dapoxetine metabolite
blood
IT Blood analysis
(dapoxetine and its metabolites detn. in human, by HPLC)
IT Chromatography, column and liquid

(high-performance, of dapoxetine and its metabolites, in human blood detn.)

IT 147199-39-1 147199-40-4

RL: ANT (Analyte); ANST (Analytical study)

(detn. of, as dapoxetine metabolite, in blood of humans by HPLC)

IT **119356-77-3**, Dapoxetine

RL: ANT (Analyte); ANST (Analytical study)

(detn. of, in blood of humans by HPLC)

=> d 12 13 all

L2 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1992:255284 CAPLUS

DN 116:255284

TI A chiral synthesis of dapoxetine hydrochloride, a serotonin reuptake inhibitor, and its ¹⁴C isotopomer

AU Wheeler, William J.; O'Bannon, Douglas D.

CS Lilly Corp. Cent., Eli Lilly and Co., Indianapolis, IN, 46285, USA

SO Journal of Labelled Compounds and Radiopharmaceuticals (1992), 31(4), 305-15

CODEN: JLCRD4; ISSN: 0362-4803

DT Journal

LA English

CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

OS CASREACT 116:255284

AB The title isotopomer was prepd. by a chiral synthesis, starting with (R)-PhCHRNH(tert-Boc) (I, R = CO₂H). Borane redn., followed by activation of the resulting alc. as its mesylate, provided I (R = CH₂OMs). The radiolabel was introduced by reaction of the mesylate with sodium cyanide-[¹⁴C]. The desired product was then elaborated from the nitrile via a 5-step synthesis in an overall 19.5% radiochem. yield.

ST dapoxetine carbon labeled chiral synthesis

IT 126568-44-3P 141625-50-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and conversion to carboxylic acid)

IT 102089-75-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyanation of)

IT 102089-74-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and mesylation of)

IT 82769-76-4P 141625-52-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and methylation of)

IT 82769-75-3P 141625-53-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction with fluoronaphthalene)

IT 83649-47-2P 141625-51-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and redn. of)

IT **129938-20-1P** 141625-54-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

IT 321-38-0, 1-Fluoronaphthalene

RL: RCT (Reactant); RACT (Reactant or reagent)


(reaction of, with aminophenylpropoxide)
IT 33125-05-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(redn. of)

=> d 12 14 all


L2 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:114467 CAPLUS
DN 110:114467
TI Preparation of 1-phenyl-3-(naphthalenyloxy)propanamines as serotonin
inhibitors
IN Robertson, David Wayne; Thompson, Dennis Charles; Wong, David Taiwan
PA Lilly, Eli, and Co., USA
SO Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07C093-00
ICS C07C093-14; C07D317-58; A61K031-135
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 288188	A1	19881026	EP 1988-303177	19880408
	EP 288188	B1	19911016		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 85988	A1	19920818	IL 1988-85988	19880406
	CA 1329937	A1	19940531	CA 1988-563374	19880406
	AU 8814335	A1	19881013	AU 1988-14335	19880407
	AU 602971	B2	19901101		
	JP 63258837	A2	19881026	JP 1988-88025	19880407
	JP 06037443	B4	19940518		
	DK 8801882	A	19890112	DK 1988-1882	19880407
	DK 170637	B1	19951120		
	ZA 8802418	A	19891227	ZA 1988-2418	19880407
	CN 88102018	A	19881026	CN 1988-102018	19880408
	CN 1020093	B	19930317		
	HU 50316	A2	19900129	HU 1988-1790	19880408
	HU 204767	B	19920228		
	SU 1568886	A3	19900530	SU 1988-4355511	19880408
	AT 68473	E	19911115	AT 1988-303177	19880408
	ES 2045109	T3	19940116	ES 1988-303177	19880408
	US 5135947	A	19920804	US 1990-561492	19900801
PRAI	US 1987-36534		19870409		
	EP 1988-303177		19880408		
	US 1988-191465		19880509		
	US 1989-372149		19890626		
OS	MARPAT 110:114467				
GI					



I



II

- AB The title compds. [I; R1,R2 = H, Me; R3 = H, halo, C1-4 alkyl, C1-3 alkoxy, CF3; R4 = H, halo, C1-4 alkyl, C1-3 alkoxy, CF3; R42 = OCH2O; m = 1, 2] and their stereoisomers and pharmaceutically acceptable salts were prepd. for selective inhibition of serotonin uptake in mammals, useful as antidepressants. PhCH2CO2H was alkylated with 2-(4-methyl-1-naphthalenoxy)ethyl chloride by using BuLi in HMPA to give carboxyphenylnaphthalenyloxypropane II (R5 = CO2H) which was treated in acetone with ClCO2Et in the presence of Et3N and then with NaN3. The resulting acid azide was rearranged to give II (R5 = NCO) which was hydrolyzed to give II (R5 = NH2) (III). Reductive alkylation of the latter with CH2O/NaBH3CN in MeCN gave II (R5 = NMe2) (IV). Serotonin uptake by rat cerebral cortex synaptosome preps. was inhibited 50% by 25 mM IV.oxalate.
- ST naphthalenyloxyphenylpropanamine prepn serotonin uptake inhibitor;
antidepressant naphthalenyloxyphenylpropanamine prepn
- IT Antidepressants
(naphthalenyloxy)phenylpropanamines)
- IT 119357-38-9 119357-40-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(antidepressant pharmaceutical compn. contg.)
- IT 325-89-3P 119357-41-4P 119357-42-5P 119357-43-6P 119357-44-7P
119357-45-8P 119357-46-9P 119357-47-0P 119357-48-1P 119357-49-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction of, in prepn. of antidepressants)
- IT 119356-76-2P **119356-77-3P** 119356-78-4P 119356-79-5P
119356-80-8P 119356-81-9P 119356-82-0P 119356-83-1P 119356-84-2P
119356-86-4P 119356-88-6P 119356-90-0P 119356-92-2P 119356-94-4P
119356-96-6P 119356-98-8P 119357-00-5P 119357-02-7P 119357-04-9P
119357-06-1P 119357-07-2P 119357-09-4P 119357-11-8P 119357-13-0P
119357-15-2P 119357-17-4P 119357-18-5P 119357-19-6P 119357-20-9P
119357-21-0P 119357-23-2P 119357-24-3P 119357-25-4P 119357-27-6P
119357-29-8P 119357-31-2P 119357-33-4P 119357-35-6P 119357-37-8P
119374-91-3P 119374-93-5P 119374-95-7P 119374-97-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as serotonin uptake inhibitor)
- IT 74-89-5, Methylamine, reactions 90-15-3, 1-Naphthalenol 103-82-2,
Phenylacetic acid, reactions 141-82-2, Malonic acid, reactions
321-38-0, 1-Fluoronaphthalene 459-57-4, 4-Fluorobenzaldehyde 541-41-3,
Ethyl chloroformate 637-59-2, (3-Bromopropyl)benzene 3570-58-9,
2-Chloroethyl methanesulfonate 10240-08-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of antidepressants)
- IT 50-67-9, Serotonin, uses and miscellaneous
RL: USES (Uses)
(uptake of, by brain, (naphthalenyloxy)phenylpropanamines inhibition
of)

=> s serotonin reuptake inhibitor
62015 SEROTONIN

6406 REUPTAKE
427374 INHIBITOR
L7 1329 SEROTONIN REUPTAKE INHIBITOR
(SEROTONIN(W) REUPTAKE(W) INHIBITOR)

=> s 17 and 15
L8 27 L7 AND L5

=> d his

(FILE 'HOME' ENTERED AT 12:20:03 ON 25 NOV 2003)

FILE 'REGISTRY' ENTERED AT 12:20:14 ON 25 NOV 2003
E DAPOXETINE

L1 2 S E3

FILE 'CAPLUS' ENTERED AT 12:21:05 ON 25 NOV 2003

L2 14 S L1
L3 0 S SELECTIVE SEROTININ REUPTAKE INHIBITOR
L4 697 S SELECTIVE SEROTONIN REUPTAKE INHIBITOR
E EJACULATION
L5 1881 S E1-E10
L6 18 S L4 AND L5
L7 1329 S SEROTONIN REUPTAKE INHIBITOR
L8 27 S L7 AND L5

=> s 18 not 16
L9 9 L8 NOT L6

=> d 19 1-9

L9 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:376842 CAPLUS
DN 138:385297
TI Methods for treating depression and other CNS disorders using
enantiomERICALLY enriched desmethyl- and didesmethyl- metabolites of
citalopram
IN Bush, Larry R.; Currie, Mark G.; Senanayake, Chris H.; Fang, Kevin Q.
PA Sepracor, Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003040121	A1	20030515	WO 2002-US35408	20021105
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2001-337608P P 20011108

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:6424 CAPLUS
 DN 138:49845
 TI Treatment of antidepressant-associated sexual dysfunction with sildenafil.
 A randomized controlled trial
 AU Nurnberg, H. George; Hensley, Paula L.; Gelenberg, Alan J.; Fava,
 Maurizio; Lauriello, John; Paine, Susan
 CS Department of Psychiatry, Health Sciences Center, University of New Mexico
 School of Medicine, Albuquerque, NM, USA
 SO JAMA, the Journal of the American Medical Association (2003), 289(1),
 56-64
 CODEN: JAMAAP; ISSN: 0098-7484
 PB American Medical Association
 DT Journal
 LA English
 RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:814103 CAPLUS
 DN 137:310821
 TI Preparation of phenyl heterocyclyl ether derivatives as potent and
 selective inhibitors of serotonin re-uptake
 IN Adam, Mavis Diane; Andrews, Mark David; Gymer, Geoffrey Edward; Hepworth,
 David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 107 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083643	A1	20021024	WO 2002-IB1032	20020327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003207857	A1	20031106	US 2002-122698	20020411
PRAI GB 2001-9103	A	20010411		
US 2001-292408P	P	20010521		
OS MARPAT 137:310821				

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:797244 CAPLUS
 DN 138:331028
 TI Escitalopram
 AU Burke, William J.
 CS University of Nebraska Department of Psychiatry, Omaha, NE, 68198-5580,
 USA
 SO Expert Opinion on Investigational Drugs (2002), 11(10), 1477-1486
 CODEN: EOIDER; ISSN: 1354-3784
 PB Ashley Publications Ltd.
 DT Journal; General Review

LA English

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:171851 CAPLUS

DN 136:232110

TI Preparation of phenoxybenzylamines as selective serotonin re-uptake inhibitors

IN Adam, Mavis Diane; Andrews, Mark David; Elliott, Mark Leonard; Gymer, Geoffrey Edward; Hepworth, David; Howard, Harry Ralph, Jr.; Middleton, Donald Stuart; Stobie, Alan

PA Pfizer Limited, UK; Pfizer Inc.

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018333	A1	20020307	WO 2001-IB1521	20010822
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001078650	A5	20020313	AU 2001-78650	20010822
	EP 1313701	A1	20030528	EP 2001-956734	20010822
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013610	A	20030624	BR 2001-13610	20010822
	US 2003060456	A1	20030327	US 2001-941177	20010827
	US 6610747	B2	20030826		
	NO 2003000842	A	20030428	NO 2003-842	20030224
	HR 2003000141	A1	20030430	HR 2003-141	20030226
PRAI	GB 2000-21593	A	20000831		
	GB 2001-7116	A	20010321		
	US 2000-240271P	P	20001013		
	US 2001-292400P	P	20010521		
	WO 2001-IB1521	W	20010822		

OS MARPAT 136:232110

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:169117 CAPLUS

DN 136:216641

TI Preparation of phenoxyphenylheterocycles as selective serotonin reuptake inhibitors (SSRIs)

IN Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan

PA Pfizer Limited, UK; Pfizer Inc.

SO Eur. Pat. Appl., 46 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI EP 1184372 A1 20020306 EP 2001-307032 20010817
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 US 2002183303 A1 20021205 US 2001-939475 20010824
 US 6630504 B2 20031007
 BR 2001003797 A 20020604 BR 2001-3797 20010830
 PRAI GB 2000-21594 A 20000831
 GB 2001-5634 A 20010307
 US 2000-240326P P 20001013
 OS MARPAT 136:216641
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:798041 CAPLUS
 DN 135:339276
 TI Use of serotonin reuptake inhibitors for the treatment of depression
 IN Druzgala, Pascal
 PA Aryx Therapeutics, USA
 SO PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001080845	A2	20011101	WO 2001-US13275	20010424
	WO 2001080845	A3	20020523		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	US 2001056119	A1	20011227	US 2001-841749	20010424
	US 6469064	B2	20021022		
	EP 1276478	A2	20030122	EP 2001-928840	20010424
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2003531169	T2	20031021	JP 2001-577944	20010424
	US 2003078284	A1	20030424	US 2002-273702	20021018
PRAI	US 2000-199343P	P	20000424		
	US 2001-841749	A1	20010424		
	WO 2001-US13275	W	20010424		
OS	MARPAT 135:339276				

L9 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:730683 CAPLUS
 DN 135:288572
 TI Preparation of diphenyl ether compounds as serotonin re-uptake inhibitors
 IN Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072687	A1	20011004	WO 2001-IB428	20010319
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002052395	A1	20020502	US 2001-810378	20010316
	US 6448293	B2	20020910		
	EP 1268396	A1	20030102	EP 2001-917347	20010319
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009547	A	20030610	BR 2001-9547	20010319
	NZ 519972	A	20030725	NZ 2001-519972	20010319
	JP 2003528845	T2	20030930	JP 2001-570602	20010319
	BG 106912	A	20030131	BG 2002-106912	20020709
	NO 2002004663	A	20020927	NO 2002-4663	20020927
PRAI	GB 2000-7884	A	20000331		
	US 2000-197127P	P	20000414		
	WO 2001-IB428	W	20010319		
OS	MARPAT 135:288572				

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:249924 CAPLUS
 DN 135:190265
 TI Effect on sexual function of long-term treatment with selective serotonin
 reuptake inhibitors in depressed patients treated in primary care
 AU Ekselius, Lisa; von Knorring, Lars
 CS Department of Neuroscience, Psychiatry, University Hospital, Uppsala,
 S-751 85, Swed.
 SO Journal of Clinical Psychopharmacology (2001), 21(2), 154-160
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 19 9 all

L9 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:249924 CAPLUS
 DN 135:190265
 TI Effect on sexual function of long-term treatment with selective serotonin
 reuptake inhibitors in depressed patients treated in primary care
 AU Ekselius, Lisa; von Knorring, Lars
 CS Department of Neuroscience, Psychiatry, University Hospital, Uppsala,
 S-751 85, Swed.
 SO Journal of Clinical Psychopharmacology (2001), 21(2), 154-160
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)

AB This study prospectively examd. the occurrence and severity of sexual dysfunction symptoms in depressed patients before and after 6 mo of treatment with selective serotonin reuptake inhibitors. The study was part of a randomized, double-blind, controlled trial of sertraline or citalopram in patients with a DSM-III-R major depressive disorder treated by general practitioners. Three hundred eight patients (221 women and 87 men) were assessed before and after 6 mo of treatment by means of the Montgomery-Asberg Depression Rating Scale and five items from the Utvalg for Kliniske Undersogelser (UKU) Side Effect Scale covering different aspects of sexual functioning. As measured by the UKU Side Effect Scale, sexual desire and mean total score improved in women, and sexual desire improved in men. Men reported no change in orgasmic dysfunction, erectile dysfunction, or mean total score, but there was a trend toward worsening of **ejaculatory** dysfunction. However, in the subgroup of women who reported no sexual problems before treatment, 11.8% reported decreased sexual desire, and 14.3% reported orgasmic dysfunction at week 24. The corresponding figures in the same subgroup of men were 16.7% and 18.9%, resp., and as many as 25% experienced **ejaculatory** dysfunction after 24 wk. There were no significant differences between sertraline and citalopram in the magnitude or frequency of adverse sexual side effects.

ST antidepressant **serotonin reuptake inhibitor**
sex function adverse effect; sertraline citalopram sex function adverse effect

IT Antidepressants
Sex
Sexual behavior
(selective serotonin reuptake inhibitors effect on sexual function in depressed men and women)

IT 50-67-9, Serotonin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(reuptake inhibitors; selective serotonin reuptake inhibitors effect on sexual function in depressed men and women)

IT 59729-33-8, Citalopram 79617-96-2, Sertraline
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(selective serotonin reuptake inhibitors effect on sexual function in depressed men and women)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Baldwin, D; Antidepressant therapy at the dawn of the third millennium 1998, P231
- (2) Balon, R; J Clin Psychiatry 1993, V554, P209
- (3) Carek, D; J Am Acad Child Adolesc Psychiatry 1996, V35, P1106 MEDLINE
- (4) Casper, R; Arch Gen Psychiatry 1985, V42, P1098 MEDLINE
- (5) Cassidy, W; JAMA 1957, V164, P1535
- (6) Clayton, A; Psychopharmacol Bull 1995, V31, P397 CAPLUS
- (7) Ekselius, L; Int Clin Psychopharmacol 1997, V12, P323 MEDLINE
- (8) Elmore, J; Pharmacotherapy 1997, V17, P612 MEDLINE
- (9) Feldman, H; J Urol 1994, V151, P54 MEDLINE
- (10) Guy, W; ECDEU manual 1976, P217
- (11) Hamilton, M; J Neurol Neurosurg Psychiatry 1960, V12, P56
- (12) Harrison, W; J Clin Psychopharmacol 1986, V6, P144 MEDLINE
- (13) Herman, J; J Clin Psychiatry 1990, V51, P25 MEDLINE
- (14) Kline, M; Am J Psychiatry 1989, V146, P804 MEDLINE
- (15) Labbate, L; Biol Psychiatry 1998, V43, P904 CAPLUS
- (16) Labbate, L; J Sex Marital Ther 1998, V24, P3 MEDLINE
- (17) Lane, R; J Psychopharmacol 1997, V11, P72 CAPLUS
- (18) Lingjaerde, O; Acta Psychiatr Scand 1987, V76(suppl 334), P1
- (19) Montejo-Gonzales, A; J Sex Marital Ther 1997, V23, P176
- (20) Montgomery, S; Br J Psychiatry 1979, V134, P382 MEDLINE
- (21) Musher, J; Am J Psychiatry 1990, V147, P948 MEDLINE

- (22) Piazza, L; Am J Psychiatry 1997, V154, P1757 MEDLINE
 (23) Rosen, R; J Clin Psychopharmacol 1999, V19, P67 CAPLUS
 (24) Wise, T; J Clin Psychiatry Update Monogr 1994, V1, P19
 (25) Zajecka, J; Psychopharmacol Bull 1997, V33, P755 CAPLUS

=> d 19 8 all

L9 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:730683 CAPLUS
 DN 135:288572
 TI Preparation of diphenyl ether compounds as serotonin re-uptake inhibitors
 IN Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07C217-58
 ICS C07C229-38; C07C237-28; C07C255-43; C07C255-59; C07C311-05;
 C07C311-08; C07C311-37; C07C317-32; C07C323-20; C07C323-32;
 C07C323-67; C07D207-12; C07D231-38; C07D233-61; C07D249-06;
 C07D249-08; C07D295-08; C07D295-18; A61K031-137
 CC 25-9 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072687	A1	20011004	WO 2001-IB428	20010319
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002052395	A1	20020502	US 2001-810378	20010316
	US 6448293	B2	20020910		
	EP 1268396	A1	20030102	EP 2001-917347	20010319
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009547	A	20030610	BR 2001-9547	20010319
	NZ 519972	A	20030725	NZ 2001-519972	20010319
	JP 2003528845	T2	20030930	JP 2001-570602	20010319
	BG 106912	A	20030131	BG 2002-106912	20020709
	NO 2002004663	A	20020927	NO 2002-4663	20020927
PRAI	GB 2000-7884	A	20000331		
	US 2000-197127P	P	20000414		
	WO 2001-IB428	W	20010319		
OS	MARPAT 135:288572				
GI					



- AB Title compds. I [wherein R1 and R2 = independently H or (cycloalkyl)alkyl; or R1 and R2 together with the N to which they are attached form an azetidine ring; R3 = independently CF₃, OCF₃, alkylthio, or alkoxy; n = 1-3; R4 and R5 = independently AX; A = CH:CH or (CH₂)_p; p = 0-2; X = H, halo, OH, alkoxy, NO₂, CN, CHO, alkylthio, alkylsulfinyl, alkylsulfonyl, or (un)substituted carbamoyl, sulfamoyl, amino, carboxy, etc.; or pharmaceutically acceptable salts, solvates, or polymorphs thereof] were prepd. as monoamine re-uptake inhibitors, particularly as selective serotonin re-uptake inhibitors. For example, 4-(methylmercapto)phenol was coupled with 2-fluorobenzaldehyde using K₂CO₃ in DMF to give 2-[4-(methylsulfanyl)phenoxy]benzaldehyde (100%). The aldehyde was dissolved in THF, DCM, Me₂NH.bul.HCl, and TEA, treated with NaBH(OAc)₃, and converted to the salt with 1M HCl in Et₂O to afford N,N-dimethyl-N-[2-[4-(methylsulfanyl)phenoxy]benzyl]amine.bul.HCl (84%). Coupling the salt with ClSO₃H in CH₂Cl₂ at 0.degree. to 5.degree.C, followed by stepwise addn. of MeCN with POCl₃ and ammonia, produced the desired sulfonamide (II) in 61% yield. The latter showed serotonin re-uptake inhibition (SRI) activity with IC₅₀ .ltoreq. 50 nM and was > 100-fold as potent in the inhibition of serotonin re-uptake than in the the inhibition of dopamine and noradrenaline re-uptake. I are useful in the treatment of disorders such as depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders, and sexual dysfunction, including premature **ejaculation** (no data).
- ST diphenyl ether prepn **serotonin reuptake inhibitor**; ether diphenyl prepn antidepressant; attention deficit hyperactivity disorder treatment diphenyl ether prepn; obsessive compulsive disorder treatment diphenyl ether prepn; posttraumatic stress disorder treatment diphenyl ether prepn; substance abuse treatment diphenyl ether prepn; sexual dysfunction treatment diphenyl ether prepn
- IT Drugs of abuse
(abuse of, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)
- IT Mental disorder
(attention deficit hyperactivity disorder, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)
- IT Sexual behavior
(disorder, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)
- IT Stress, animal
(emotional, treatment of post-traumatic; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)
- IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(monoamine-transporting, modulator; prepn. of di-Ph ether compds. as

serotonin re-uptake inhibitors)

IT Mental disorder
(obsession-compulsion, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Sexual behavior
(premature **ejaculation**, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Antidepressants
(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 19555-09-0P, 3-Methoxy-4-(methysulfanyl)phenol 60789-49-3P,
1-(Methysulfanyl)-4-nitro-2-(trifluoromethyl)benzene 63094-56-4P,
4-(Methysulfanyl)-3-(trifluoromethyl)aniline 78940-67-7P 95920-60-8P,
5-(Allyloxy)-1,3-benzoxathiol-2-one 127087-14-3P, 4-Methoxy-3-
(methysulfanyl)phenol 170282-24-3P, 5-(Benzyloxy)-2-sulfanyphenol
170283-11-1P, 6-(Benzyloxy)-1,3-benzoxathiol-2-one 217186-17-9P
289717-37-9P 361212-81-9P 364323-56-8P 364323-57-9P 364323-58-0P
364323-59-1P 364323-60-4P 364323-61-5P 364323-62-6P 364323-63-7P
364323-64-8P 364323-65-9P 364323-66-0P 364323-67-1P 364323-68-2P
364323-69-3P 364323-71-7P 364323-72-8P 364323-73-9P 364323-74-0P
364323-75-1P 364323-76-2P 364323-77-3P 364323-78-4P 364323-79-5P
364323-80-8P 364323-81-9P 364323-82-0P 364323-83-1P 364323-84-2P
364323-85-3P 364323-86-4P 364323-87-5P 364323-88-6P 364323-89-7P
364323-90-0P 364323-91-1P 364323-92-2P 364323-93-3P 364323-95-5P
364323-96-6P 364323-97-7P 364323-98-8P 364323-99-9P 364324-00-5P
364324-01-6P 364324-02-7P 364324-03-8P 364324-04-9P 364324-05-0P
364324-06-1P 364324-07-2P 364324-08-3P 364324-09-4P 364324-10-7P
364324-11-8P 364324-12-9P 364324-13-0P 364324-14-1P 364324-15-2P
364324-16-3P 364324-17-4P 364324-18-5P 364324-19-6P 364324-20-9P
364324-22-1P 364324-23-2P 364324-24-3P 364324-25-4P 364324-26-5P
364324-27-6P 364324-28-7P 364324-29-8P 364324-30-1P 364324-31-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; prepn. of di-Ph ether compds. as serotonin re-uptake
inhibitors)

IT 364321-43-7P 364321-47-1P 364321-48-2P 364321-49-3P 364321-52-8P
364321-53-9P 364321-54-0P 364321-56-2P 364321-57-3P 364321-58-4P
364321-59-5P 364321-61-9P 364321-62-0P 364321-64-2P 364321-65-3P
364321-66-4P 364321-67-5P 364321-68-6P 364321-70-0P 364322-18-9P
364322-19-0P 364322-20-3P 364322-21-4P 364322-28-1P 364322-29-2P
364322-33-8P 364322-34-9P 364322-35-0P 364322-36-1P 364322-37-2P
364322-39-4P 364322-42-9P 364322-43-0P 364322-59-8P 364322-60-1P
364322-61-2P 364322-62-3P 364322-64-5P 364322-65-6P 364322-66-7P
364322-67-8P 364322-77-0P 364322-79-2P 364322-80-5P 364322-81-6P
364322-95-2P 364322-96-3P 364322-97-4P 364322-98-5P 364323-06-8P
364323-07-9P 364323-08-0P 364323-13-7P 364323-24-0P 364323-31-9P
364323-32-0P 364323-36-4P 364323-37-5P 364323-42-2P 364323-46-6P
364323-48-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)
(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 364321-41-5P 364321-42-6P 364321-44-8P 364321-45-9P 364321-46-0P
364321-50-6P 364321-51-7P 364321-55-1P 364321-71-1P 364321-72-2P
364321-73-3P 364321-74-4P 364321-76-6P 364321-78-8P 364321-80-2P
364321-81-3P 364321-83-5P 364321-85-7P 364321-87-9P 364321-89-1P
364321-90-4P 364321-91-5P 364321-92-6P 364321-93-7P 364321-94-8P
364321-95-9P 364321-96-0P 364321-97-1P 364321-98-2P 364321-99-3P
364322-00-9P 364322-01-0P 364322-02-1P 364322-03-2P 364322-04-3P
364322-06-5P 364322-07-6P 364322-08-7P 364322-09-8P 364322-10-1P
364322-11-2P 364322-12-3P 364322-13-4P 364322-14-5P 364322-15-6P
364322-16-7P 364322-17-8P 364322-22-5P 364322-23-6P 364322-24-7P

364322-25-8P	364322-26-9P	364322-27-0P	364322-30-5P	364322-31-6P
364322-32-7P	364322-38-3P	364322-41-8P	364322-44-1P	364322-45-2P
364322-46-3P	364322-47-4P	364322-48-5P	364322-49-6P	364322-50-9P
364322-51-0P	364322-52-1P	364322-53-2P	364322-54-3P	364322-55-4P
364322-56-5P	364322-57-6P	364322-58-7P	364322-68-9P	364322-69-0P
364322-70-3P	364322-71-4P	364322-72-5P	364322-73-6P	364322-74-7P
364322-76-9P	364322-78-1P	364322-82-7P	364322-83-8P	364322-84-9P
364322-85-0P	364322-86-1P	364322-87-2P	364322-88-3P	364322-89-4P
364322-90-7P	364322-91-8P	364322-92-9P	364322-93-0P	364322-94-1P
364322-99-6P	364323-00-2P	364323-01-3P	364323-02-4P	364323-04-6P
364323-05-7P	364323-09-1P	364323-10-4P	364323-11-5P	364323-12-6P
364323-14-8P	364323-15-9P	364323-16-0P	364323-17-1P	364323-18-2P
364323-19-3P	364323-20-6P	364323-21-7P	364323-22-8P	364323-23-9P
364323-25-1P	364323-26-2P	364323-27-3P	364323-28-4P	364323-29-5P
364323-30-8P	364323-33-1P	364323-34-2P	364323-35-3P	364323-38-6P
364323-39-7P	364323-40-0P	364323-41-1P	364323-43-3P	364323-45-5P
364323-47-7P	364323-49-9P	364323-50-2P	364323-51-3P	364323-52-4P
364323-53-5P	364323-54-6P	364323-55-7P	364324-32-3P	364324-33-4P
364324-34-5P	364324-36-7P	364324-37-8P	364324-38-9P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 50-67-9, Serotonin, biological studies 51-41-2, Noradrenaline 51-61-6, Dopamine, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 79-06-1, Acrylamide, reactions 98-17-9, 3-(Trifluoromethyl)phenol
 105-56-6 106-41-2, 4-Bromophenol 106-95-6, Allyl bromide, reactions
 109-85-3, 2-Methoxyethylamine 110-91-8, Morpholine, reactions
 288-32-4, Imidazole, reactions 288-36-8, 1H-1,2,3-Triazole 400-74-8,
 2-Fluoro-5-nitrobenzotrifluoride 402-45-9, 4-(Trifluoromethyl)phenol
 446-52-6, 2-Fluorobenzaldehyde 598-41-4, Glycinamide 771-61-9,
 Pentafluorophenol 827-99-6, 3-(Trifluoromethoxy)phenol 828-27-3,
 4-(Trifluoromethoxy)phenol 1073-72-9, 4-(Methylmercapto)phenol
 1820-80-0, 3-Amino-1H-pyrazole 2386-58-5, Vinylsulfonamide 2516-47-4,
 Cyclopropylmethanamine 2646-90-4, 2,5-Difluorobenzaldehyde 2749-11-3,
 (S)-2-Amino-1-propanol 2799-21-5 4991-65-5,
 6-Hydroxy-1,3-benzoxathiol-2-one 6361-21-3, 2-Chloro-5-nitrobenzaldehyde
 7735-56-0, 5-Hydroxy-1,3-benzoxathiol-2-one 10147-37-2, 2-Propylsulfonyl
 chloride 16114-05-9 16588-02-6, 2-Chloro-5-nitrobenzonitrile
 35320-23-1 36520-39-5, Azetidine hydrochloride 51517-01-2,
 2-Methoxyethylsulfonyl chloride 57848-46-1, 4-Bromo-2-fluorobenzaldehyde
 71924-62-4, 2-Fluoro-4,5-dimethoxybenzaldehyde 93777-26-5,
 5-Bromo-2-fluorobenzaldehyde 105728-90-3, 2-Fluoro-5-methoxybenzaldehyde
 112887-25-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Akzo; EP 0516234 A 1992 CAPLUS
- (2) Buckley, A; US 5334748 A 1994 CAPLUS
- (3) Kametani, T; JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY 1968, 23, P2877 CAPLUS
- (4) Manske, R; JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 1950, V72(10), P4797
- (5) Pfizer; EP 0415613 A 1991 CAPLUS
- (6) Pfizer Products; WO 0050380 A 2000 CAPLUS
- (7) Yeager, G; SYNTHESIS 1995, 1, P28 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 12:20:03 ON 25 NOV 2003)

FILE 'REGISTRY' ENTERED AT 12:20:14 ON 25 NOV 2003

E DAPOXETINE

L1 2 S E3

FILE 'CAPLUS' ENTERED AT 12:21:05 ON 25 NOV 2003

L2 14 S L1

L3 0 S SELECTIVE SEROTININ REUPTAKE INHIBITOR

L4 697 S SELECTIVE SEROTONIN REUPTAKE INHIBITOR

E EJACULATION

L5 1881 S E1-E10

L6 18 S L4 AND L5

L7 1329 S SEROTONIN REUPTAKE INHIBITOR

L8 27 S L7 AND L5

L9 9 S L8 NOT L6

=> s serotonin

L10 62015 SEROTONIN

=> s l10 and l5

L11 166 L10 AND L5

=> s l11 not l9

L12 157 L11 NOT L9

=> s l12 not l6

L13 139 L12 NOT L6

=> d l13 20-50

L13 ANSWER 20 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:732456 CAPLUS

DN 136:47860

TI Venlafaxine extended-release: A review of its use in the management of major depression

AU Wellington, Keri; Perry, Caroline M.

CS Adis International Limited, Auckland, N. Z.

SO CNS Drugs (2001), 15(8), 643-669

CODEN: CNDREF; ISSN: 1172-7047

PB Adis International Ltd.

DT Journal; General Review

LA English

RE.CNT 125 THERE ARE 125 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 21 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:666884 CAPLUS

DN 135:190426

TI Use of antidepressants for treatment of premature **ejaculation**

IN Claro do Nascimento, Edson

PA Brazil

SO Braz. Pedido PI, 12 pp.

CODEN: BPXXDX

DT Patent

LA Portuguese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	BR 9806330	A	20000912	BR 1998-6330	19980826

L13 ANSWER 22 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:429363 CAPLUS
DN 135:251859
TI Antidepressants and **ejaculation**: a double-blind, randomized,
placebo-controlled, fixed-dose study with paroxetine, sertraline, and
nefazodone
AU Waldinger, Marcel D.; Zwinderman, Aeilko H.; Olivier, Berend
CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, The Hague,
2545 CH, Neth.
SO Journal of Clinical Psychopharmacology (2001), 21(3), 293-297
CODEN: JCPYDR; ISSN: 0271-0749
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 23 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:424774 CAPLUS
DN 136:177788
TI Comparison of peripheral inhibitory effects of clomipramine with selective
serotonin re-uptake inhibitors on contraction of vas deferens: In
vitro and in vivo studies
AU Seo, Kyung Keun; Kim, Sae Chul; Lee, Moo Yeol
CS Department of Urology and Physiology, College of Medicine, Chung-Ang
University, Seoul, S. Korea
SO Journal of Urology (Hagerstown, MD, United States) (2001), 165(6, Pt. 1),
2110-2114
CODEN: JOURAA; ISSN: 0022-5347
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 24 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:341653 CAPLUS
DN 135:31573
TI New reproductive anomalies in fruitless-mutant Drosophila males: extreme
lengthening of mating durations and infertility correlated with defective
serotonergic innervation of reproductive organs
AU Lee, Gyunghhee; Vilella, Adriana; Taylor, Barbara J.; Hall, Jeffrey C.
CS Department of Biology, Brandeis University, Waltham, MA, 02454, USA
SO Journal of Neurobiology (2001), 47(2), 121-149
CODEN: JNEUBZ; ISSN: 0022-3034
PB John Wiley & Sons, Inc.
DT Journal
LA English
RE.CNT 92 THERE ARE 92 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 25 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:331316 CAPLUS
DN 134:320885
TI Administration of 5-HT receptor agonists and antagonists to treat
premature **ejaculation**
IN Smith, William L.; Doherty, Paul C., Jr.; Place, Virgil A.
PA Vivus, Inc., USA
SO U.S., 13 pp., Cont.-in-part of U.S. 6,037,360.
CODEN: USXXAM

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6228864	B1	20010508	US 1998-181071	19981027
	US 6037360	A	20000314	US 1997-959061	19971028
	CA 2305293	AA	19990506	CA 1998-2305293	19981028
	EP 1027011	A1	20000816	EP 1998-955189	19981028
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AU 742339	B2	20011220	AU 1999-12054	19981028
	JP 2003525844	T2	20030902	JP 2000-517673	19981028
	US 2001008896	A1	20010719	US 2001-793839	20010226
PRAI	US 1997-958571	A2	19971028		
	US 1997-959061	A2	19971028		
	US 1998-181071	A	19981027		
	WO 1998-US22929	W	19981028		

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 26 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:209893 CAPLUS
DN 135:175118
TI Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients
AU Montejo, Angel L.; Llorca, Gines; Izquierdo, Juan A.; Rico-Villademoros, Fernando
CS University Hospital of Salamanca, University of Salamanca, Salamanca, Spain
SO Journal of Clinical Psychiatry (2001), 62(Suppl. 3), 10-21
CODEN: JCLPDE; ISSN: 0160-6689
PB Physicians Postgraduate Press, Inc.
DT Journal
LA English

RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 27 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:164143 CAPLUS
DN 134:217494
TI Selectively bred male rat lines differ in naive and experienced sexual behavior
AU Sura, A.; Overstreet, D. H.; Marson, L.
CS Department of Urology, University of North Carolina, Chapel Hill, NC, 27599, USA
SO Physiology & Behavior (2001), 72(1/2), 13-20
CODEN: PHBHA4; ISSN: 0031-9384
PB Elsevier Science Inc.
DT Journal
LA English

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 28 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:50017 CAPLUS
DN 135:116245
TI Venlafaxine extended-release: A review of its clinical potential in the management of generalized anxiety disorder
AU Balfour, Julia A. Barman; Jarvis, Blair
CS Adis International Limited, Auckland, N. Z.
SO CNS Drugs (2000), 14(6), 483-503

CODEN: CNDREF; ISSN: 1172-7047

PB Adis International Ltd.
DT Journal; General Review
LA English

RE.CNT 119 THERE ARE 119 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 29 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:49512 CAPLUS

DN 134:172981

TI Effect of **serotonin** uptake inhibitors on **serotonin**
metabolism in the hypothalamus of freely moving rats

AU Song, Yun Seob; Yoon, Se Na; Jung, Dong Sik; Yoo, Sang Hee; Ryu, Hyong
Kyun; Kim, Hyung Gun

CS Department of Urology, College of Medicine, Soonchunhyang University,
Seoul, 140 - 743, S. Korea

SO Korean Journal of Physiology & Pharmacology (2000), 4(6), 439-444
CODEN: KJPPFS; ISSN: 1226-4512

PB Korean Physiological Society

DT Journal

LA English

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 30 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:834273 CAPLUS

DN 134:37414

TI Characterization of p-chloroamphetamine-induced penile erection and
ejaculation in anesthetized rats

AU Yonezawa, Akihiko; Watanabe, Chizuko; Ando, Ryuichiro; Furuta, Seiichi;
Sakurada, Shinobu; Yoshimura, Hiroyuki; Iwanaga, Toshihiko; Kimura, Yukio

CS Department of Physiology and Anatomy, Tohoku Pharmaceutical University,
Sendai, 981-8558, Japan

SO Life Sciences (2000), 67(25), 3031-3039

CODEN: LIFSAK; ISSN: 0024-3205

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 31 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:821422 CAPLUS

DN 134:95578

TI The neurobiology of sexual function

AU Meston, Cindy M.; Frohlich, Penny F.

CS Department of Psychology, University of Texas, Austin, USA

SO Archives of General Psychiatry (2000), 57(11), 1012-1030

CODEN: ARGPAQ; ISSN: 0003-990X

PB American Medical Association

DT Journal; General Review

LA English

RE.CNT 299 THERE ARE 299 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 32 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:709284 CAPLUS

DN 134:25652

TI **Serotonin** and sexual behavior in the male rabbit

AU Paredes, R. G.; Contreras, J. L.; Agmo, A.

CS Escuela de Psicología, Universidad Anahuac, Mexico City, Mex.

SO Journal of Neural Transmission (2000), 107(7), 767-777

CODEN: JNTRF3; ISSN: 1435-1463

PB Springer-Verlag Wien

DT Journal

LA English

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 33 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:660962 CAPLUS

DN 133:305842

TI Acute low doses of melatonin restore full sexual activity in impotent male rats

AU Drago, F.; Busa, L.

CS Institute of Pharmacology, Faculty of Medicine, University of Catania Medical School, Catania, 95125, Italy

SO Brain Research (2000), 878(1,2), 98-104

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 34 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:628107 CAPLUS

DN 133:222454

TI Preparation of 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamines for treatment of disorders involving regulation of monoamine transporter function.

IN Middleton, Donald Stuart; Stobie, Alan

PA Pfizer Limited, UK; Pfizer Inc.

SO PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051972	A1	20000908	WO 2000-IB182	20000218
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
BR 2000009238	A	20011120	BR 2000-9238	20000218
EP 1157002	A1	20011128	EP 2000-901861	20000218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002538134	T2	20021112	JP 2000-602200	20000218
PRAI GB 1999-4691	A	19990301		
GB 1999-21314	A	19990909		
WO 2000-IB182	W	20000218		

OS CASREACT 133:222454; MARPAT 133:222454

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 35 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:530570 CAPLUS

DN 133:217588
TI Stimulation of **ejaculatory** behavior by the 5-HT1B receptor
antagonist isamoltane in citalopram-pretreated male rats
AU Ahlenius, Sven; Larsson, Knut
CS Department of Physiology and Pharmacology, Karolinska Institute,
Stockholm, SE-171 77, Swed.
SO Pharmacy and Pharmacology Communications (2000), 6(7), 317-320
CODEN: PPCOFN; ISSN: 1460-8081
PB Royal Pharmaceutical Society of Great Britain
DT Journal
LA English
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 36 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:382813 CAPLUS
DN 133:165
TI New directions in the treatment of antidepressant-induced sexual
dysfunction
AU Rothschild, Anthony J.
CS Department of Psychiatry, University of Massachusetts Medical School,
Worcester, MA, USA
SO Clinical Therapeutics (2000), 22(Suppl. A), A42-A61
CODEN: CLTHDG; ISSN: 0149-2918
PB Excerpta Medica, Inc.
DT Journal; General Review
LA English
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 37 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:381064 CAPLUS
DN 133:247195
TI Inhibitory effect of serotonergic drugs on contractile response of the rat
vas deferens to electrical nerve stimulation: in vivo study
AU Kim, Sae Chul; Seo, Kyung Keun; Han, Jun Hyun; Lee, Moo Yeol
CS Department of Urology and Physiology, Chung-Ang University, Seoul,
140-757, S. Korea
SO Journal of Urology (Baltimore) (2000), 163(6), 1988-1991
CODEN: JOURAA; ISSN: 0022-5347
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 38 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:155970 CAPLUS
DN 132:289035
TI Melatonin enhances sexual behavior in the male rat
AU Brotto, L. A.; Gorzalka, B. B.
CS Department of Psychology, The University of British Columbia, Vancouver,
BC, Can.
SO Physiology & Behavior (2000), 68(4), 483-486
CODEN: PHBHA4; ISSN: 0031-9384
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 39 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:775955 CAPLUS
DN 132:117832
TI Acute low doses of melatonin stimulate rat sex behavior: the role of
serotonin neurotransmission
AU Drago, F.; Busa, L.; Benelli, A.; Bertolini, A.
CS Viale Andrea Doria 6, Institute of Pharmacology, University of Catania
Medical School, Catania, 95125, Italy
SO European Journal of Pharmacology (1999), 385(1), 1-6
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 40 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:635861 CAPLUS
DN 131:306687
TI Synergistic actions of the 5-HT1A receptor antagonist WAY-100635 and
citalopram on male rat **ejaculatory** behavior
AU Ahlenius, Sven; Larsson, Knut
CS Department of Physiology and Pharmacology, Karolinska Institute,
Stockholm, SE-171 77, Swed.
SO European Journal of Pharmacology (1999), 379(1), 1-6
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 41 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:578145 CAPLUS
DN 131:208360
TI Paroxetine: A review of its use in social anxiety disorder
AU Prakash, Amitabh; Foster, Rachel H.
CS Adis International Limited, Auckland, N. Z.
SO CNS Drugs (1999), 12(2), 151-169
CODEN: CNDREF; ISSN: 1172-7047
PB Adis International Ltd.
DT Journal; General Review
LA English
RE.CNT 101 THERE ARE 101 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 42 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:476697 CAPLUS
DN 131:252438
TI Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with
oxytocin
AU Cantor, James M.; Binik, Yitzchak M.; Pfaus, James G.
CS Department of Psychology, McGill University, Montreal, QC, Can.
SO Psychopharmacology (Berlin) (1999), 144(4), 355-362
CODEN: PSCHDL; ISSN: 0033-3158
PB Springer-Verlag
DT Journal
LA English
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 43 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:443336 CAPLUS

DN 131:194676
TI 5-Hydroxytryptamine2C receptors on spinal neurons controlling penile erection in the rat
AU Bancila, M.; Verge, D.; Rampin, O.; Backstrom, J. R.; Sanders-Bush, E.; Mckenna, K. E.; Marson, L.; Calas, A.; Giuliano, F.
CS Departement de Neurobiologie des Signaux Intercellulaires, Institut des Neurosciences, CNRS UMR 7624, Universite Pierre et Marie Curie, Paris, 75005, Fr.
SO Neuroscience (Oxford) (1999), 92(4), 1523-1537
CODEN: NRSCDN; ISSN: 0306-4522
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 44 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:237729 CAPLUS
DN 131:39044
TI Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders
AU Heydorn, William E.
CS Synaptic Pharmaceutical Corporation, Paramus, NJ, 07652, USA
SO Expert Opinion on Investigational Drugs (1999), 8(4), 417-441
CODEN: EOIDER; ISSN: 1354-3784
PB Ashley Publications
DT Journal; General Review
LA English
RE.CNT 174 THERE ARE 174 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 45 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:112861 CAPLUS
DN 130:321086
TI Partial antagonism of 8-OH-DPAT'S effects on male rat sexual behavior with a D2, but not a 5-HT1A, antagonist
AU Matuszewich, Leslie; Lorrain, Daniel S.; Trujillo, Robert; Dominguez, Juan; Putnam, Susan K.; Hull, Elaine M.
CS Department of Psychology, State University of New York at Buffalo, Buffalo, NY, 14260-4110, USA
SO Brain Research (1999), 820(1,2), 55-62
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 46 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:98999 CAPLUS
DN 130:246107
TI Effects of SSRIs on sexual function: a critical review
AU Rosen, Raymond C.; Lane, Roger M.; Menza, Matthew
CS Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, 08854, USA
SO Journal of Clinical Psychopharmacology (1999), 19(1), 67-85
CODEN: JCPYDR; ISSN: 0271-0749
PB Lippincott Williams & Wilkins
DT Journal; General Review
LA English
RE.CNT 255 THERE ARE 255 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 47 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:21279 CAPLUS
DN 130:218141
TI The effects of fluoxetine on several neurophysiological variables in patients with premature **ejaculation**
AU Yilmaz, Ugur; Tatlisin, Atila; Turan, Handan; Arman, Fehim; Ekmekcioglu, Oguz
CS Departments of Urology and Neurology, Erciyes University Medical Faculty, Gevher Nesibe Research and Training Hospital, Kayseri, Turk.
SO Journal of Urology (Baltimore) (1999), 161(1), 107-111
CODEN: JOURAA; ISSN: 0022-5347
PB Lippincott Williams & Wilkins
DT Journal
LA English

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 48 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:708535 CAPLUS
DN 130:205295
TI Sexual behavior and wet dog shakes in the male rat: regulation by corticosterone
AU Gorzalka, Boris B.; Hanson, Laura A.
CS Department of Psychology, The University of British Columbia, Vancouver, BC, V6T 1Z4, Can.
SO Behavioural Brain Research (1998), 97(1,2), 143-151
CODEN: BBREDI; ISSN: 0166-4328
PB Elsevier Science B.V.
DT Journal
LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 49 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:571942 CAPLUS
DN 129:310807
TI In vivo evaluation of serotonergic agents and .alpha.-adrenergic blockers on premature **ejaculation** by inhibiting the seminal vesicle pressure response to electrical nerve stimulation
AU Hsieh, J. T.; Chang, H. C.; Law, H. S.; Hsieh, C. H.; Cheng, J. T.
CS Department of Urology, College of Medicine, National Taiwan University, Taipei, Taiwan
SO British Journal of Urology (1998), 82(2), 237-240
CODEN: BJURAN; ISSN: 0007-1331
PB Blackwell Science Ltd.
DT Journal
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 50 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:550222 CAPLUS
DN 129:288230
TI Potentiation of **ejaculatory** activity by median raphe nucleus lesions in male rats: effect of p-chlorophenylalanine
AU Kondo, Yasuhiko; Yamanouchi, Korehito
CS Department of Physiology, Nippon Medical School, Tokyo, 113, Japan
SO Endocrine Journal (Tokyo) (1997), 44(6), 873-879
CODEN: ENJOEO; ISSN: 0918-8959
PB Japan Endocrine Society
DT Journal

LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 113 46 all

L13 ANSWER 46 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:98999 CAPLUS

DN 130:246107

TI Effects of SSRIs on sexual function: a critical review

AU Rosen, Raymond C.; Lane, Roger M.; Menza, Matthew

CS Department of Psychiatry, Robert Wood Johnson Medical School, University
of Medicine and Dentistry of New Jersey, Piscataway, NJ, 08854, USA

SO Journal of Clinical Psychopharmacology (1999), 19(1), 67-85

CODEN: JCPYDR; ISSN: 0271-0749

PB Lippincott Williams & Wilkins

DT Journal; General Review

LA English

CC 1-0 (Pharmacology)

AB A review with 255 refs. Sexual problems are highly prevalent in both men and women and are affected by, among other factors, mood state, interpersonal functioning, and psychotropic medications. The incidence of antidepressant-induced sexual dysfunction is difficult to est. because of the potentially confounding effects of the illness itself, social and interpersonal comorbidities, medication effects, and design and assessment problems in most studies. Ests. of sexual dysfunction vary from a small percentage to more than 80%. This article reviews current evidence regarding sexual side effects of selective **serotonin** reuptake inhibitors (SSRIs). Among the sexual side effects most commonly assocd. with SSRIs are delayed **ejaculation** and absent or delayed orgasm. Sexual desire (libido) and arousal difficulties are also frequently reported, although the specific assocn. of these disorders to SSRI use has not been consistently shown. The effects of SSRIs on sexual functioning seem strongly dose-related and may vary among the group according to **serotonin** and dopamine reuptake mechanisms, induction of prolactin release, anticholinergic effects, inhibition of nitric oxide synthetase, and propensity for accumulation over time. A variety of strategies have been reported in the management of SSRI-induced sexual dysfunction, including waiting for tolerance to develop, dosage redn., drug holidays, substitution of another antidepressant drug, and various augmentation strategies with 5-hydroxytryptamine-2 (5-HT₂), 5-HT₃, and .alpha.₂ adrenergic receptor antagonists, 5-HT_{1A} and dopamine receptor agonists, and phosphodiesterase (PDE5) enzyme inhibitors. Sexual side effects of SSRIs should not be viewed as entirely neg.; some studies have shown improved control of premature **ejaculation** in men. The impacts of sexual side effects of SSRIs on treatment compliance and on patients' quality of life are important clin. considerations.

ST **serotonin** reuptake inhibitors sexual disorder review

IT Sexual behavior

(disorder; effects of SSRIs on sexual function in humans)

IT 50-67-9, **Serotonin**, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(selective **serotonin** reuptake inhibitors; effects of SSRIs on sexual function in humans)

RE.CNT 255 THERE ARE 255 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Adaikan, P; J Auton Pharmacol 1983, V3, P107 CAPLUS

(2) Agren, H; New Research Abstracts from the American Psychiatric Association Annual Meeting 1998

(3) Ahlenius, S; Pharmacol Biochem Behav 1981, V15, P758

(4) Ahmad, S; Arch Intern Med 1995, V155, P645 MEDLINE

- (5) Aizenberg, D; Clin Neuropharmacol 1995, V18, P320 CAPLUS
- (6) Aizenberg, D; Clin Neuropharmacol 1997, V20, P210 CAPLUS
- (7) Aldrich, A; Clin Drug Invest 1996, V11, P353 CAPLUS
- (8) Amsterdam, J; J Affect Disord 1998, V46, P151
- (9) Anand, V; Br J Psychiatry 1985, V147, P87 MEDLINE
- (10) Araujo, A; Psychosom Med 1998, V60, P458 MEDLINE
- (11) Arnott, S; Br J Psychiatry 1994, V164, P838 MEDLINE
- (12) Ascher, J; J Clin Psychiatry 1995, V56, P395 MEDLINE
- (13) Ashton, A; J Clin Psychiatry 1998, V59, P112 CAPLUS
- (14) Ashton, A; J Sex Marital Ther 1997, V23, P165
- (15) Assalian, P; J Sex Res 1988, V24, P213
- (16) Ayd, F; Int Drug Ther Newslett 1982, V17, P37
- (17) Baier, D; Fortschr Neurol Psychiatr 1994, V62, P14 MEDLINE
- (18) Baldessarini, R; Arch Gen Psychiatry 1990, V47, P191 MEDLINE
- (19) Ballenger, J; Am J Psychiatry 1998, V155, P36 MEDLINE
- (20) Balogh, S; J Clin Psychiatry 1992, V53, P212 MEDLINE
- (21) Balogh, S; J Clin Psychiatry 1993, V54, P115
- (22) Balon, R; J Clin Psychiatry 1993, V54, P209 MEDLINE
- (23) Balon, R; J Sex Marital Ther 1996, V22, P290 MEDLINE
- (24) Barbeau, A; Can Med Assoc J 1969, V101, P59 MEDLINE
- (25) Bartlick, B; J Sex Marital Ther 1995, V21, P264
- (26) Bartlick, B; Primary Psychiatry 1995, V2, P13
- (27) Bennazi, F; J Psychopharmacol 1997, V2, P190
- (28) Bennazi, F; Pharmacopsychiatry 1994, V27, P246
- (29) Bennie, E; J Clin Psychiatry 1995, V56, P229 MEDLINE
- (30) Benson, G; J Clin Invest 1980, V65, P506 CAPLUS
- (31) Berk, M; Int J Psychopharmacol 1997, V12, P121 MEDLINE
- (32) Bisserbe, J; Eur Psychiatry 1997, V12, P82
- (33) Bitran, D; Neurosci Biobehav Rev 1998, V11, P365
- (34) Blashko, C; Eur Neuropsychopharmacol 1995, V5, P258
- (35) Bodkin, J; J Clin Psychiatry 1997, V58, P137 CAPLUS
- (36) Bolden-Watson, C; Life Sci 1993, V52, P1023 CAPLUS
- (37) Bouchard, R; Am J Psychiatry 1989, V146, P1352
- (38) Bradford, J; Poster presented at the 148th annual meeting of the American Psychiatric Association 1995
- (39) Bredt, D; Nature 1991, V351, P714 CAPLUS
- (40) Bronzo, M; Am J Psychiatry 1993, V150, P1269 MEDLINE
- (41) Carek, D; J Am Acad Child Adolesc Psychiatry 1996, V35, P1106 MEDLINE
- (42) Casper, R; Arch Gen Psychiatry 1985, V42, P1098 MEDLINE
- (43) Cassidy, W; JAMA 1957, V164, P1535
- (44) Castaneda, R; J Clin Psychiatry 1996, V57, P485 MEDLINE
- (45) Cavallini, G; Eur Urol 1996, V30(suppl 2), P840
- (46) Christensen, R; J Clin Psychiatry 1995, V56, P433 MEDLINE
- (47) Clayton, A; Poster presented at the 37th Annual New Clinical Drug Evaluation Unit Meeting 1997
- (48) Clayton, A; Psychopharmacol Bull 1995, V31, P397 CAPLUS
- (49) Clayton, A; Psychopharmacol Bull 1997, V33, P747 MEDLINE
- (50) Cohen, A; J Sex Marital Ther 1998, V24, P139 MEDLINE
- (51) Cohen, M; Adverse Drug React Bull 1998, V190, P723
- (52) Coupland, M; J Clin Psychopharmacol 1996, V16, P356
- (53) Cowen, P; J Psychopharmacol 1997, V4, P345
- (54) Crenshaw, T; Sexual pharmacology:drugs that affect sexual functioning 1996, P285
- (55) Crenshaw, T; Sexual pharmacology:drugs that affect sexual functioning 1996, P369
- (56) Danjou, P; Br J Clin Pharmacol 1988, V26, P733 CAPLUS
- (57) Deijen, J; J Psychopharmacol 1989, V3, P149 CAPLUS
- (58) Derogatis, L; J Sex Marital Ther 1979, V5, P244 MEDLINE
- (59) Dorevitch, A; Ann Pharmacother 1994, V28, P872 MEDLINE
- (60) Dunner, D; J Clin Psychiatry 1992, V53(suppl 2), P21
- (61) Eaton, H; J Int Med Res 1973, V18, P701
- (62) Eke, T; BMJ 1997, V314, P1387 MEDLINE

- (63) Ekselius, L; Eur Neuropsychopharmacology 1997, V7(suppl 2), PS147
- (64) Ellison, J; J Clin Psychiatry 1996, V57, P596 MEDLINE
- (65) Elmore, J; Pharmacol Ther 1997, V17, P612 MEDLINE
- (66) Ereshefsky, L; J Clin Psychopharmacol 1996, V16(suppl 2), P37S
- (67) Fabre, L; Biol Psychiatry 1995, V38, P592 CAPLUS
- (68) Fahlen, T; Eur Neuropsychopharmacol 1996, V6(suppl 3), P127
- (69) Fava, M; Poster presented at the first CINP Congress 1998
- (70) Fava, M; Psychosom Psychother (in press)
- (71) Feder, R; J Clin Psychiatry 1991, V52, P163 MEDLINE
- (72) Feiger, A; J Clin Psychiatry 1996, V57(suppl 2), P53
- (73) Feighner, J; Presented at the 37th annual meeting of the New Clinical Drug Evaluation Unit 1997
- (74) Feldman, H; J Urol 1994, V151, P54 MEDLINE
- (75) Fernandez-Guasti, A; Pharmacol Biochem Behav 1992, V42, P529 CAPLUS
- (76) Finkel, M; Psychopharmacol Bull 1996, V32, P653 CAPLUS
- (77) Fisher, S; J Clin Psychopharmacol 1993, V13, P235 MEDLINE
- (78) Florante, J; J Urol 1998, V159(suppl), P241
- (79) Foreman, M; Life Sci 1989, V45, P1263 CAPLUS
- (80) Forster, P; Am J Psychiatry 1994, V151, P1523 MEDLINE
- (81) Fowlie, S; Scott Med J 1987, V32, P52 MEDLINE
- (82) Freeman, P; J Clin Psychiatry 1994, V55, P301
- (83) Garcia-Campayo, J; Acta Psychiatr Scand 1995, V91, P69 MEDLINE
- (84) Gardner, E; J Clin Psychopharmacol 1995, V15, P24
- (85) Gelenberg, A; Poster presented at the 36th annual meeting of the American College of Neuropsychopharmacology 1997
- (86) Gelenberg, A; The practitioner's guide to psychoactive drugs 3rd ed 1991, P1997
- (87) Geretsegger, C; Int Clin Psychopharmacol 1994, V9, P25 MEDLINE
- (88) Gerner, R; Biol Psychiatry 1998, V43, P99S
- (89) Gitlin, M; J Clin Psychiatry 1994, V55, P406 MEDLINE
- (90) Gitlin, M; J Clin Psychiatry 1995, V56, P124 MEDLINE
- (91) Goldbloom, D; J Clin Psychiatry 1991, V52, P261 MEDLINE
- (92) Goldstein, B; J Psychopharmacol 1998, V12(suppl B), PS55
- (93) Goodnick, P; J Psychopharmacol 1998, V12(suppl), P5
- (94) Gordon, C; Psychopharmacology (Berl) 1998, V137, P201 CAPLUS
- (95) Grady, T; J Clin Psychopharmacol 1992, V12, P70 MEDLINE
- (96) Graziottin, A; Psychopharmacology 1995, V153, P474A
- (97) Greist, J; Arch Gen Psychiatry 1995, V52, P289 MEDLINE
- (98) Grimes, J; Biol Psychiatry 1996, V40, P1184 MEDLINE
- (99) Haensel, S; J Clin Psychopharmacol 1998, V18, P72 CAPLUS
- (100) Hall, M; Am J Psychiatry 1994, V129, P738
- (101) Hamilton, M; J Neurol Neurosurg Psychiatry 1960, V12, P56
- (102) Harrison, W; J Clin Psychopharmacol 1986, V6, P144 MEDLINE
- (103) Harvey, K; Ann Clin Psychiatry 1995, V7, P189 MEDLINE
- (104) Hawton, K; Br J Psychiatry 1982, V140, P94 MEDLINE
- (105) Herman, J; J Clin Psychiatry 1990, V51, P25 MEDLINE
- (106) Hindmarch, I; Hum Psychopharmacol 1988, V3, P13
- (107) Hollander, E; J Clin Psychiatry 1992, V53, P207 MEDLINE
- (108) Hollander, E; J Clin Psychiatry 1992, V53, P28 MEDLINE
- (109) Hsu, J; Int J Psychiatry Med 1995, V25, P191 MEDLINE
- (110) Hyttel, J; Nordic J Psychiatry 1993, V47(suppl 30), P5
- (111) Jacobsen, F; J Clin Psychiatry 1991, V52S, P271
- (112) Jacobsen, F; J Clin Psychiatry 1992, V53, P119 MEDLINE
- (113) Joffe, R; J Clin Psychiatry 1993, V54, P269 MEDLINE
- (114) Kafka, M; Ann Clin Psychiatry 1994, V6, P189 MEDLINE
- (115) Kaplan, P; J Sex Marital Ther 1994, V20, P321 MEDLINE
- (116) Kara, H; J Urol 1996, V156, P1631 CAPLUS
- (117) Katz, R; J Clin Psychiatry 1994, V55, P314 MEDLINE
- (118) Kavoussi, R; J Clin Psychiatry 1997, V58, P532 CAPLUS
- (119) Kerr, J; Int Clin Psychopharmacol 1992, V7, P101 MEDLINE
- (120) Kiev, A; J Clin Psychiatry 1997, V58, P146 CAPLUS
- (121) Kindler, S; Clin Neuropharmacol 1997, V20, P466 CAPLUS

- (122) Kivela, S; Z Gerontol 1988, V21, P257 MEDLINE
- (123) Kline, M; Am J Psychiatry 1989, V146, P804 MEDLINE
- (124) Klinge, E; Acta Physiol Scand 1997, V100, P354
- (125) Klug, B; Med J Aust 1984, V141, P71 MEDLINE
- (126) Koutouvidis, N; Eur Neuropsychopharmacol 1997, V7(suppl 2), P156
- (127) Kowalski, A; Br J Psychiatry 1985, V147, P413 MEDLINE
- (128) Labbate, L; Ann Clin Psychiatry 1994, V6, P13 MEDLINE
- (129) Labbate, L; Biol Psychiatry 1998, V43, P904 CAPLUS
- (130) Labbate, L; J Sex Marital Ther 1998, V24, P3 MEDLINE
- (131) Laine, K; Clin Neuropharmacol 1997, V20, P419 CAPLUS
- (132) Lal, S; Prog Neuropsychopharmacol Biol Psychiatry 1984, V8, P695 CAPLUS
- (133) Landen, M; New Research Abstracts from the American Psychiatric Association Annual Meeting 1998
- (134) Lane, R; Int Clin Psychopharmacol 1996, V11(suppl 5), P31
- (135) Lane, R; J Psychopharmacol 1997, V11, P72 CAPLUS
- (136) Lane, R; J Serotonin Res 1996, V3, P75 CAPLUS
- (137) Latimer, P; Eur Neuropsychopharmacol 1996, V6(suppl 3), P124
- (138) Lauerma, H; Acta Psychiatr Scand 1996, V93, P69 CAPLUS
- (139) Laumann, E; The social organization of sexuality 1994
- (140) Lebert, F; Am J Psychiatry 1993, V150, P167 MEDLINE
- (141) Lecrubier, Y; Acta Psychiatr Scand 1997, V95, P145 CAPLUS
- (142) Lee, H; J Clin Psychopharmacol 1996, V16, P379 CAPLUS
- (143) Lepine, J; Eur Neuropsychopharmacol 1996, V6, P123
- (144) Lewis, C; J Clin Psychiatry 1997, V58, P123 MEDLINE
- (145) Leyman, S; Eur J Clin Res 1995, V7, P287
- (146) Linden, R; Poster presented at the 148th Meeting of the American Psychiatric Association 1995
- (147) Linggjaerde, O; Acta Psychiatr Scand 1987, V76(suppl 334), P1
- (148) Londborg, P; Br J Psychiatry 1998, V173, P54 MEDLINE
- (149) Ludovico, G; Br J Urol 1996, V77, P881 CAPLUS
- (150) Lydiard, R; South Med J 1989, V82, P933 MEDLINE
- (151) Machale, S; Br J Psychiatry 1994, V164, P854 MEDLINE
- (152) Mackay, F; Pharmacoepidemiol Drug Saf 1997, V6, P235 CAPLUS
- (153) Marino, M; Clin Pharmacol Ther 1996, V59, P180
- (154) Massand, P; Depression 1995, V2, P319
- (155) Mathew, R; Arch Sex Behav 1982, V11, P323 MEDLINE
- (156) Mathew, R; Psychopharmacol Bull 1980, V16, P53
- (157) McConnell, J; J Neural Transm 1979, V45, P227 CAPLUS
- (158) McCormick, S; J Clin Psychiatry 1990, V51, P383 MEDLINE
- (159) McGahuey, C; New Research Program and Abstracts 150th Annual Meeting of the American Psychiatric Association 1997, P116
- (160) McLean, J; Can J Psychiatry 1983, V28, P569 MEDLINE
- (161) Medical Economics Data Production Co; Physician's desk reference 51st ed 1997
- (162) Meltzer, H; J Neural Transm 1979, V45, P165 MEDLINE
- (163) Mendels, J; J Clin Psychopharmacol 1995, V15, P341 MEDLINE
- (164) Mendelson, S; Neurosci Biobehav Rev 1991, V16, P309
- (165) Mendelson, W; J Clin Psychopharmacol 1994, V14, P434 MEDLINE
- (166) Menkes, D; Br J Psychiatry 1995, V166, P823 MEDLINE
- (167) Michael, A; Br J Psychiatry 1997, V171, P90 MEDLINE
- (168) Mills, I; Br J Clin Pract 1979, V61(suppl 4), P61
- (169) Modell, J; J Clin Psychopharmacol 1989, V9, P63 MEDLINE
- (170) Modell, J; Pharmacoepidemiol Drug Util 1997, V61, P476 CAPLUS
- (171) Monteiro, W; Br J Psychiatry 1987, V151, P107 MEDLINE
- (172) Montejo-Gonzalez, A; J Sex Marital Ther 1997, V23, P176 MEDLINE
- (173) Montorsi, F; Drugs 1995, V50, P465 CAPLUS
- (174) Morris, P; Int J Psychiatry Med 1991, V4, P379
- (175) Murray, M; Am J Psychiatry 1993, V8(150), P167
- (176) Musher, J; Am J Psychiatry 1990, V147, P948 MEDLINE
- (177) Naranjo, C; Clin Pharmacol Ther 1987, V41, P266 MEDLINE
- (178) Nelson, E; J Clin Psychiatry 1997, V58(11), P496 MEDLINE
- (179) Nelson, J; Am J Psychiatry 1981, V138, P1 MEDLINE

- (180) Nemeroff, C; Eur Neuropsychopharmacol 1995, V5, P304
- (181) Nemeth, A; Am J Psychiatry 1996, V153, P1365 MEDLINE
- (182) Nih Consensus Development Panel On Impotence; Impotence NIH Consensus Conference JAMA 1993, V270, P83
- (183) Nofzinger, E; Arch Gen Psychiatry 1993, V50, P24 MEDLINE
- (184) Norden, M; Depression 1994, V2, P109
- (185) Nyth, A; Br J Psychiatry 1990, V157, P894 MEDLINE
- (186) Olivera, A; J Sex Educ Ther 1994, V20, P119
- (187) O'Brien, C; Arch Gen Psychiatry 1971, V24, P61 MEDLINE
- (188) Paick, J; J Urol 1998, V159(suppl), P241
- (189) Patterson, W; J Clin Psychiatry 1993, V54, P71 MEDLINE
- (190) Piazza, L; Am J Psychiatry 1997, V154, P1757 MEDLINE
- (191) Pigott, T; Arch Gen Psychiatry 1990, V47, P926 MEDLINE
- (192) Pollack, B; Am J Psychiatry 1998, V155, P1110
- (193) Pollack, M; Int J Psychiatry Med 1992, V22, P305 MEDLINE
- (194) Pollock, B; Ther Drug Monit 1996, V18, P581 CAPLUS
- (195) Pomerantz, S; Eur J Pharmacol 1993, V243, P227 CAPLUS
- (196) Power-Smith, P; Br J Psychol 1994, V164, P249 MEDLINE
- (197) Preskorn, S; Int Clin Psychopharmacol 1995, V10, P129 MEDLINE
- (198) Preskorn, S; J Pract Psychiatry Behav Health 1997, V6, P99
- (199) Preskorn, S; Psychopharmacol Bull 1991, V27, P637 MEDLINE
- (200) Price, J; Br J Clin Pharmacol 1996, V42, P757 CAPLUS
- (201) Price, L; Arch Gen Psychiatry 1989, V46, P625 CAPLUS
- (202) Raptopoulos, P; Extended abstracts and poster presentations of the Paroxetine Symposium 1998
- (203) Ravindran, A; J Clin Psychiatry 1997, V58, P112 CAPLUS
- (204) Renodon, A; FEBS Lett 1997, V406, P33 CAPLUS
- (205) Reynolds, C; Psychiatry Res 1993, V24, P231
- (206) Reynolds, R; J Clin Psychiatry 1997, V58, P89 MEDLINE
- (207) Richelson, E; J Clin Psychiatry 1994, V55(suppl A), P34
- (208) Riley, A; Sexual pharmacology 1993, P114
- (209) Robbe, H; Eur Neuropsychopharmacol 1995, V5, P35 CAPLUS
- (210) Robillard, M; Can J Psychiatry 1995, V40, P639 MEDLINE
- (211) Roeloffs, C; J Clin Psychiatry 1996, V57, P548 MEDLINE
- (212) Rosen, R; Ann Rev Sex Res 1991, V2, P119
- (213) Rosen, R; Arch Sex Behav 1993, V22, P521 MEDLINE
- (214) Rosen, R; Erectile disorders:assessment and treatment 1992
- (215) Rothschild, A; Am J Psychiatry 1995, V152, P1514 MEDLINE
- (216) Santon, T; Biochem Pharmacol 1993, V45, P2352
- (217) Schwartz, V; Am J Psychiatry 1995, V152, P1698 MEDLINE
- (218) Segraves, R; Arch Gen Psychiatry 1989, V46, P275 CAPLUS
- (219) Segraves, R; Br J Psychiatry 1994, V165, P554 MEDLINE
- (220) Segraves, R; J Clin Psychiatry 1998, V59(suppl 4), P48
- (221) Segraves, R; J Clin Psychiatry Monogr 1993, V11, P57
- (222) Shahr, E; Fam Pract 1991, V8, P206 MEDLINE
- (223) Shrivastava, R; J Clin Psychopharmacol 1995, V15, P83 MEDLINE
- (224) Smeraldi, E; New Trends Exper Clin Psychiatry 1992, V8, P63
- (225) Smirai, M; Tohoku J Exp Med 1972, V104, P403
- (226) Smith, D; J Clin Psychiatry 1993, V54, P317 MEDLINE
- (227) Spector, L; Arch Sex Behav 1990, V19, P389
- (228) Stahl, S; J Clin Psychiatry 1988, V59, P47
- (229) Stoll, A; J Clin Psychiatry 1996, V57, P72 MEDLINE
- (230) Stratta, P; J Urol 1993, V151, P345A
- (231) Sullivan, G; Hosp Community Psychiatry 1990, V41, P1238 MEDLINE
- (232) Swartz, D; J Urol 1994, V151(suppl), P345A
- (233) Swenson, J; Can J Psychiatry 1993, V38, P297 MEDLINE
- (234) Tatsumi, M; Eur J Pharmacol 1997, V340, P249 CAPLUS
- (235) Thase, M; Biol Psychiatry 1988, V24, P33 MEDLINE
- (236) Tollefson, G; Arch Gen Psychiatry 1994, V51, P559 MEDLINE
- (237) Tome, M; Poster presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology 1997
- (238) van Moffaert, M; Hum Psychopharmacol 1995, V10, P393 CAPLUS

- (239) van Putten, T; J Clin Psychopharmacol 1990, V10, P234 MEDLINE
- (240) Wade, A; Br J Psychiatry 1997, V170, P549 MEDLINE
- (241) Walczak, D; Ann Clin Psychiatry 1996, V8, P139 MEDLINE
- (242) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (243) Waldinger, M; Br J Urol 1997, V79, P592 CAPLUS
- (244) Waldinger, M; J Clin Psychopharmacol 1998, V18, P274 CAPLUS
- (245) Walker, P; J Clin Psychiatry 1993, V54, P459 MEDLINE
- (246) Weiner, D; Sexual function in people with disability and chronic illness 1997, P85
- (247) Wernicke, J; Psychopharmacol Bull 1987, V23, P164 MEDLINE
- (248) Wheadon, D; Presented at the American Congress of Neuropharmacology 1993
- (249) Wing, Y; Psychopharmacology (Berl) 1996, V124, P377 CAPLUS
- (250) Wise, T; J Clin Psychiatry 1994, V55, P417 MEDLINE
- (251) Wise, T; J Clin Psychiatry Monogr 1994, V1, P19
- (252) Zajecka, J; J Clin Psychiatry 1991, V52, P66 MEDLINE
- (253) Zajecka, J; Psychopharmacol Bull 1997, V33, P755 CAPLUS
- (254) Zohar, J; Arch Gen Psychiatry 1988, V45, P167 MEDLINE
- (255) Zubieta, J; J Clin Psychopharmacol 1991, V11, P327 MEDLINE

=> d 113 51-70

L13 ANSWER 51 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:510509 CAPLUS
 DN 129:270469
 TI Effect of SSRI antidepressants on **ejaculation**: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
 AU Waldinger, Marcel D.; Hengeveld, Michiel W.; Zwinderman, Aeilko H.; Olivier, Berend
 CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, The Hague, Neth.
 SO Journal of Clinical Psychopharmacology (1998), 18(4), 274-281
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Williams & Wilkins
 DT Journal
 LA English
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 52 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:305858 CAPLUS
 DN 129:76361
 TI 8-OH-DPAT influences extracellular levels of **serotonin** and dopamine in the medial preoptic area of male rats
 AU Lorrain, Daniel S.; Matuszewich, Leslie; Hull, Elaine M.
 CS Department of Psychology, State University of New York at Buffalo, Buffalo, NY, 14260-4110, USA
 SO Brain Research (1998), 790(1,2), 217-223
 CODEN: BRREAP; ISSN: 0006-8993
 PB Elsevier Science B.V.
 DT Journal
 LA English
 RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 53 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:264650 CAPLUS
 DN 129:103665
 TI Premature **ejaculation** and serotonergic antidepressants-induced delayed **ejaculation**. The involvement of the serotonergic system
 AU Waldinger, Marcel D.; Berendsen, Hemmie H. G.; Blok, Bertil F. M.;

Olivier, Berend; Holstege, Gert
 CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, Leyweg
 275, The Hague, 2545 CH, Neth.
 SO Behavioural Brain Research (1998), 92(2), 111-118
 CODEN: BBREDI; ISSN: 0166-4328
 PB Elsevier Science B.V.
 DT Journal; General Review
 LA English

RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 54 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:260914 CAPLUS
 DN 128:303544
 TI Antidepressant-induced sexual dysfunction
 AU Segraves, Robert Taylor
 CS Department of Psychiatry, School of Medicine, Case Western Reserve
 University, Cleveland, OH, USA
 SO Journal of Clinical Psychiatry (1998), 59(Suppl. 4), 48-54
 CODEN: JCLPDE; ISSN: 0160-6689
 PB Physicians Postgraduate Press
 DT Journal; General Review
 LA English

RE.CNT 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 55 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:219796 CAPLUS
 DN 128:270613
 TI Preparation of aralkyl and aralkylidene heterocyclic lactams and imides as
serotonin 1 agonists and antagonists.
 IN Howard, Harry Ralph
 PA Pfizer Inc., USA; Howard, Harry Ralph
 SO PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814433	A1	19980409	WO 1997-IB1062	19970908
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9739514	A1	19980424	AU 1997-39514	19970908
AU 732451	B2	20010426		
EP 929528	A1	19990721	EP 1997-936823	19970908
EP 929528	B1	20030723		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
CN 1231661	A	19991013	CN 1997-198344	19970908
CN 1093123	B	20021023		
JP 2000503679	T2	20000328	JP 1998-516337	19970908
JP 3121355	B2	20001225		
BR 9713239	A	20000404	BR 1997-13239	19970908
CA 2266107	C	20021203	CA 1997-2266107	19970908
AT 245630	E	20030815	AT 1997-936823	19970908

TW 491842	B	20020621	TW 1997-86114090	19970926
ZA 9708703	A	19990330	ZA 1997-8703	19970929
HR 970540	B1	20020831	HR 1997-970540	19970930
NO 9901525	A	19990528	NO 1999-1525	19990329
KR 2000048731	A	20000725	KR 1999-702707	19990329
US 6380186	B1	20020430	US 1999-254999	19991008
HK 1022313	A1	20030627	HK 2000-101230	20000229
US 2002049214	A1	20020425	US 2000-733346	20001208
US 6423708	B2	20020723		
CN 1329002	A	20020102	CN 2001-118954	20010518
US 6403592	B1	20020611	US 2001-11505	20011106
US 2002091118	A1	20020711		
US 2002072519	A1	20020613	US 2001-993741	20011106
US 6627627	B2	20030930		
US 2002091119	A1	20020711	US 2001-11568	20011106
US 2002091117	A1	20020711	US 2001-994027	20011106
US 6472388	B2	20021029		
US 2002147194	A1	20021010	US 2002-91963	20020306
US 6562813	B2	20030513		
PRAI US 1996-27111P	P	19960930		
WO 1997-IB1062	W	19970908		
US 1999-254999	A2	19991008		

OS MARPAT 128:270613

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 56 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:672097 CAPLUS

DN 127:326407

TI The treatment of comorbid premature **ejaculation** and panic disorder with fluoxetine

AU Kindler, S.; Dolberg, O.T.; Cohen, H.; Hirschmann, S.; Kotler, M.

CS Anxiety Clinic, Psychiatric Division, Sheba Medical Center, Rammat-Gan, and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, 52621, Israel

SO Clinical Neuropharmacology (1997), 20(5), 466-471

CODEN: CLNEDB; ISSN: 0362-5664

PB Lippincott-Raven

DT Journal

LA English

L13 ANSWER 57 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:586274 CAPLUS

DN 127:257916

TI Demonstration of **ejaculation**-induced neural activity in the male rat brain using 5-HT1A agonist 8-OH-DPAT

AU Coolen, Lique M.; Olivier, Berend; Peters, Hans J. P. W.; Veening, Jan G.

CS Department of Anatomy and Embryology, University of Nijmegen, Nijmegen, 6500 HB, Neth.

SO Physiology & Behavior (1997), 62(4), 881-891

CODEN: PHBHA4; ISSN: 0031-9384

PB Elsevier

DT Journal

LA English

L13 ANSWER 58 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:478034 CAPLUS

DN 127:156762

TI Specific involvement of central 5-HT1A receptors in the mediation of male rat **ejaculatory** behavior

AU Ahlenius, Sven; Larsson, Knut

CS Department of Physiology and Pharmacology, Karolinska Institute,

Stockholm, S-171 77, Swed.
SO Neurochemical Research (1997), 22(8), 1065-1070
CODEN: NEREDZ; ISSN: 0364-3190
PB Plenum
DT Journal; General Review
LA English

L13 ANSWER 59 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:388426 CAPLUS
DN 127:90405
TI Flesinoxan: a prosexual drug for male rats
AU Haensel, Stefan M.; Slob, A. Koos
CS Department of Endocrinology and Reproduction, Faculty of Medicine and
Health Sciences, Erasmus University and Dijkzigt Academic Hospital, P.O.
Box 1738, 3000 DR, Rotterdam, Neth.
SO European Journal of Pharmacology (1997), 330(1), 1-9
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier
DT Journal
LA English

L13 ANSWER 60 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:348152 CAPLUS
DN 127:13376
TI A double-blind comparison of fluvoxamine and paroxetine in the treatment
of depressed outpatients
AU Kiev, Ari; Feiger, Alan
CS Social Psychiatry Res. Inst., New York, NY, 10021, USA
SO Journal of Clinical Psychiatry (1997), 58(4), 146-152
CODEN: JCLPDE; ISSN: 0160-6689
PB Physicians Postgraduate Press
DT Journal
LA English

L13 ANSWER 61 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:260110 CAPLUS
DN 126:305591
TI Preparation of heteroaryloxy alkanamines having effects on
serotonin-related systems
IN Audia, James E.; Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco,
Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PA Eli Lilly and Company, USA
SO U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5614523	A	19970325	US 1995-470512	19950606
	CN 1178530	A	19980408	CN 1996-192598	19960111
PRAI	US 1995-373823	B2	19950117		
OS	MARPAT 126:305591				

L13 ANSWER 62 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:134796 CAPLUS
DN 126:144111
TI 6-Substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-
cyclohepta[7,6-b]indoles useful as 5-HT1F receptor agonists.
IN Flaugh, Michael Edward; Kiefer, Anton Daniel, Jr.; Walker, Clint Duane;
Xu, Yao Chang
PA Lilly, Eli, and Co., USA

SO Eur. Pat. Appl., 69 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 749962	A1	19961227	EP 1996-304612	19960621
	EP 749962	B1	20001102		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2179678	AA	19961224	CA 1996-2179678	19960621
PRAI	US 1995-1970	A	19950623		
OS	MARPAT 126:144111				

L13 ANSWER 63 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:43252 CAPLUS

DN 126:139312

TI Central & peripheral nervous systems. Venlafaxine: a novel antidepressant compound

AU Schweizer, Edward; Thielen, Richard J.; Frazer, Alan

CS Dep. Psychiatry, Univ. Pennsylvania Sch. Med., Philadelphia, PA, 19104, USA

SO Expert Opinion on Investigational Drugs (1997), 6(1), 65-78

CODEN: EOIDER; ISSN: 0967-8298

PB Ashley Publications

DT Journal; General Review

LA English

RE.CNT 89 THERE ARE 89 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 64 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:697269 CAPLUS

DN 126:1583

TI Effects of 8-OH-DPAT on sexual behavior of male rats castrated at different ages

AU Rasia-Filho, A. A.; Lucion, A. B.

CS Department Physiology, Federal University Rio Grande do Sul, Porto Alegre, RS 90050-170, Brazil

SO Hormones and Behavior (1996), 30(3), 251-258

CODEN: HOBEAO; ISSN: 0018-506X

PB Academic

DT Journal

LA English

L13 ANSWER 65 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:657688 CAPLUS

DN 125:317071

TI The efficacy of fluoxetine in the treatment of premature
ejaculation: A double-blind placebo controlled study

AU Kara, Hayrettin; Aydin, Sabahattin; Agargun, M. Yucel; Odabas, Oner; Yilmaz, Yuksel

CS Medical School Yuzuncu, Yil University, Van, Turk.

SO Journal of Urology (Baltimore) (1996), 156(5), 1631-1632

CODEN: JOURAA; ISSN: 0022-5347

PB Williams & Wilkins

DT Journal

LA English

L13 ANSWER 66 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:614257 CAPLUS

DN 125:264724

TI Use of psychoactive agents in the treatment of sexual dysfunction

AU Waldinger, Marcel D.

CS Department Psychiatry and Neurosexology, Leyenburg Hospital, The Hague, Neth.
 SO CNS Drugs (1996), 6(3), 204-216
 CODEN: CNDREF; ISSN: 1172-7047
 PB Adis
 DT Journal; General Review
 LA English

L13 ANSWER 67 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:428601 CAPLUS
 DN 125:67810
 TI Formulations for potentiation of drug responses by a **serotonin** 51A receptor antagonist
 IN Oguiza, Juan Ignacio; Wong, David Taiwai
 PA Lilly, Eli, and Co., USA
 SO Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 714663	A2	19960605	EP 1995-308407	19951125
	EP 714663	A3	19970115		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CA 2163840	AA	19960529	CA 1995-2163840	19951127
	JP 08208471	A2	19960813	JP 1995-307263	19951127
PRAI	US 1994-345672	A	19941128		
OS	MARPAT 125:67810				

L13 ANSWER 68 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:377358 CAPLUS
 DN 125:26296
 TI Treatment of obsessive-compulsive disorder, panic, substance abuse, and other disorders with duloxetine
 IN Heiligenstein, John Harrison; Tollefson, Gary Dennis; Wong, David Taiwai
 PA Lilly, Eli, and Co., USA
 SO PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9612485	A1	19960502	WO 1995-US13289	19951018
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9508725	A	19970416	ZA 1995-8725	19951016
	AU 9641312	A1	19960515	AU 1996-41312	19951018
PRAI	US 1994-326634	A	19941020		
	WO 1995-US13289	W	19951018		

L13 ANSWER 69 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:915732 CAPLUS
 DN 123:307130
 TI Monoaminergic influences on temporal patterning of sexual behavior in male rats

AU Yells, David P.; Prendergast, Mark A.; Hendricks, Shelton E.; Miller, Marnie E.
 CS Department of Psychology, University of Nebraska at Omaha, Omaha, NE, 68182, USA
 SO Physiology & Behavior (1995), 58(5), 847-52
 CODEN: PHBHA4; ISSN: 0031-9384
 PB Elsevier
 DT Journal
 LA English

L13 ANSWER 70 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:666209 CAPLUS
 DN 123:74764
 TI Clozapine acts as a 5-HT2 antagonist by attenuating DOI-induced inhibition of male rat sexual behavior
 AU Klint, T.; Larsson, K.
 CS Dep. of Psychology, Univ. of Goeteborg, Goeteborg, S-41314, Swed.
 SO Psychopharmacology (Berlin) (1995), 119(3), 291-4
 CODEN: PSCHDL; ISSN: 0033-3158
 PB Springer
 DT Journal
 LA English

=> d l13 51 all

L13 ANSWER 51 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:510509 CAPLUS
 DN 129:270469
 TI Effect of SSRI antidepressants on **ejaculation**: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
 AU Waldinger, Marcel D.; Hengeveld, Michiel W.; Zwinderman, Aeilko H.; Olivier, Berend
 CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, The Hague, Neth.
 SO Journal of Clinical Psychopharmacology (1998), 18(4), 274-281
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Depression is a common cause of sexual dysfunction, but also antidepressant medication is often assocd. with sexual side effects. This article includes two related studies. The first double-blind, placebo-controlled study was conducted in men with lifelong rapid **ejaculation** and aimed to assess putative differences between the major selective **serotonin** reuptake inhibitors (SSRIs) (fluoxetine, fluvoxamine, paroxetine, and sertraline) with regard to their **ejaculation**-delaying effect. Sixty men with an intravaginal **ejaculation** latency time (IELT) of 1 min or less were randomly assigned to receive fluoxetine 20 mg/day, fluvoxamine 100 mg/day, paroxetine 20 mg/day, sertraline 50 mg/day, or placebo for 6 wk. During the 1-mo baseline and 6-wk treatment periods, the men measured their IELT at home using a stopwatch. The trial was completed by 51 men. During the 6-wk treatment period, the geometric mean IELT in the placebo group was const. at approx. 20 s. Anal. of variance revealed a between-groups difference in the evolution of IELT delay ($p = 0.0004$); in the paroxetine, fluoxetine, and sertraline groups there was a gradual increase to about 110 s, whereas in the fluvoxamine group, IELT was increased to only approx. 40 s. The paroxetine, fluoxetine, and sertraline groups differed significantly ($p < 0.001$, $p < 0.001$, $p = 0.017$, resp.) from placebo but

the fluvoxamine group did not ($p = 0.38$). Compared with baseline, paroxetine exerted the strongest delay in **ejaculation**, followed by fluoxetine and sertraline. There was no clin. relevant delay in **ejaculation** with fluvoxamine. In men with lifelong rapid **ejaculation**, paroxetine delayed **ejaculation** most strongly, whereas fluvoxamine delayed **ejaculation** the least. The second double-blind, placebo-controlled study was carried out in men with lifelong rapid **ejaculation** (IELT ≤ 1 min) and in men with lifelong less-rapid **ejaculation** (IELT > 1 min) to investigate whether data about SSRI-induced delayed **ejaculation** in men with rapid **ejaculation** may be extrapolated to men with less-rapid **ejaculation**. After measurement of IELT at home (using a stopwatch) during a 1-mo baseline assessment, 32 men with an IELT of 1 min or less (group 1) or more than 1 min (group 2) were randomly assigned to receive paroxetine 20 mg/day or placebo for 6 wk in a double-blind manner. Patients continued to measure their IELTs at home during the 6 wk of the study. At baseline, 24 patients consistently had IELTs of one minute or less (group 1), and eight patients had IELTs of more than 1 min (group 2). The geometric mean IELT was 14 s in group 1 and 83 s in group 2. Twelve patients in group 1 and five in group 2 were randomized to the paroxetine 20 mg/day. The percentage increase in the geometric mean IELT compared with baseline in patients treated with paroxetine was 420% (95% confidence interval [CI], 216-758%) in group 1 and 480% (95% CI, 177-1,118%) in group 2 ($p = 0.81$). After 6 wk of treatment with paroxetine, the geometric mean IELT was 92 s in group 1 and 602 s in group 2. Therefore, the paroxetine-induced percentage increase in IELT seems to be independent of the baseline IELT. This suggests that **ejaculation**-delaying side effects of some SSRIs investigated in men with lifelong rapid **ejaculation** may be generalized to men with less-rapid **ejaculation**.

ST SSRI antidepressant **ejaculation** fluoxetine fluvoxamine
paroxetine; sertraline SSRI antidepressant **ejaculation**
fluoxetine fluvoxamine

IT Sexual behavior
(**ejaculation**; vSSRIs antidepressants fluoxetine, fluvoxamine
paroxetine, and sertraline effects on **ejaculation** latency in
men)

IT Sexual behavior
(premature **ejaculation**; SSRIs antidepressants fluoxetine,
fluvoxamine paroxetine, and sertraline effects on **ejaculation**
latency in men)

IT Antidepressants
(selective **serotonin** reuptake inhibitors; SSRIs
antidepressants fluoxetine, fluvoxamine paroxetine, and sertraline
effects on **ejaculation** latency in men)

IT 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7, Paroxetine
79617-96-2, Sertraline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(SSRIs antidepressants fluoxetine, fluvoxamine paroxetine, and
sertraline effects on **ejaculation** latency in men)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Ahlenius, S; Pharmacol Biochem Behav 1981, V15, P758
- (2) Anon; Informatorium Medicamentorum 1996 1996
- (3) Casper, R; Arch Gen Psychiatry 1985, V42, P1098 MEDLINE
- (4) Derogatis, L; SCL-90, Handleiding bij een Multidimensionale
Psychopathologie-indicator 1986
- (5) Dunner, D; J Clin Psychiatry 1992, V53(2 suppl), P21
- (6) Fabre, L; Biol Psychiatry 1995, V38, P592 CAPLUS
- (7) Gommans, J; Psychopharmacology (Berl), in press

- (8) Kara, H; J Urol 1996, V156, P1631 CAPLUS
- (9) Kennedy, S; Eur Neuropsychopharmacol 1996, V6, P177 CAPLUS
- (10) Kowalski, A; Br J Psychiatry 1985, V147, P413 MEDLINE
- (11) Lemberger, L; J Clin Psychiatry 1985, V46, P14 CAPLUS
- (12) Lingjaerde, O; Acta Psychiatr Scand 1987, V76(suppl 334), P1
- (13) Marsden, C; Psychopharmacology 1987, V1, P244 CAPLUS
- (14) Marson, L; Brain Res 1990, V515, P303 MEDLINE
- (15) Mathew, R; Arch Sex Behav 1982, V11, P323 MEDLINE
- (16) Mendels, J; J Clin Psychopharmacol 1995, V15, P341 MEDLINE
- (17) Meston, C; J Psychoactive Drugs 1992, V24, P1 MEDLINE
- (18) Mos, J; Eur Neuropsychopharmacol, in press
- (19) Olivier, B; Pharmacopsychiatry 1993, V26(suppl 1), P2
- (20) Preskorn, S; Int Clin Psychopharmacol 1995, V10, P129 MEDLINE
- (21) Simpson, G; Dis Nerv Syst 1965, V26, P787 MEDLINE
- (22) Steiger, A; J Clin Psychopharmacol 1988, V8, P349 MEDLINE
- (23) Thase, M; Biol Psychiatry 1992, V31, P1136 MEDLINE
- (24) Walczak, D; Ann Clin Psychiatry 1996, V8, P139 MEDLINE
- (25) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (26) Waldinger, M; Behav Brain Res 1998, V92, P111 MEDLINE
- (27) Waldinger, M; Br J Urol 1997, V79, P592 CAPLUS
- (28) Waldinger, M; CNS Drugs 1996, V6, P204 CAPLUS
- (29) Waldinger, M; PhD thesis, University of Utrecht 1997, P127
- (30) Waldinger, M; Psychiatr Genet 1998, V8, P37 MEDLINE
- (31) Wernicke, J; Psychopharmacol Bull 1987, V23, P164 MEDLINE
- (32) Yells, D; Pharmacol Biochem Behav 1994, V49, P121 CAPLUS

=> d 113 53 all

L13 ANSWER 53 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:264650 CAPLUS
 DN 129:103665
 TI Premature **ejaculation** and serotonergic antidepressants-induced delayed **ejaculation**. The involvement of the serotonergic system
 AU Waldinger, Marcel D.; Berendsen, Hemmie H. G.; Blok, Bertil F. M.; Olivier, Berend; Holstege, Gert
 CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, Leyweg 275, The Hague, 2545 CH, Neth.
 SO Behavioural Brain Research (1998), 92(2), 111-118
 CODEN: BBREDI; ISSN: 0166-4328
 PB Elsevier Science B.V.
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 Section cross-reference(s): 14
 AB A review with 58 refs. Premature **ejaculation** has generally been considered a psychosexual disorder with psychogenic etiol. Although still mainly treated by behavioral therapy, in recent years double-blind studies have indicated the beneficial effects of some of the serotonergic antidepressants (SSRIs) in delaying **ejaculation**. We describe here the neurophysiol. and the peripheral neuroanatomy of **ejaculation** and provide a review of the involvement of **serotonin** in the central nervous system in relation to serotonergic nuclei and their projections. A hypothesis of the role of 5-HT1A and 5-HT2C receptors in premature **ejaculation** is postulated.
 ST review antidepressant premature **ejaculation** serotonergic system
 IT 5-HT receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (5-HT1A; serotonergic system in antidepressants-induced delayed

ejaculation)
IT 5-HT receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-HT2C; serotonergic system in antidepressants-induced delayed **ejaculation)**
IT Sexual behavior
Sexual behavior
(premature **ejaculation**; serotonergic system in antidepressants-induced delayed **ejaculation)**
IT Antidepressants
(serotonergic system in antidepressants-induced delayed **ejaculation)**
IT Nerve
(serotonergic; serotonergic system in antidepressants-induced delayed **ejaculation)**
IT 50-67-9, **Serotonin**, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(serotonergic system in antidepressants-induced delayed **ejaculation)**

RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Abraham, K; Psychoanalyse 1917, VIV, P171
- (2) Ahlenius, S; Pharmacol Biochem Behav 1981, V15, P785 CAPLUS
- (3) Althof, S; J Clin Psychiatry 1995, V56, P402 MEDLINE
- (4) American Psychiatric Association; Diagnostic and Statistical Manual of Mental Disorders, 4th ed 1994
- (5) Aycock, L; J Urol 1949, V62, P361
- (6) Bennett, D; Lancet 1961, VII, P1309
- (7) Benson, G; The Physiology of Reproduction 1988
- (8) Berendsen, H; Br J Pharmacol 1990, V101, P667 CAPLUS
- (9) Berendsen, H; Eur J Pharmacol 1987, V338, P191
- (10) Berendsen, H; Eur J Pharmacol 1994, V253, P83 CAPLUS
- (11) Berendsen, H; Pharmacol Biochem Behav 1989, V33, P821 CAPLUS
- (12) Berendsen, H; Psychopharmacology 1990, V101, P57 CAPLUS
- (13) Berkovitch, M; J Urol 1995, V154, P1360 MEDLINE
- (14) Bertacinni, G; Lancet 1960, VI, P881
- (15) Crenshaw, R; Annual Meeting of the American Association of Sex Educators, Counselors and Therapists 1992
- (16) Damrau, F; J Urol 1963, V89, P936 MEDLINE
- (17) de Groat, W; Central Regulation of Autonomic Functions 1990, P310
- (18) Deamicis, L; Arch Sexual Behav 1985, V14, P467 MEDLINE
- (19) Erspamer, V; Arch f Exp Path Pharmacol 1940, V196, P336
- (20) Erspamer, V; Nature 1952, V169, P800 CAPLUS
- (21) Farthing, M; Scand J Gastroenterol 1991, V26, P92 CAPLUS
- (22) Foreman, M; Life Sci 1989, V45, P1263 CAPLUS
- (23) Girgis, S; Andrologia 1982, V29, P364
- (24) Goodman, R; J Int Med Res 1980, V8(S3), P53
- (25) Grahame-Smith, D; Q J Med 1988, V67, P459 MEDLINE
- (26) Haensel, S; J Urol 1996, V156, P1310 CAPLUS
- (27) Hawton, K; Behav Res Ther 1986, V24, P665 MEDLINE
- (28) Holstege, G; Progr Brain Res 1991, V87, P307 MEDLINE
- (29) Holstege, J; The Emotional Motor System Progr Brain Res 1996, V107, P159 CAPLUS
- (30) Hoyer, D; Pharmacol Rev 1994, V46, P157 CAPLUS
- (31) Jacobs, B; Physiol Rev 1992, V72, P165 CAPLUS
- (32) Lawrence, J; Int J Psychiatry Med 1992, V22, P77
- (33) Marberger, H; Physiology and Genetics of Reproduction; Basic Life Sciences 1974, V4 MEDLINE
- (34) Masters, W; Human Sexual Inadequacy 1970, P92
- (35) Mendels, J; J Clin Psychopharmacol 1995, V15, P341 MEDLINE

- (36) Meston, C; J Psychoactive Drugs 1992, V24, P1 MEDLINE
- (37) Molewijk, H; Eur J Neurosci 1989, V214(2), P121
- (38) Molliver, M; Ann NY Acad Sci 1990, V600, P640
- (39) Peroutka, S; Mol Pharmacol 1979, V16, P687 CAPLUS
- (40) Rapport, M; J Biol Chem 1949, V180, P961 CAPLUS
- (41) Retief, P; S Afr Med J 1950, V24, P509
- (42) Ruff, G; Clin Psychol Rev 1985, V5, P627
- (43) Segraves, R; Am J Psychiatry 1987, V144, P1240 MEDLINE
- (44) Segraves, R; J Sex Marital Ther 1993, V19, P198 MEDLINE
- (45) Semans, J; J Urol 1938, V40, P836
- (46) Semans, J; S Afr Med J 1956, V49, P353
- (47) Singer, C; Sexual Dysfunction, a Neuro-Medical Approach 1994, P30
- (48) Steinbush, H; Neuroscience 1981, V4, P557
- (49) Szele, F; Life Sci 1988, V43, P1297 CAPLUS
- (50) Tork, I; Ann NY Acad Sci 1990, V600, P6
- (51) Twarag, B; Am J Physiol 1953, V174, P157
- (52) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (53) Waldinger, M; Br J Urol 1997, V79, P592 CAPLUS
- (54) Waldinger, M; Diagnostic Criteria for Premature Ejaculation, submitted 1997
- (55) Waldinger, M; J Clin Psychopharmacol, in press 1997
- (56) Waldinger, M; Psychiatr Genet, in press 1997
- (57) Woolley, D; Proc Natl Acad Sci 1954, V40, P228 CAPLUS
- (58) Yap, C; Neuropharmacology 1983, V22, P801 CAPLUS

=> d 113 56 all

L13 ANSWER 56 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:672097 CAPLUS
 DN 127:326407
 TI The treatment of comorbid premature **ejaculation** and panic disorder with fluoxetine
 AU Kindler, S.; Dolberg, O.T.; Cohen, H.; Hirschmann, S.; Kotler, M.
 CS Anxiety Clinic, Psychiatric Division, Sheba Medical Center, Rammat-Gan, and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, 52621, Israel
 SO Clinical Neuropharmacology (1997), 20(5), 466-471
 CODEN: CLNEDB; ISSN: 0362-5664
 PB Lippincott-Raven
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Premature **ejaculation** is a common sexual disturbance among men. Both open-label and double-blind studies have demonstrated the effectiveness of serotonergic medications for this disorder. These studies support the hypothesis that the serotonergic system has an important role in the modulation of sexual response, esp. attainment of orgasm. Serotonergic dysfunction also has been linked to the pathogenesis of panic disorder. Several studies have demonstrated the efficacy of serotonergic drugs in this disorder. The purpose of the present study was to examine the efficacy of fluoxetine, a **serotonin** selective reuptake inhibitor for the treatment of comorbid premature **ejaculation** and panic disorder, in 10 men in an open-label design. The patients were given 20 mg of fluoxetine for 8 wk of the study. Parameters pertaining to sexual function and measures of anxiety were examd. Improvement of premature **ejaculation** was noted as of week 2 of the study, whereas measures of panic and sexual satisfaction became statistically significant only as of week 4. Further studies with larger samples and longer periods of follow-up are needed in order to det. the usefulness of fluoxetine for the treatment of comorbid premature **ejaculation** and panic disorder.

ST fluoxetine premature **ejaculation** panic disorder antipsychotic
 IT Anxiety
 (panic disorder; treatment of comorbid premature **ejaculation**
 and panic disorder with fluoxetine in humans)
 IT Sexual behavior
 Sexual behavior
 (premature **ejaculation**; treatment of comorbid premature
 ejaculation and panic disorder with fluoxetine in humans)
 IT Antipsychotics
 (treatment of comorbid premature **ejaculation** and panic
 disorder with fluoxetine in humans)
 IT 54910-89-3, Fluoxetine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (treatment of comorbid premature **ejaculation** and panic
 disorder with fluoxetine in humans)

=> d 113 57 all

L13 ANSWER 57 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:586274 CAPLUS
 DN 127:257916
 TI Demonstration of **ejaculation**-induced neural activity in the male
 rat brain using 5-HT1A agonist 8-OH-DPAT
 AU Coolen, Lique M.; Olivier, Berend; Peters, Hans J. P. W.; Veening, Jan G.
 CS Department of Anatomy and Embryology, University of Nijmegen, Nijmegen,
 6500 HB, Neth.
 SO Physiology & Behavior (1997), 62(4), 881-891
 CODEN: PHBHA4; ISSN: 0031-9384
 PB Elsevier
 DT Journal
 LA English
 CC 2-8 (Mammalian Hormones)
 AB Previous studies from our lab. indicated the existence of
 ejaculation-related neural activation within the circuitry
 underlying mating behavior in the male rat. Clusters of
 Fos-immunoreactive neurons were present only following
 ejaculations and not after intromissions. However, it was not
 clear if this pattern of neural activation was specific to
 ejaculation or a result of summation of sexual activity preceding
 ejaculation. In the present study, the facilitative effect of the
 5-HT1A receptor agonist 8-OH-DPAT on **ejaculatory** behavior was
 used to analyze the pattern of Fos immunoreactivity following
 ejaculation preceded by minimal sexual activity. Male rats
 treated with 8-OH-DPAT (0.4 mg/kg) achieved **ejaculation** after a
 shortened latency and low nos. of mounts and intromissions.
 Ejaculation-induced Fos immunoreactivity was present in clusters
 of neurons in the lateral part of the posterodorsal medial amygdala, in
 two subregions of the posteromedial bed nucleus of the stria terminalis,
 in the posterodorsal preoptic nucleus, and in the parvicellular part of
 the subparafascicular thalamic nucleus. Males that ejaculated with the
 first intromission and were treated with a higher dose of 8-OH-DPAT (0.8
 mg/kg) exhibited similar clusters of Fos-pos. neurons in all areas except
 the posterodorsal preoptic nucleus. The results demonstrate the existence
 of a specific **ejaculation**-related subcircuit within a larger
 neural circuitry involved in male sexual behavior.
 ST brain **serotonin** 5IA sexual behavior
 IT 5-HT receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)

(5-HT1A; demonstration of **ejaculation**-induced neural activity in male rat brain using 5-HT1A agonist 8-OH-DPAT)

IT Brain
(amygdala, medial amygdaloid body; demonstration of **ejaculation**-induced neural activity in male rat brain using 5-HT1A agonist 8-OH-DPAT)

IT Brain
Neurotransmission
Sexual behavior
(demonstration of **ejaculation**-induced neural activity in male rat brain using 5-HT1A agonist 8-OH-DPAT)

IT Brain
(hypothalamus, preoptic area; demonstration of **ejaculation**-induced neural activity in male rat brain using 5-HT1A agonist 8-OH-DPAT)

IT Brain
(parafascicular nucleus; demonstration of **ejaculation**-induced neural activity in male rat brain using 5-HT1A agonist 8-OH-DPAT)

IT Brain
(stria terminalis bed nucleus; demonstration of **ejaculation**-induced neural activity in male rat brain using 5-HT1A agonist 8-OH-DPAT)

IT 78950-78-4, 8-OH-DPAT
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(demonstration of **ejaculation**-induced neural activity in male rat brain using 5-HT1A agonist 8-OH-DPAT)

=> d 113 58 all

L13 ANSWER 58 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:478034 CAPLUS
DN 127:156762
TI Specific involvement of central 5-HT1A receptors in the mediation of male rat **ejaculatory** behavior
AU Ahlenius, Sven; Larsson, Knut
CS Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, S-171 77, Swed.
SO Neurochemical Research (1997), 22(8), 1065-1070
CODEN: NEREDZ; ISSN: 0364-3190
PB Plenum
DT Journal; General Review
LA English
CC 2-0 (Mammalian Hormones)
AB A review, with 34 refs. The aminotetralin 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), pharmacol. characterized as a 5-HT1A receptor agonist, produces a pronounced decrease in **ejaculation** latency in the male rat. Stimulation of 5-HT receptors by a pharmacol. induced increase in the synaptic availability of 5-HT has been shown to produce the opposite effect. The 8-OH-DPAT-induced decrease in **ejaculation** latency is specific for this compd., and some chem. related ergot derivs. In this paper the authors review the evidence in support for stimulation of serotonergic autoreceptors of the 5-HT1A receptor subtype as a mechanism of action for effects by 8-OH-DPAT on male rat **ejaculatory** behavior. The authors also present the questions posed by the fact that quinpirole and lisuride both produce 8-OH-DPAT-like effects on male rat **ejaculatory** behavior. The effects by quinpirole, lisuride or 8-OH-DPAT are not sensitive to pretreatment with the DA D2/3 receptor antagonist raclopride. Continued studies will show whether the effects of quinpirole and lisuride can be related to stimulation of 5-HT1A receptors, or if all these compds. have

as yet undefined common properties.

ST **serotonin** 51A receptor brain **ejaculation** review
IT 5-HT receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(5-HT1A; central 5-HT1A receptors in mediation of male rat **ejaculatory** behavior)
IT Brain
(central 5-HT1A receptors in mediation of male rat **ejaculatory** behavior)
IT Sexual behavior
(**ejaculation**; central 5-HT1A receptors in mediation of male rat **ejaculatory** behavior)

=> d 113 65 all

L13 ANSWER 65 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:657688 CAPLUS
DN 125:317071
TI The efficacy of fluoxetine in the treatment of premature **ejaculation**: A double-blind placebo controlled study
AU Kara, Hayrettin; Aydin, Sabahattin; Agargun, M. Yucel; Odabas, Oner; Yilmaz, Yuksel
CS Medical School Yuzuncu, Yil University, Van, Turk.
SO Journal of Urology (Baltimore) (1996), 156(5), 1631-1632
CODEN: JOURAA; ISSN: 0022-5347
PB Williams & Wilkins
DT Journal
LA English
CC 1-11 (Pharmacology)
AB The efficacy of the selective **serotonin** re-uptake inhibitor fluoxetine in the treatment of premature **ejaculation** was examd. The study comprized 17 patients with premature **ejaculation** who presented to the urol. clinic of the authors' medical school. In this double-blind study the patients were randomized into treatment groups receiving 20 mg. fluoxetine daily for 1 wk and 40 mg. daily afterward (group (1)) or 1 capsule placebo daily for 1 wk and 2 capsules daily afterward (group (2)). The groups were evaluated according to the latent period of intravaginal **ejaculation**. The latent period of intravaginal **ejaculation** in group 1 was significantly longer than that in group 2. Nausea, headache and insomnia were reported side effects. Fluoxetine may be regarded as a safe and effective alternative in the treatment of premature **ejaculation**.
ST fluoxetine premature **ejaculation**
IT Sexual behavior
(disorder, premature **ejaculation**, efficacy of fluoxetine in treatment of premature **ejaculation** dealing with a double-blind placebo controlled study in humans)
IT 54910-89-3, Fluoxetine
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(efficacy of fluoxetine in treatment of premature **ejaculation** dealing with a double-blind placebo controlled study in humans)

=> d 113 66 all

L13 ANSWER 66 OF 139 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:614257 CAPLUS
DN 125:264724

TI Use of psychoactive agents in the treatment of sexual dysfunction
 AU Waldinger, Marcel D.
 CS Department Psychiatry and Neurosexology, Leyenburg Hospital, The Hague, Neth.
 SO CNS Drugs (1996), 6(3), 204-216
 CODEN: CNDREF; ISSN: 1172-7047
 PB Adis
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 AB A review with 86 refs. Sexual function can be subdivided into phases of sexual desire, penile erection, **ejaculation** and orgasm. Dysfunction of these processes is manifest as disorders that include hypoactive sexual desire, male erectile dysfunction, premature and retarded **ejaculation**, and anorgasmia. These disorders can be primary in etiol. or can be caused by a no. of psychoactive drugs including, commonly, antidepressants. At present, sexual dysfunction is rarely treated with pharmacol. agents. The usual approach consists of psychotherapy. However, in recent years, more interest has arisen in treating disorders of sexual function with psychopharmacol. drugs, particularly sexual dysfunction that is the adverse effect of antidepressants. Clin. reports suggest that primary premature **ejaculation** can be successfully treated with clomipramine and selective **serotonin** (5-hydroxytryptamine; 5-HT) reuptake inhibitors. At present, only a few oral medications have been shown to be useful in the treatment of erectile dysfunction (including yohimbine and trazodone), although these have not been developed specifically for this indication. The pharmacol. treatment of primary retarded **ejaculation** and female primary anorgasmia still offers no efficacy. There are, on the other hand, .
 ST psychotropic sexual dysfunction review
 IT Psychotropics
 (use of psychoactive agents in the treatment of sexual dysfunction in humans)
 IT Sexual behavior
 (disorder, use of psychoactive agents in the treatment of sexual dysfunction in humans)

=> d his

(FILE 'HOME' ENTERED AT 12:20:03 ON 25 NOV 2003)

FILE 'REGISTRY' ENTERED AT 12:20:14 ON 25 NOV 2003

E DAPOXETINE

L1 2 S E3

FILE 'CAPLUS' ENTERED AT 12:21:05 ON 25 NOV 2003

L2 14 S L1

L3 0 S SELECTIVE SEROTONIN REUPTAKE INHIBITOR

L4 697 S SELECTIVE SEROTONIN REUPTAKE INHIBITOR

E EJACULATION

L5 1881 S E1-E10

L6 18 S L4 AND L5

L7 1329 S SEROTONIN REUPTAKE INHIBITOR

L8 27 S L7 AND L5

L9 9 S L8 NOT L6

L10 62015 S SEROTONIN

L11 166 S L10 AND L5

L12 157 S L11 NOT L9

L13 139 S L12 NOT L6

AN 1999:45466 CAPLUS
 DN 130:306414
 TI A comparison of the effects of different serotonin reuptake blockers on sexual behavior of the male rat
 AU Mos, Jan; Mollet, Ian; Tolboom, Jeroen T. B. M.; Waldinger, Marcel D.; Olivier, Berend
 CS Solvay Pharmaceuticals, Department of Pharmacology, Weesp, 1380 DA, Neth.
 SO European Neuropsychopharmacology (1999), 9(1-2), 123-135
 CODEN: EURNE8; ISSN: 0924-977X
 PB Elsevier Science Ireland Ltd.
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB In human males, SSRIs differentially affect (premature) **ejaculation**; paroxetine and fluoxetine markedly and sertraline, moderately inhibited **ejaculation** latency, whereas fluvoxamine did not inhibit this parameter (Waldinger, M.D., Hengeveld, M.W., Zwinderman, A.H., Olivier, B., The effect of SSRI antidepressants on **ejaculation**: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J. Clin. Psychopharmacol. (in press)). The present studies tried to investigate, using sexual behavior in male rats, whether such differences could also be found in animal paradigms of sexual behavior. In a series of three expts. we compared various specific serotonin reuptake inhibitors (SSRIs) for their ability to suppress sexual behavior in male rats. In the first expt. sexually experienced rats were tested 60 min after oral administration of clomipramine, fluvoxamine, fluoxetine (all in a range of 0, 3, 10 and 30 mg/kg p.o.), sertraline or paroxetine (both in a range of 0, 1, 3 and 10 mg/kg p.o.). Clomipramine, paroxetine and fluvoxamine did not significantly inhibit male sexual behavior, although some trends were obsd. Sertraline inhibited sexual behavior at 3 and 10 mg/kg p.o., the effects being stronger at 3 mg/kg p.o. Fluoxetine (3 mg/kg p.o.) facilitated sexual behavior, while at 30 mg/kg p.o. a modest increase in the postejaculatory interval was noted. In the second expt., sexual behavior of sexually naive male rats was slightly inhibited by paroxetine 10 mg/kg p.o., but sertraline (range 1-10 mg/kg p.o.), fluvoxamine and fluoxetine (both in a range of 3-30 mg/kg p.o.) were ineffective. In the last expt. the effects of paroxetine (0-10 mg/kg p.o.), fluvoxamine and fluoxetine (both 0-30 mg/kg p.o.) were studied during an exhaustion design in sexually experienced male rats. As rats get more 'sluggish' when they have had multiple **ejaculations**, we hoped to see stronger inhibitory effects in the last cycle prior to exhaustion. None of the drugs dose-dependently inhibited the pattern of sexual behavior during the first sexual cycle. In the last cycle the patterning of sexual behavior differed, but only paroxetine (10 mg/kg p.o.) inhibited sexual behavior significantly. The total no. of **ejaculations** during the test was not reduced by any of the SSRIs tested. Contrary to human findings, we did not find major inhibitory effects of SSRIs on male rat sexual behavior at non-sedative doses. The only differentiation that could be made is that paroxetine and sertraline had slightly stronger effects than the other 5-HT reuptake inhibitors. Masculine sexual behavior in rats does not constitute a suitable model to investigate the differential mechanism of sexual inhibition of SSRIs that have been described in human males.
 ST serotonin reuptake clomipramine paroxetine fluvoxamine sertraline fluoxetine
 IT Antidepressants
 Sexual behavior
 (a comparison of effects of different serotonin reuptake blockers on sexual behavior of male rat)
 IT 303-49-1, Clomipramine 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7, Paroxetine 79617-96-2, Sertraline

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(a comparison of effects of different serotonin reuptake blockers on sexual behavior of male rat)

IT 50-67-9, Serotonin, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**selective serotonin reuptake**

inhibitor; a comparison of effects of different serotonin reuptake blockers on sexual behavior of male rat)

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Agmo, A; J Neural Transm 1989, V77, P21 MEDLINE
- (2) Agmo, A; Pharmacol Biochem Behav 1990, V35, P327 CAPLUS
- (3) Ahlenius, S; Eur J Pharmacol 1984, V99, P279 CAPLUS
- (4) Ahlenius, S; Psychopharmacologia 1971, V20, P383 CAPLUS
- (5) Ahlenius, S; Psychopharmacology 1979, V65, P137 CAPLUS
- (6) Ahlenius, S; Psychopharmacology 1980, V68, P217 CAPLUS
- (7) Aizenberg, D; Clin Neuropharmacol 1995, V18, P320 CAPLUS
- (8) Althof, S; J Clin Psychiatry 1995, V56, P402 MEDLINE
- (9) Assalian, P; J Sex Res 1988, V24, P213
- (10) Baldwin, D; Int Rev Psychiatry 1995, V7, P261
- (11) Baum, M; Pharmacol Biochem Behav 1980, V13, P57 CAPLUS
- (12) Beach, F; Q J Exp Psychol 1956, V8, P121
- (13) Benazzi, F; Pharmacopsychiatry 1994, V27, P246 MEDLINE
- (14) Bitran, D; Neurosci Biobehav Rev 1987, V11, P365 CAPLUS
- (15) Collet, D; Modelling Survival Data in Medical Research Chapman and Hall 1994
- (16) Devane, C; Hum Psychopharmacol 1995, V10(S3), P185
- (17) Dorevitch, A; Ann Pharmacother 1994, V28, P872 MEDLINE
- (18) Eaton, H; J Int Med Res 1973, V1, P432
- (19) Forster, P; Am J Psychiatry 1994, V151, P1523 MEDLINE
- (20) Haensel, S; J Urol 1996, V156, P1310 CAPLUS
- (21) Haensel, S; Pharmacol Biochem Behav 1991, V40, P221 CAPLUS
- (22) Hamburger-Bar, R; Life Sci 1978, V22, P1827 CAPLUS
- (23) Hillegaart, V; Behav Brain Res 1989, V33, P279 CAPLUS
- (24) Hyttel, J; Int Clin Psychopharmacol 1994, V9(S1), P19
- (25) Lane, R; J Psychopharmacol 1995, V9, P163 CAPLUS
- (26) Machale, S; Br J Psychiatry 1994, V164, P854 MEDLINE
- (27) Maritz, J; J Am Stat Assoc 1978, V73, P194
- (28) Meston, C; J Psychoact Drugs 1992, V24, P1 MEDLINE
- (29) Monteiro, W; Br J Psychiatry 1987, V151, P107 MEDLINE
- (30) Mos, J; The Netherlands 1990, P221
- (31) Murdoch, D; Drugs 1992, V44, P604 CAPLUS
- (32) Olivier, B; Depression, Anxiety and Aggression-Preclinical and Clinical Interfaces Medidact 1988, P121
- (33) Patterson, W; J Clin Psychiatry 1993, V54, P71 MEDLINE
- (34) Power-Smith, P; Br J Psychiatry 1994, V164, P249 MEDLINE
- (35) Rothchild, A; Am J Psychiatry 1995, V152, P1514
- (36) Salis, P; Nature 1971, V232, P400 CAPLUS
- (37) Sanchez, C; Eur J Pharmacol 1994, V264, P241 CAPLUS
- (38) Sanchez, C; Psychopharmacology 1997, V129, P197 CAPLUS
- (39) Segraves, R; J Sex Marital Ther 1995, V21, P192 MEDLINE
- (40) Shen, W; Int J Psychiatry Med 1995, V25, P239 MEDLINE
- (41) Sodersten, P; Pharmacol Biochem Behav 1976, V5, P310
- (42) Taylor, G; Physiol Behav 1996, V59, P479 CAPLUS
- (43) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (44) Waldinger, M; J Clin Psychopharmacol (in press)
- (45) Walker, P; J Clin Psychiatry 1993, V54, P459 MEDLINE
- (46) Wise, T; J Clin Psychiatry 1994, V55, P417 MEDLINE
- (47) Yells, D; Pharmacol Biochem Behav 1994, V49, P121 CAPLUS
- (48) Zajecka, J; J Clin Psychiatry 1991, V52, P66 MEDLINE

DN 132:146650
 TI Treating depression with a combination of a serotonin uptake inhibitor, a 5-HT1A presynaptic antagonist, and a 5-HT1A agonist
 IN Depoortere, Henri
 PA Sanofi-Synthelabo, Fr.
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 IC ICM A61K031-40
 ICS A61K031-135; A61K031-505; A61K031-135; A61K031-505
 CC 1-11 (Pharmacology)
 Section cross-reference(s): 63
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000006160	A1	20000210	WO 1999-FR1825	19990726
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	FR 2781671	A1	20000204	FR 1998-9603	19980728
	AU 9949167	A1	20000221	AU 1999-49167	19990726
PRAI	FR 1998-9603	A	19980728		
	WO 1999-FR1825	W	19990726		
AB	Pharmaceutical compns. are provided which contain a serotonin uptake inhibitor (e.g. fluoxetine), a 5-HT1A presynaptic antagonist (e.g. pindolol), and a 5-HT1A agonist (e.g. buspirone) as a combination product for simultaneous, sep., or prolonged use for treating various forms of depression.				
ST	depression fluoxetine pindolol buspirone combination; serotoninergic 5-HT1A presynaptic antagonist combination depression; 5-HT1A serotoninergic agonist combination depression				
IT	5-HT agonists				
	5-HT antagonists				
	(5-HT1A; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)				
IT	Mental disorder				
	(depression, major; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)				
IT	Mental disorder				
	(depression, neurotic; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)				
IT	Sleep				
	(disorder; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)				
IT	Mental disorder				
	(manic bipolar disorder; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)				
IT	Mental disorder				
	(obsession-compulsion; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)				
IT	Drug delivery systems				
	(oral; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)				
IT	Anxiety				
	(panic; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A				

agonist combination for treatment of depression)

IT Mental disorder
(phobia, social; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)

IT Antidepressants
Antipsychotics
Anxiolytics
Cognition enhancers
Drug delivery systems
Drug interactions
(serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)

IT Drug interactions
(synergistic; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)

IT 50-67-9, Serotonin, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(reuptake inhibitors; serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)

IT 13523-86-9, Pindolol 36505-84-7, Buspirone 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 59729-33-8, Citalopram 61869-08-7, Paroxetine 71827-56-0, Clemeprol 79617-96-2, Sertraline 83366-66-9, Nefazodone 83455-48-5, Bromerguride 83928-76-1, Gepirone 87760-53-0, Tandoxpirone 90494-76-1, SR 57746 92623-85-3, Milnacipran 93413-69-5, Venlafaxine 95847-70-4, Ipsapirone 98206-10-1, Flesinoxan 99487-26-0, MCI 225 102908-59-8, Binospirone 112922-55-1, Cericlamine 114298-18-9, Zalospirore **119356-77-3**, Dapoxetine 127266-56-2, WY 50324 132449-45-7, E4414 132449-46-8, Lesopitron 132501-12-3, WY 48723 132873-35-9, LY 274600 133109-86-1, EMD 56551 135722-27-9, S 14671 138298-79-0, Alnespirore 141318-62-9, LY 293284 142348-14-9, Pyricapirone 144340-02-3, CP 119333 144980-77-8, BAYx 3702 145969-30-8, OPC 14523 146479-45-0, BMS 181101 146998-34-7, S 15535 149494-37-1, Ebalezotan 149654-41-1, U 92016A 150019-94-6, BMS 184111 150527-35-8, FG 5865 150710-80-8, HT 90B 156896-33-2, LY 301317 161178-10-5, YM 35992 161312-09-0 162408-66-4, GR 103691 162581-80-8, LY 297996 163521-12-8, EMD 68843 167933-07-5, Flibanaserin 177975-08-5, EMD 77697 179756-58-2, F 11440 208516-87-4, NAD 299 214686-27-8, F 12439 221452-76-2, EF 7412 257614-79-2 257863-96-0, NS 2389 257863-98-2, EMD 80084 257864-13-4, AP 521 257864-15-6, AZ 16596 257864-30-5, DDR 203901 257864-31-6, DDR 205852 257864-33-8, DDR 208978 257864-35-0, DDR 211278 257864-36-1, DDR 212219 257864-37-2, FCE 23892 257864-38-3, LY 315535 257864-39-4, S 215521 257864-41-8, WAY 100802 257864-47-4, EMD 67478
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(serotonin uptake inhibitor-5-HT1A presynaptic antagonist-5-HT1A agonist combination for treatment of depression)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Cadieux, R; AMERICAN FAMILY PHYSICIAN 1998, P1
- (2) Devane, C; HTTP://MBLCOMMUNICATIONS.COM/PP998_DEVANE P10
- (3) Devane, C; PRIMARY PSYCHIATRY 1998, V5(9)
- (4) Eli, L; EP 0687472 A 1995 CAPLUS
- (5) Eli, L; EP 0792649 A 1997 CAPLUS
- (6) Majeroni, B; JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE,
<http://www.medscape.com/ABFP/JABFP/1998/v1.1.n02/fp1102.05.maje/fp1102.05.maje.html> abrege 1998, V11(2), P127 MEDLINE
- (7) Nemeroff, C; DEPRESSION AND ANXIETY 1996, P169
- (8) Perez, M; BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1998, V8(23), P3423 CAPLUS

- (9) Puzantian, T; PHARMACOTHERAPY 1999, P205 CAPLUS
- (10) Redrobe, J; CNS SPECTRUMS 1999, V4/4, P73
- (11) Schweitzer, I; AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY 1997,
V31(3) MEDLINE

=>

AN 1993:204601 CAPLUS
 DN 118:204601
 TI Determination of dapoxetine, an investigational agent with the potential
 for treating depression, and its mono- and di-desmethyl metabolites in
 human plasma using column-switching high-performance liquid chromatography
 AU Hamilton, Cristi L.; Cornpropst, J. David
 CS Lilly Res. Lab., Eli Lilly and Co., Indianapolis, IN, 46285, USA
 SO Journal of Chromatography, Biomedical Applications (1993), 612(2), 253-61
 CODEN: JCBADL; ISSN: 0378-4347
 DT Journal
 LA English
 CC 1-1 (Pharmacology)
 AB A column-switching high-performance liq. chromatog. (HPLC) method is
 described for the detn. of dapoxetine and its mono- and di-desmethyl
 metabolites in human plasma. The analytes, including an internal std.,
 were extd. from plasma at basic pH with hexane-Et acetate. The org. ext.
 was evapd. to dryness and the residue reconstituted with acetonitrile.
 The analytes were sepd. from late-eluting endogenous substances on a
 Zorbax RX-C8 pre-column. The front-cut fraction contg. the analytes was
 further sepd. on a second RX-C8 column. The analytes were detected by
 their native fluorescence, using excitation and emission wavelengths of
 230 and 330 nm, resp. The limit of quantitation was detd. to be 20 ng/mL,
 and the response was linear from 20 to 200 ng/mL. The method has been
 successfully applied to human plasma samples in a Phase I study.
 ST dapoxetine metabolite detn blood HPLC; liq chromatog dapoxetine metabolite
 blood
 IT Blood analysis
 (dapoxetine and its metabolites detn. in human, by HPLC)
 IT Chromatography, column and liquid
 (high-performance, of dapoxetine and its metabolites, in human blood
 detn.)
 IT 147199-39-1 147199-40-4
 RL: ANT (Analyte); ANST (Analytical study)
 (detn. of, as dapoxetine metabolite, in blood of humans by HPLC)
 IT **119356-77-3**, Dapoxetine
 RL: ANT (Analyte); ANST (Analytical study)
 (detn. of, in blood of humans by HPLC)


=>

AN 1992:255284 CAPLUS
 DN 116:255284
 TI A chiral synthesis of dapoxetine hydrochloride, a serotonin reuptake inhibitor, and its ¹⁴C isotopomer
 AU Wheeler, William J.; O'Bannon, Douglas D.
 CS Lilly Corp. Cent., Eli Lilly and Co., Indianapolis, IN, 46285, USA
 SO Journal of Labelled Compounds and Radiopharmaceuticals (1992), 31(4), 305-15
 CODEN: JLCRD4; ISSN: 0362-4803
 DT Journal
 LA English
 CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
 OS CASREACT 116:255284
 AB The title isotopomer was prepd. by a chiral synthesis, starting with (R)-PhCHRNH(tert-Boc) (I, R = CO₂H). Borane redn., followed by activation of the resulting alc. as its mesylate, provided I (R = CH₂OMs). The radiolabel was introduced by reaction of the mesylate with sodium cyanide-[¹⁴C]. The desired product was then elaborated from the nitrile via a 5-step synthesis in an overall 19.5% radiochem. yield.
 ST dapoxetine carbon labeled chiral synthesis
 IT 126568-44-3P 141625-50-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and conversion to carboxylic acid)
 IT 102089-75-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and cyanation of)
 IT 102089-74-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and mesylation of)
 IT 82769-76-4P 141625-52-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and methylation of)
 IT 82769-75-3P 141625-53-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and reaction with fluoronaphthalene)
 IT 83649-47-2P 141625-51-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and redn. of)
 IT **129938-20-1P** 141625-54-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 IT 321-38-0, 1-Fluoronaphthalene
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with aminophenylpropoxide)
 IT 33125-05-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (redn. of)


=>

AN 1989:114467 CAPLUS
 DN 110:114467
 TI Preparation of 1-phenyl-3-(naphthalenyloxy)propanamines as serotonin inhibitors
 IN Robertson, David Wayne; Thompson, Dennis Charles; Wong, David Taiwai
 PA Lilly, Eli, and Co., USA
 SO Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 IC ICM C07C093-00
 ICS C07C093-14; C07D317-58; A61K031-135
 CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1, 63
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 288188	A1	19881026	EP 1988-303177	19880408
	EP 288188	B1	19911016		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	IL 85988	A1	19920818	IL 1988-85988	19880406
	CA 1329937	A1	19940531	CA 1988-563374	19880406
	AU 8814335	A1	19881013	AU 1988-14335	19880407
	AU 602971	B2	19901101		
	JP 63258837	A2	19881026	JP 1988-88025	19880407
	JP 06037443	B4	19940518		
	DK 8801882	A	19890112	DK 1988-1882	19880407
	DK 170637	B1	19951120		
	ZA 8802418	A	19891227	ZA 1988-2418	19880407
	CN 88102018	A	19881026	CN 1988-102018	19880408
	CN 1020093	B	19930317		
	HU 50316	A2	19900129	HU 1988-1790	19880408
	HU 204767	B	19920228		
	SU 1568886	A3	19900530	SU 1988-4355511	19880408
	AT 68473	E	19911115	AT 1988-303177	19880408
	ES 2045109	T3	19940116	ES 1988-303177	19880408
	US 5135947	A	19920804	US 1990-561492	19900801
PRAI	US 1987-36534		19870409		
	EP 1988-303177		19880408		
	US 1988-191465		19880509		
	US 1989-372149		19890626		
OS	MARPAT 110:114467				
GI					



I



II

AB The title compds. [I; R₁, R₂ = H, Me; R₃ = H, halo, C1-4 alkyl, C1-3 alkoxy, CF₃; R₄ = H, halo, C1-4 alkyl, C1-3 alkoxy, CF₃; R₄ = H, halo, C1-4 alkyl, C1-3 alkoxy, CF₃; R₄₂ = OCH₂O; m = 1, 2] and their stereoisomers and pharmaceutically acceptable salts were prepd. for selective inhibition of serotonin uptake in mammals, useful as

antidepressants. PhCH₂CO₂H was alkylated with 2-(4-methyl-1-naphthalenoxy)ethyl chloride by using BuLi in HMPA to give carboxyphenylnaphthalenyloxypropane II (R₅ = CO₂H) which was treated in acetone with ClCO₂Et in the presence of Et₃N and then with NaN₃. The resulting acid azide was rearranged to give II (R₅ = NCO) which was hydrolyzed to give II (R₅ = NH₂) (III). Reductive alkylation of the latter with CH₂O/NaBH₃CN in MeCN gave II (R₅ = NMe₂) (IV). Serotonin uptake by rat cerebral cortex synaptosome preps. was inhibited 50% by 25 mM IV.oxalate.

- ST naphthalenyloxyphenylpropanamine prepn serotonin uptake inhibitor;
antidepressant naphthalenyloxyphenylpropanamine prepn
- IT Antidepressants
((naphthalenyloxy)phenylpropanamines)
- IT 119357-38-9 119357-40-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(antidepressant pharmaceutical compn. contg.)
- IT 325-89-3P 119357-41-4P 119357-42-5P 119357-43-6P 119357-44-7P
119357-45-8P 119357-46-9P 119357-47-0P 119357-48-1P 119357-49-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction of, in prepn. of antidepressants)
- IT 119356-76-2P **119356-77-3P** 119356-78-4P 119356-79-5P
119356-80-8P 119356-81-9P 119356-82-0P 119356-83-1P 119356-84-2P
119356-86-4P 119356-88-6P 119356-90-0P 119356-92-2P 119356-94-4P
119356-96-6P 119356-98-8P 119357-00-5P 119357-02-7P 119357-04-9P
119357-06-1P 119357-07-2P 119357-09-4P 119357-11-8P 119357-13-0P
119357-15-2P 119357-17-4P 119357-18-5P 119357-19-6P 119357-20-9P
119357-21-0P 119357-23-2P 119357-24-3P 119357-25-4P 119357-27-6P
119357-29-8P 119357-31-2P 119357-33-4P 119357-35-6P 119357-37-8P
119374-91-3P 119374-93-5P 119374-95-7P 119374-97-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as serotonin uptake inhibitor)
- IT 74-89-5, Methylamine, reactions 90-15-3, 1-Naphthalenol 103-82-2,
Phenylacetic acid, reactions 141-82-2, Malonic acid, reactions
321-38-0, 1-Fluoronaphthalene 459-57-4, 4-Fluorobenzaldehyde 541-41-3,
Ethyl chloroformate 637-59-2, (3-Bromopropyl)benzene 3570-58-9,
2-Chloroethyl methanesulfonate 10240-08-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of antidepressants)
- IT 50-67-9, Serotonin, uses and miscellaneous
RL: USES (Uses)
(uptake of, by brain, (naphthalenyloxy)phenylpropanamines inhibition
of)

=>


AN 2001:249924 CAPLUS
 DN 135:190265
 TI Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care
 AU Ekselius, Lisa; von Knorring, Lars
 CS Department of Neuroscience, Psychiatry, University Hospital, Uppsala, S-751 85, Swed.
 SO Journal of Clinical Psychopharmacology (2001), 21(2), 154-160
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB This study prospectively examd. the occurrence and severity of sexual dysfunction symptoms in depressed patients before and after 6 mo of treatment with selective serotonin reuptake inhibitors. The study was part of a randomized, double-blind, controlled trial of sertraline or citalopram in patients with a DSM-III-R major depressive disorder treated by general practitioners. Three hundred eight patients (221 women and 87 men) were assessed before and after 6 mo of treatment by means of the Montgomery-Asberg Depression Rating Scale and five items from the Utvalg for Kliniske Undersøgelser (UKU) Side Effect Scale covering different aspects of sexual functioning. As measured by the UKU Side Effect Scale, sexual desire and mean total score improved in women, and sexual desire improved in men. Men reported no change in orgasmic dysfunction, erectile dysfunction, or mean total score, but there was a trend toward worsening of **ejaculatory** dysfunction. However, in the subgroup of women who reported no sexual problems before treatment, 11.8% reported decreased sexual desire, and 14.3% reported orgasmic dysfunction at week 24. The corresponding figures in the same subgroup of men were 16.7% and 18.9%, resp., and as many as 25% experienced **ejaculatory** dysfunction after 24 wk. There were no significant differences between sertraline and citalopram in the magnitude or frequency of adverse sexual side effects.
 ST antidepressant **serotonin reuptake inhibitor**
 sex function adverse effect; sertraline citalopram sex function adverse effect
 IT Antidepressants
 Sex
 Sexual behavior
 (selective serotonin reuptake inhibitors effect on sexual function in depressed men and women)
 IT 50-67-9, Serotonin, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (reuptake inhibitors; selective serotonin reuptake inhibitors effect on sexual function in depressed men and women)
 IT 59729-33-8, Citalopram 79617-96-2, Sertraline
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (selective serotonin reuptake inhibitors effect on sexual function in depressed men and women)
 RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Baldwin, D; Antidepressant therapy at the dawn of the third millennium 1998, P231
 (2) Balon, R; J Clin Psychiatry 1993, V554, P209
 (3) Carek, D; J Am Acad Child Adolesc Psychiatry 1996, V35, P1106 MEDLINE
 (4) Casper, R; Arch Gen Psychiatry 1985, V42, P1098 MEDLINE
 (5) Cassidy, W; JAMA 1957, V164, P1535
 (6) Clayton, A; Psychopharmacol Bull 1995, V31, P397 CAPLUS
 (7) Ekselius, L; Int Clin Psychopharmacol 1997, V12, P323 MEDLINE
 (8) Elmore, J; Pharmacotherapy 1997, V17, P612 MEDLINE

- (9) Feldman, H; J Urol 1994, V151, P54 MEDLINE
- (10) Guy, W; ECDEU manual 1976, P217
- (11) Hamilton, M; J Neurol Neurosurg Psychiatry 1960, V12, P56
- (12) Harrison, W; J Clin Psychopharmacol 1986, V6, P144 MEDLINE
- (13) Herman, J; J Clin Psychiatry 1990, V51, P25 MEDLINE
- (14) Kline, M; Am J Psychiatry 1989, V146, P804 MEDLINE
- (15) Labbate, L; Biol Psychiatry 1998, V43, P904 CAPLUS
- (16) Labbate, L; J Sex Marital Ther 1998, V24, P3 MEDLINE
- (17) Lane, R; J Psychopharmacol 1997, V11, P72 CAPLUS
- (18) Lingjaerde, O; Acta Psychiatr Scand 1987, V76(suppl 334), P1
- (19) Montejo-Gonzales, A; J Sex Marital Ther 1997, V23, P176
- (20) Montgomery, S; Br J Psychiatry 1979, V134, P382 MEDLINE
- (21) Musher, J; Am J Psychiatry 1990, V147, P948 MEDLINE
- (22) Piazza, L; Am J Psychiatry 1997, V154, P1757 MEDLINE
- (23) Rosen, R; J Clin Psychopharmacol 1999, V19, P67 CAPLUS
- (24) Wise, T; J Clin Psychiatry Update Monogr 1994, V1, P19
- (25) Zajecka, J; Psychopharmacol Bull 1997, V33, P755 CAPLUS


=>

AN 2001:730683 CAPLUS
 DN 135:288572
 TI Preparation of diphenyl ether compounds as serotonin re-uptake inhibitors
 IN Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan
 PA Pfizer Limited, UK; Pfizer Inc.
 SO PCT Int. Appl., 158 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07C217-58
 ICS C07C229-38; C07C237-28; C07C255-43; C07C255-59; C07C311-05; C07C311-08; C07C311-37; C07C317-32; C07C323-20; C07C323-32; C07C323-67; C07D207-12; C07D231-38; C07D233-61; C07D249-06; C07D249-08; C07D295-08; C07D295-18; A61K031-137
 CC 25-9 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072687	A1	20011004	WO 2001-IB428	20010319
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002052395	A1	20020502	US 2001-810378	20010316
	US 6448293	B2	20020910		
	EP 1268396	A1	20030102	EP 2001-917347	20010319
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001009547	A	20030610	BR 2001-9547	20010319
	NZ 519972	A	20030725	NZ 2001-519972	20010319
	JP 2003528845	T2	20030930	JP 2001-570602	20010319
	BG 106912	A	20030131	BG 2002-106912	20020709
	NO 2002004663	A	20020927	NO 2002-4663	20020927
PRAI	GB 2000-7884	A	20000331		
	US 2000-197127P	P	20000414		
	WO 2001-IB428	W	20010319		
OS	MARPAT 135:288572				
GI					



I



II

AB Title compds. I [wherein R1 and R2 = independently H or (cycloalkyl)alkyl; or R1 and R2 together with the N to which they are attached form an azetidine ring; R3 = independently CF3, OCF3, alkylthio, or alkoxy; n = 1-3; R4 and R5 = independently AX; A = CH:CH or (CH2)p; p = 0-2; X = H, halo, OH, alkoxy, NO2, CN, CHO, alkylthio, alkylsulfinyl, alkylsulfonyl, or (un)substituted carbamoyl, sulfamoyl, amino, carboxy, etc.; or pharmaceutically acceptable salts, solvates, or polymorphs thereof] were prep'd. as monoamine re-uptake inhibitors, particularly as selective serotonin re-uptake inhibitors. For example, 4-(methylmercapto)phenol was coupled with 2-fluorobenzaldehyde using K2CO3 in DMF to give 2-[4-(methylsulfanyl)phenoxy]benzaldehyde (100%). The aldehyde was dissolved in THF, DCM, Me2NH.bul.HCl, and TEA, treated with NaBH(OAc)3, and converted to the salt with 1M HCl in Et2O to afford N,N-dimethyl-N-[2-[4-(methylsulfanyl)phenoxy]benzyl]amine.bul.HCl (84%). Coupling the salt with ClSO3H in CH2Cl2 at 0.degree. to 5.degree.C, followed by stepwise addn. of MeCN with POCl3 and ammonia, produced the desired sulfonamide (II) in 61% yield. The latter showed serotonin re-uptake inhibition (SRI) activity with IC50 .ltoreq. 50 nM and was > 100-fold as potent in the inhibition of serotonin re-uptake than in the the inhibition of dopamine and noradrenaline re-uptake. I are useful in the treatment of disorders such as depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders, and sexual dysfunction, including premature **ejaculation** (no data).

ST diphenyl ether prepn **serotonin reuptake inhibitor**; ether diphenyl prepn antidepressant; attention deficit hyperactivity disorder treatment diphenyl ether prepn; obsessive compulsive disorder treatment diphenyl ether prepn; posttraumatic stress disorder treatment diphenyl ether prepn; substance abuse treatment diphenyl ether prepn; sexual dysfunction treatment diphenyl ether prepn

IT Drugs of abuse
(abuse of, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Mental disorder
(attention deficit hyperactivity disorder, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Sexual behavior
(disorder, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Stress, animal
(emotional, treatment of post-traumatic; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Transport proteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(monoamine-transporting, modulator; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Mental disorder
(obsession-compulsion, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Sexual behavior
(premature **ejaculation**, treatment; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT Antidepressants
(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 19555-09-0P, 3-Methoxy-4-(methylsulfanyl)phenol 60789-49-3P,
1-(Methylsulfanyl)-4-nitro-2-(trifluoromethyl)benzene 63094-56-4P,
4-(Methylsulfanyl)-3-(trifluoromethyl)aniline 78940-67-7P 95920-60-8P,
5-(Allyloxy)-1,3-benzoxathiol-2-one 127087-14-3P, 4-Methoxy-3-(methylsulfanyl)phenol 170282-24-3P, 5-(Benzyloxy)-2-sulfanylphenol 170283-11-1P, 6-(Benzyloxy)-1,3-benzoxathiol-2-one 217186-17-9P

289717-37-9P	361212-81-9P	364323-56-8P	364323-57-9P	364323-58-0P
364323-59-1P	364323-60-4P	364323-61-5P	364323-62-6P	364323-63-7P
364323-64-8P	364323-65-9P	364323-66-0P	364323-67-1P	364323-68-2P
364323-69-3P	364323-71-7P	364323-72-8P	364323-73-9P	364323-74-0P
364323-75-1P	364323-76-2P	364323-77-3P	364323-78-4P	364323-79-5P
364323-80-8P	364323-81-9P	364323-82-0P	364323-83-1P	364323-84-2P
364323-85-3P	364323-86-4P	364323-87-5P	364323-88-6P	364323-89-7P
364323-90-0P	364323-91-1P	364323-92-2P	364323-93-3P	364323-95-5P
364323-96-6P	364323-97-7P	364323-98-8P	364323-99-9P	364324-00-5P
364324-01-6P	364324-02-7P	364324-03-8P	364324-04-9P	364324-05-0P
364324-06-1P	364324-07-2P	364324-08-3P	364324-09-4P	364324-10-7P
364324-11-8P	364324-12-9P	364324-13-0P	364324-14-1P	364324-15-2P
364324-16-3P	364324-17-4P	364324-18-5P	364324-19-6P	364324-20-9P
364324-22-1P	364324-23-2P	364324-24-3P	364324-25-4P	364324-26-5P
364324-27-6P	364324-28-7P	364324-29-8P	364324-30-1P	364324-31-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 364321-43-7P	364321-47-1P	364321-48-2P	364321-49-3P	364321-52-8P
364321-53-9P	364321-54-0P	364321-56-2P	364321-57-3P	364321-58-4P
364321-59-5P	364321-61-9P	364321-62-0P	364321-64-2P	364321-65-3P
364321-66-4P	364321-67-5P	364321-68-6P	364321-70-0P	364322-18-9P
364322-19-0P	364322-20-3P	364322-21-4P	364322-28-1P	364322-29-2P
364322-33-8P	364322-34-9P	364322-35-0P	364322-36-1P	364322-37-2P
364322-39-4P	364322-42-9P	364322-43-0P	364322-59-8P	364322-60-1P
364322-61-2P	364322-62-3P	364322-64-5P	364322-65-6P	364322-66-7P
364322-67-8P	364322-77-0P	364322-79-2P	364322-80-5P	364322-81-6P
364322-95-2P	364322-96-3P	364322-97-4P	364322-98-5P	364323-06-8P
364323-07-9P	364323-08-0P	364323-13-7P	364323-24-0P	364323-31-9P
364323-32-0P	364323-36-4P	364323-37-5P	364323-42-2P	364323-46-6P
364323-48-8P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 364321-41-5P	364321-42-6P	364321-44-8P	364321-45-9P	364321-46-0P
364321-50-6P	364321-51-7P	364321-55-1P	364321-71-1P	364321-72-2P
364321-73-3P	364321-74-4P	364321-76-6P	364321-78-8P	364321-80-2P
364321-81-3P	364321-83-5P	364321-85-7P	364321-87-9P	364321-89-1P
364321-90-4P	364321-91-5P	364321-92-6P	364321-93-7P	364321-94-8P
364321-95-9P	364321-96-0P	364321-97-1P	364321-98-2P	364321-99-3P
364322-00-9P	364322-01-0P	364322-02-1P	364322-03-2P	364322-04-3P
364322-06-5P	364322-07-6P	364322-08-7P	364322-09-8P	364322-10-1P
364322-11-2P	364322-12-3P	364322-13-4P	364322-14-5P	364322-15-6P
364322-16-7P	364322-17-8P	364322-22-5P	364322-23-6P	364322-24-7P
364322-25-8P	364322-26-9P	364322-27-0P	364322-30-5P	364322-31-6P
364322-32-7P	364322-38-3P	364322-41-8P	364322-44-1P	364322-45-2P
364322-46-3P	364322-47-4P	364322-48-5P	364322-49-6P	364322-50-9P
364322-51-0P	364322-52-1P	364322-53-2P	364322-54-3P	364322-55-4P
364322-56-5P	364322-57-6P	364322-58-7P	364322-68-9P	364322-69-0P
364322-70-3P	364322-71-4P	364322-72-5P	364322-73-6P	364322-74-7P
364322-76-9P	364322-78-1P	364322-82-7P	364322-83-8P	364322-84-9P
364322-85-0P	364322-86-1P	364322-87-2P	364322-88-3P	364322-89-4P
364322-90-7P	364322-91-8P	364322-92-9P	364322-93-0P	364322-94-1P
364322-99-6P	364323-00-2P	364323-01-3P	364323-02-4P	364323-04-6P
364323-05-7P	364323-09-1P	364323-10-4P	364323-11-5P	364323-12-6P
364323-14-8P	364323-15-9P	364323-16-0P	364323-17-1P	364323-18-2P
364323-19-3P	364323-20-6P	364323-21-7P	364323-22-8P	364323-23-9P
364323-25-1P	364323-26-2P	364323-27-3P	364323-28-4P	364323-29-5P
364323-30-8P	364323-33-1P	364323-34-2P	364323-35-3P	364323-38-6P

364323-39-7P 364323-40-0P 364323-41-1P 364323-43-3P 364323-45-5P
 364323-47-7P 364323-49-9P 364323-50-2P 364323-51-3P 364323-52-4P
 364323-53-5P 364323-54-6P 364323-55-7P 364324-32-3P 364324-33-4P
 364324-34-5P 364324-36-7P 364324-37-8P 364324-38-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 50-67-9, Serotonin, biological studies 51-41-2, Noradrenaline 51-61-6, Dopamine, biological studies

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

IT 79-06-1, Acrylamide, reactions 98-17-9, 3-(Trifluoromethyl)phenol
 105-56-6 106-41-2, 4-Bromophenol 106-95-6, Allyl bromide, reactions
 109-85-3, 2-Methoxyethylamine 110-91-8, Morpholine, reactions
 288-32-4, Imidazole, reactions 288-36-8, 1H-1,2,3-Triazole 400-74-8,
 2-Fluoro-5-nitrobenzotrifluoride 402-45-9, 4-(Trifluoromethyl)phenol
 446-52-6, 2-Fluorobenzaldehyde 598-41-4, Glycinamide 771-61-9,
 Pentafluorophenol 827-99-6, 3-(Trifluoromethoxy)phenol 828-27-3,
 4-(Trifluoromethoxy)phenol 1073-72-9, 4-(Methylmercapto)phenol
 1820-80-0, 3-Amino-1H-pyrazole 2386-58-5, Vinylsulfonamide 2516-47-4,
 Cyclopropylmethanamine 2646-90-4, 2,5-Difluorobenzaldehyde 2749-11-3,
 (S)-2-Amino-1-propanol 2799-21-5 4991-65-5,
 6-Hydroxy-1,3-benzoxathiol-2-one 6361-21-3, 2-Chloro-5-nitrobenzaldehyde
 7735-56-0, 5-Hydroxy-1,3-benzoxathiol-2-one 10147-37-2, 2-Propylsulfonyl
 chloride 16114-05-9 16588-02-6, 2-Chloro-5-nitrobenzonitrile
 35320-23-1 36520-39-5, Azetidine hydrochloride 51517-01-2,
 2-Methoxyethylsulfonyl chloride 57848-46-1, 4-Bromo-2-fluorobenzaldehyde
 71924-62-4, 2-Fluoro-4,5-dimethoxybenzaldehyde 93777-26-5,
 5-Bromo-2-fluorobenzaldehyde 105728-90-3, 2-Fluoro-5-methoxybenzaldehyde
 112887-25-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(reactant; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE

- (1) Akzo; EP 0516234 A 1992 CAPLUS
- (2) Buckley, A; US 5334748 A 1994 CAPLUS
- (3) Kametani, T; JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY 1968, 23, P2877 CAPLUS
- (4) Manske, R; JOURNAL OF THE AMERICAN CHEMICAL SOCIETY 1950, V72(10), P4797
- (5) Pfizer; EP 0415613 A 1991 CAPLUS
- (6) Pfizer Products; WO 0050380 A 2000 CAPLUS
- (7) Yeager, G; SYNTHESIS 1995, 1, P28 CAPLUS

=>

AN 1999:98999 CAPLUS
 DN 130:246107
 TI Effects of SSRIs on sexual function: a critical review
 AU Rosen, Raymond C.; Lane, Roger M.; Menza, Matthew
 CS Department of Psychiatry, Robert Wood Johnson Medical School, University
 of Medicine and Dentistry of New Jersey, Piscataway, NJ, 08854, USA
 SO Journal of Clinical Psychopharmacology (1999), 19(1), 67-85
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Lippincott Williams & Wilkins
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 AB A review with 255 refs. Sexual problems are highly prevalent in both men
 and women and are affected by, among other factors, mood state,
 interpersonal functioning, and psychotropic medications. The incidence of
 antidepressant-induced sexual dysfunction is difficult to est. because of
 the potentially confounding effects of the illness itself, social and
 interpersonal comorbidities, medication effects, and design and assessment
 problems in most studies. Ests. of sexual dysfunction vary from a small
 percentage to more than 80%. This article reviews current evidence
 regarding sexual side effects of selective **serotonin** reuptake
 inhibitors (SSRIs). Among the sexual side effects most commonly assocd.
 with SSRIs are delayed **ejaculation** and absent or delayed orgasm.
 Sexual desire (libido) and arousal difficulties are also frequently
 reported, although the specific assocn. of these disorders to SSRI use has
 not been consistently shown. The effects of SSRIs on sexual functioning
 seem strongly dose-related and may vary among the group according to
serotonin and dopamine reuptake mechanisms, induction of prolactin
 release, anticholinergic effects, inhibition of nitric oxide synthetase,
 and propensity for accumulation over time. A variety of strategies have
 been reported in the management of SSRI-induced sexual dysfunction,
 including waiting for tolerance to develop, dosage redn., drug holidays,
 substitution of another antidepressant drug, and various augmentation
 strategies with 5-hydroxytryptamine-2 (5-HT₂), 5-HT₃, and .alpha.₂
 adrenergic receptor antagonists, 5-HT_{1A} and dopamine receptor agonists,
 and phosphodiesterase (PDE5) enzyme inhibitors. Sexual side effects of
 SSRIs should not be viewed as entirely neg.; some studies have shown
 improved control of premature **ejaculation** in men. The impacts
 of sexual side effects of SSRIs on treatment compliance and on patients'
 quality of life are important clin. considerations.
 ST **serotonin** reuptake inhibitors sexual disorder review
 IT Sexual behavior
 (disorder; effects of SSRIs on sexual function in humans)
 IT 50-67-9, **Serotonin**, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (selective **serotonin** reuptake inhibitors; effects of SSRIs on
 sexual function in humans)
 RE.CNT 255 THERE ARE 255 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Adaikan, P; J Auton Pharmacol 1983, V3, P107 CAPLUS
 (2) Agren, H; New Research Abstracts from the American Psychiatric Association
 Annual Meeting 1998
 (3) Ahlenius, S; Pharmacol Biochem Behav 1981, V15, P758
 (4) Ahmad, S; Arch Intern Med 1995, V155, P645 MEDLINE
 (5) Aizenberg, D; Clin Neuropharmacol 1995, V18, P320 CAPLUS
 (6) Aizenberg, D; Clin Neuropharmacol 1997, V20, P210 CAPLUS
 (7) Aldrich, A; Clin Drug Invest 1996, V11, P353 CAPLUS
 (8) Amsterdam, J; J Affect Disord 1998, V46, P151
 (9) Anand, V; Br J Psychiatry 1985, V147, P87 MEDLINE
 (10) Araujo, A; Psychosom Med 1998, V60, P458 MEDLINE
 (11) Arnott, S; Br J Psychiatry 1994, V164, P838 MEDLINE
 (12) Ascher, J; J Clin Psychiatry 1995, V56, P395 MEDLINE

- (13) Ashton, A; J Clin Psychiatry 1998, V59, P112 CAPLUS
- (14) Ashton, A; J Sex Marital Ther 1997, V23, P165
- (15) Assalian, P; J Sex Res 1988, V24, P213
- (16) Ayd, F; Int Drug Ther Newslett 1982, V17, P37
- (17) Baier, D; Fortschr Neurol Psychiatr 1994, V62, P14 MEDLINE
- (18) Baldessarini, R; Arch Gen Psychiatry 1990, V47, P191 MEDLINE
- (19) Ballenger, J; Am J Psychiatry 1998, V155, P36 MEDLINE
- (20) Balogh, S; J Clin Psychiatry 1992, V53, P212 MEDLINE
- (21) Balogh, S; J Clin Psychiatry 1993, V54, P115
- (22) Balon, R; J Clin Psychiatry 1993, V54, P209 MEDLINE
- (23) Balon, R; J Sex Marital Ther 1996, V22, P290 MEDLINE
- (24) Barbeau, A; Can Med Assoc J 1969, V101, P59 MEDLINE
- (25) Bartlick, B; J Sex Marital Ther 1995, V21, P264
- (26) Bartlick, B; Primary Psychiatry 1995, V2, P13
- (27) Bennazi, F; J Psychopharmacol 1997, V2, P190
- (28) Bennazi, F; Pharmacopsychiatry 1994, V27, P246
- (29) Bennie, E; J Clin Psychiatry 1995, V56, P229 MEDLINE
- (30) Benson, G; J Clin Invest 1980, V65, P506 CAPLUS
- (31) Berk, M; Int J Psychopharmacol 1997, V12, P121 MEDLINE
- (32) Bisserbe, J; Eur Psychiatry 1997, V12, P82
- (33) Bitran, D; Neurosci Biobehav Rev 1998, V11, P365
- (34) Blashko, C; Eur Neuropsychopharmacol 1995, V5, P258
- (35) Bodkin, J; J Clin Psychiatry 1997, V58, P137 CAPLUS
- (36) Bolden-Watson, C; Life Sci 1993, V52, P1023 CAPLUS
- (37) Bouchard, R; Am J Psychiatry 1989, V146, P1352
- (38) Bradford, J; Poster presented at the 148th annual meeting of the American Psychiatric Association 1995
- (39) Bredt, D; Nature 1991, V351, P714 CAPLUS
- (40) Bronzo, M; Am J Psychiatry 1993, V150, P1269 MEDLINE
- (41) Carek, D; J Am Acad Child Adolesc Psychiatry 1996, V35, P1106 MEDLINE
- (42) Casper, R; Arch Gen Psychiatry 1985, V42, P1098 MEDLINE
- (43) Cassidy, W; JAMA 1957, V164, P1535
- (44) Castaneda, R; J Clin Psychiatry 1996, V57, P485 MEDLINE
- (45) Cavallini, G; Eur Urol 1996, V30(suppl 2), P840
- (46) Christensen, R; J Clin Psychiatry 1995, V56, P433 MEDLINE
- (47) Clayton, A; Poster presented at the 37th Annual New Clinical Drug Evaluation Unit Meeting 1997
- (48) Clayton, A; Psychopharmacol Bull 1995, V31, P397 CAPLUS
- (49) Clayton, A; Psychopharmacol Bull 1997, V33, P747 MEDLINE
- (50) Cohen, A; J Sex Marital Ther 1998, V24, P139 MEDLINE
- (51) Cohen, M; Adverse Drug React Bull 1998, V190, P723
- (52) Coupland, M; J Clin Psychopharmacol 1996, V16, P356
- (53) Cowen, P; J Psychopharmacol 1997, V4, P345
- (54) Crenshaw, T; Sexual pharmacology:drugs that affect sexual functioning 1996, P285
- (55) Crenshaw, T; Sexual pharmacology:drugs that affect sexual functioning 1996, P369
- (56) Danjou, P; Br J Clin Pharmacol 1988, V26, P733 CAPLUS
- (57) Deijen, J; J Psychopharmacol 1989, V3, P149 CAPLUS
- (58) Derogatis, L; J Sex Marital Ther 1979, V5, P244 MEDLINE
- (59) Dorevitch, A; Ann Pharmacother 1994, V28, P872 MEDLINE
- (60) Dunner, D; J Clin Psychiatry 1992, V53(suppl 2), P21
- (61) Eaton, H; J Int Med Res 1973, V18, P701
- (62) Eke, T; BMJ 1997, V314, P1387 MEDLINE
- (63) Ekselius, L; Eur Neuropsychopharmacology 1997, V7(suppl 2), P147
- (64) Ellison, J; J Clin Psychiatry 1996, V57, P596 MEDLINE
- (65) Elmore, J; Pharmacol Ther 1997, V17, P612 MEDLINE
- (66) Ereshefsky, L; J Clin Psychopharmacol 1996, V16(suppl 2), P37S
- (67) Fabre, L; Biol Psychiatry 1995, V38, P592 CAPLUS
- (68) Fahlen, T; Eur Neuropsychopharmacol 1996, V6(suppl 3), P127
- (69) Fava, M; Poster presented at the first CINP Congress 1998
- (70) Fava, M; Psychosom Psychother (in press)

- (71) Feder, R; J Clin Psychiatry 1991, V52, P163 MEDLINE
- (72) Feiger, A; J Clin Psychiatry 1996, V57(suppl 2), P53
- (73) Feighner, J; Presented at the 37th annual meeting of the New Clinical Drug Evaluation Unit 1997
- (74) Feldman, H; J Urol 1994, V151, P54 MEDLINE
- (75) Fernandez-Guasti, A; Pharmacol Biochem Behav 1992, V42, P529 CAPLUS
- (76) Finkel, M; Psychopharmacol Bull 1996, V32, P653 CAPLUS
- (77) Fisher, S; J Clin Psychopharmacol 1993, V13, P235 MEDLINE
- (78) Florante, J; J Urol 1998, V159(suppl), P241
- (79) Foreman, M; Life Sci 1989, V45, P1263 CAPLUS
- (80) Forster, P; Am J Psychiatry 1994, V151, P1523 MEDLINE
- (81) Fowlie, S; Scott Med J 1987, V32, P52 MEDLINE
- (82) Freeman, P; J Clin Psychiatry 1994, V55, P301
- (83) Garcia-Campayo, J; Acta Psychiatr Scand 1995, V91, P69 MEDLINE
- (84) Gardner, E; J Clin Psychopharmacol 1995, V15, P24
- (85) Gelenberg, A; Poster presented at the 36th annual meeting of the American College of Neuropsychopharmacology 1997
- (86) Gelenberg, A; The practitioner's guide to psychoactive drugs 3rd ed 1991, P1997
- (87) Geretsegger, C; Int Clin Psychopharmacol 1994, V9, P25 MEDLINE
- (88) Gerner, R; Biol Psychiatry 1998, V43, P99S
- (89) Gitlin, M; J Clin Psychiatry 1994, V55, P406 MEDLINE
- (90) Gitlin, M; J Clin Psychiatry 1995, V56, P124 MEDLINE
- (91) Goldbloom, D; J Clin Psychiatry 1991, V52, P261 MEDLINE
- (92) Goldstein, B; J Psychopharmacol 1998, V12(suppl B), PS55
- (93) Goodnick, P; J Psychopharmacol 1998, V12(suppl), P5
- (94) Gordon, C; Psychopharmacology (Berl) 1998, V137, P201 CAPLUS
- (95) Grady, T; J Clin Psychopharmacol 1992, V12, P70 MEDLINE
- (96) Graziottin, A; Psychopharmacology 1995, V153, P474A
- (97) Greist, J; Arch Gen Psychiatry 1995, V52, P289 MEDLINE
- (98) Grimes, J; Biol Psychiatry 1996, V40, P1184 MEDLINE
- (99) Haensel, S; J Clin Psychopharmacol 1998, V18, P72 CAPLUS
- (100) Hall, M; Am J Psychiatry 1994, V129, P738
- (101) Hamilton, M; J Neurol Neurosurg Psychiatry 1960, V12, P56
- (102) Harrison, W; J Clin Psychopharmacol 1986, V6, P144 MEDLINE
- (103) Harvey, K; Ann Clin Psychiatry 1995, V7, P189 MEDLINE
- (104) Hawton, K; Br J Psychiatry 1982, V140, P94 MEDLINE
- (105) Herman, J; J Clin Psychiatry 1990, V51, P25 MEDLINE
- (106) Hindmarch, I; Hum Psychopharmacol 1988, V3, P13
- (107) Hollander, E; J Clin Psychiatry 1992, V53, P207 MEDLINE
- (108) Hollander, E; J Clin Psychiatry 1992, V53, P28 MEDLINE
- (109) Hsu, J; Int J Psychiatry Med 1995, V25, P191 MEDLINE
- (110) Hyttel, J; Nordic J Psychiatry 1993, V47(suppl 30), P5
- (111) Jacobsen, F; J Clin Psychiatry 1991, V52S, P271
- (112) Jacobsen, F; J Clin Psychiatry 1992, V53, P119 MEDLINE
- (113) Joffe, R; J Clin Psychiatry 1993, V54, P269 MEDLINE
- (114) Kafka, M; Ann Clin Psychiatry 1994, V6, P189 MEDLINE
- (115) Kaplan, P; J Sex Marital Ther 1994, V20, P321 MEDLINE
- (116) Kara, H; J Urol 1996, V156, P1631 CAPLUS
- (117) Katz, R; J Clin Psychiatry 1994, V55, P314 MEDLINE
- (118) Kavoussi, R; J Clin Psychiatry 1997, V58, P532 CAPLUS
- (119) Kerr, J; Int Clin Psychopharmacol 1992, V7, P101 MEDLINE
- (120) Kiev, A; J Clin Psychiatry 1997, V58, P146 CAPLUS
- (121) Kindler, S; Clin Neuropharmacol 1997, V20, P466 CAPLUS
- (122) Kivela, S; Z Gerontol 1988, V21, P257 MEDLINE
- (123) Kline, M; Am J Psychiatry 1989, V146, P804 MEDLINE
- (124) Klinge, E; Acta Physiol Scand 1997, V100, P354
- (125) Klug, B; Med J Aust 1984, V141, P71 MEDLINE
- (126) Koutouvidis, N; Eur Neuropsychopharmacol 1997, V7(suppl 2), PS156
- (127) Kowalski, A; Br J Psychiatry 1985, V147, P413 MEDLINE
- (128) Labbate, L; Ann Clin Psychiatry 1994, V6, P13 MEDLINE
- (129) Labbate, L; Biol Psychiatry 1998, V43, P904 CAPLUS

- (130) Labbate, L; J Sex Marital Ther 1998, V24, P3 MEDLINE
- (131) Laine, K; Clin Neuropsychopharmacol 1997, V20, P419 CAPLUS
- (132) Lal, S; Prog Neuropsychopharmacol Biol Psychiatry 1984, V8, P695 CAPLUS
- (133) Landen, M; New Research Abstracts from the American Psychiatric Association Annual Meeting 1998
- (134) Lane, R; Int Clin Psychopharmacol 1996, V11(suppl 5), P31
- (135) Lane, R; J Psychopharmacol 1997, V11, P72 CAPLUS
- (136) Lane, R; J Serotonin Res 1996, V3, P75 CAPLUS
- (137) Latimer, P; Eur Neuropsychopharmacol 1996, V6(suppl 3), P124
- (138) Lauerman, H; Acta Psychiatr Scand 1996, V93, P69 CAPLUS
- (139) Laumann, E; The social organization of sexuality 1994
- (140) Lebert, F; Am J Psychiatry 1993, V150, P167 MEDLINE
- (141) Lecrubier, Y; Acta Psychiatr Scand 1997, V95, P145 CAPLUS
- (142) Lee, H; J Clin Psychopharmacol 1996, V16, P379 CAPLUS
- (143) Lepine, J; Eur Neuropsychopharmacol 1996, V6, P123
- (144) Lewis, C; J Clin Psychiatry 1997, V58, P123 MEDLINE
- (145) Leyman, S; Eur J Clin Res 1995, V7, P287
- (146) Linden, R; Poster presented at the 148th Meeting of the American Psychiatric Association 1995
- (147) Linggjaerde, O; Acta Psychiatr Scand 1987, V76(suppl 334), P1
- (148) Londborg, P; Br J Psychiatry 1998, V173, P54 MEDLINE
- (149) Ludovico, G; Br J Urol 1996, V77, P881 CAPLUS
- (150) Lydiard, R; South Med J 1989, V82, P933 MEDLINE
- (151) Machale, S; Br J Psychiatry 1994, V164, P854 MEDLINE
- (152) Mackay, F; Pharmacoepidemiol Drug Saf 1997, V6, P235 CAPLUS
- (153) Marino, M; Clin Pharmacol Ther 1996, V59, P180
- (154) Massand, P; Depression 1995, V2, P319
- (155) Mathew, R; Arch Sex Behav 1982, V11, P323 MEDLINE
- (156) Mathew, R; Psychopharmacol Bull 1980, V16, P53
- (157) McConnell, J; J Neural Transm 1979, V45, P227 CAPLUS
- (158) McCormick, S; J Clin Psychiatry 1990, V51, P383 MEDLINE
- (159) McGahuey, C; New Research Program and Abstracts 150th Annual Meeting of the American Psychiatric Association 1997, P116
- (160) McLean, J; Can J Psychiatry 1983, V28, P569 MEDLINE
- (161) Medical Economics Data Production Co; Physician's desk reference 51st ed 1997
- (162) Meltzer, H; J Neural Transm 1979, V45, P165 MEDLINE
- (163) Mendels, J; J Clin Psychopharmacol 1995, V15, P341 MEDLINE
- (164) Mendelson, S; Neurosci Biobehav Rev 1991, V16, P309
- (165) Mendelson, W; J Clin Psychopharmacol 1994, V14, P434 MEDLINE
- (166) Menkes, D; Br J Psychiatry 1995, V166, P823 MEDLINE
- (167) Michael, A; Br J Psychiatry 1997, V171, P90 MEDLINE
- (168) Mills, I; Br J Clin Pract 1979, V61(suppl 4), P61
- (169) Modell, J; J Clin Psychopharmacol 1989, V9, P63 MEDLINE
- (170) Modell, J; Pharmacoepidemiol Drug Util 1997, V61, P476 CAPLUS
- (171) Monteiro, W; Br J Psychiatry 1987, V151, P107 MEDLINE
- (172) Montejo-Gonzalez, A; J Sex Marital Ther 1997, V23, P176 MEDLINE
- (173) Montorsi, F; Drugs 1995, V50, P465 CAPLUS
- (174) Morris, P; Int J Psychiatry Med 1991, V4, P379
- (175) Murray, M; Am J Psychiatry 1993, V8(150), P167
- (176) Musher, J; Am J Psychiatry 1990, V147, P948 MEDLINE
- (177) Naranjo, C; Clin Pharmacol Ther 1987, V41, P266 MEDLINE
- (178) Nelson, E; J Clin Psychiatry 1997, V58(11), P496 MEDLINE
- (179) Nelson, J; Am J Psychiatry 1981, V138, P1 MEDLINE
- (180) Nemeroff, C; Eur Neuropsychopharmacol 1995, V5, P304
- (181) Nemeth, A; Am J Psychiatry 1996, V153, P1365 MEDLINE
- (182) Nih Consensus Development Panel On Impotence; Impotence NIH Consensus Conference JAMA 1993, V270, P83
- (183) Nofzinger, E; Arch Gen Psychiatry 1993, V50, P24 MEDLINE
- (184) Norden, M; Depression 1994, V2, P109
- (185) Nyth, A; Br J Psychiatry 1990, V157, P894 MEDLINE
- (186) Olivera, A; J Sex Educ Ther 1994, V20, P119

- (187) O'Brien, C; Arch Gen Psychiatry 1971, V24, P61 MEDLINE
- (188) Paick, J; J Urol 1998, V159(suppl), P241
- (189) Patterson, W; J Clin Psychiatry 1993, V54, P71 MEDLINE
- (190) Piazza, L; Am J Psychiatry 1997, V154, P1757 MEDLINE
- (191) Pigott, T; Arch Gen Psychiatry 1990, V47, P926 MEDLINE
- (192) Pollack, B; Am J Psychiatry 1998, V155, P1110
- (193) Pollack, M; Int J Psychiatry Med 1992, V22, P305 MEDLINE
- (194) Pollock, B; Ther Drug Monit 1996, V18, P581 CAPLUS
- (195) Pomerantz, S; Eur J Pharmacol 1993, V243, P227 CAPLUS
- (196) Power-Smith, P; Br J Psychol 1994, V164, P249 MEDLINE
- (197) Preskorn, S; Int Clin Psychopharmacol 1995, V10, P129 MEDLINE
- (198) Preskorn, S; J Pract Psychiatry Behav Health 1997, V6, P99
- (199) Preskorn, S; Psychopharmacol Bull 1991, V27, P637 MEDLINE
- (200) Price, J; Br J Clin Pharmacol 1996, V42, P757 CAPLUS
- (201) Price, L; Arch Gen Psychiatry 1989, V46, P625 CAPLUS
- (202) Raptopoulos, P; Extended abstracts and poster presentations of the Paroxetine Symposium 1998
- (203) Ravindran, A; J Clin Psychiatry 1997, V58, P112 CAPLUS
- (204) Renodon, A; FEBS Lett 1997, V406, P33 CAPLUS
- (205) Reynolds, C; Psychiatry Res 1993, V24, P231
- (206) Reynolds, R; J Clin Psychiatry 1997, V58, P89 MEDLINE
- (207) Richelson, E; J Clin Psychiatry 1994, V55(suppl A), P34
- (208) Riley, A; Sexual pharmacology 1993, P114
- (209) Robbe, H; Eur Neuropsychopharmacol 1995, V5, P35 CAPLUS
- (210) Robillard, M; Can J Psychiatry 1995, V40, P639 MEDLINE
- (211) Roeloffs, C; J Clin Psychiatry 1996, V57, P548 MEDLINE
- (212) Rosen, R; Ann Rev Sex Res 1991, V2, P119
- (213) Rosen, R; Arch Sex Behav 1993, V22, P521 MEDLINE
- (214) Rosen, R; Erectile disorders:assessment and treatment 1992
- (215) Rothschild, A; Am J Psychiatry 1995, V152, P1514 MEDLINE
- (216) Santon, T; Biochem Pharmacol 1993, V45, P2352
- (217) Schwartz, V; Am J Psychiatry 1995, V152, P1698 MEDLINE
- (218) Segraves, R; Arch Gen Psychiatry 1989, V46, P275 CAPLUS
- (219) Segraves, R; Br J Psychiatry 1994, V165, P554 MEDLINE
- (220) Segraves, R; J Clin Psychiatry 1998, V59(suppl 4), P48
- (221) Segraves, R; J Clin Psychiatry Monogr 1993, V11, P57
- (222) Shahr, E; Fam Pract 1991, V8, P206 MEDLINE
- (223) Shrivastava, R; J Clin Psychopharmacol 1995, V15, P83 MEDLINE
- (224) Smeraldi, E; New Trends Exper Clin Psychiatry 1992, V8, P63
- (225) Smirai, M; Tohoku J Exp Med 1972, V104, P403
- (226) Smith, D; J Clin Psychiatry 1993, V54, P317 MEDLINE
- (227) Spector, L; Arch Sex Behav 1990, V19, P389
- (228) Stahl, S; J Clin Psychiatry 1988, V59, P47
- (229) Stoll, A; J Clin Psychiatry 1996, V57, P72 MEDLINE
- (230) Stratta, P; J Urol 1993, V151, P345A
- (231) Sullivan, G; Hosp Community Psychiatry 1990, V41, P1238 MEDLINE
- (232) Swartz, D; J Urol 1994, V151(suppl), P345A
- (233) Swenson, J; Can J Psychiatry 1993, V38, P297 MEDLINE
- (234) Tatsumi, M; Eur J Pharmacol 1997, V340, P249 CAPLUS
- (235) Thase, M; Biol Psychiatry 1988, V24, P33 MEDLINE
- (236) Tollefson, G; Arch Gen Psychiatry 1994, V51, P559 MEDLINE
- (237) Tome, M; Poster presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology 1997
- (238) van Moffaert, M; Hum Psychopharmacol 1995, V10, P393 CAPLUS
- (239) van Putten, T; J Clin Psychopharmacol 1990, V10, P234 MEDLINE
- (240) Wade, A; Br J Psychiatry 1997, V170, P549 MEDLINE
- (241) Walczak, D; Ann Clin Psychiatry 1996, V8, P139 MEDLINE
- (242) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (243) Waldinger, M; Br J Urol 1997, V79, P592 CAPLUS
- (244) Waldinger, M; J Clin Psychopharmacol 1998, V18, P274 CAPLUS
- (245) Walker, P; J Clin Psychiatry 1993, V54, P459 MEDLINE
- (246) Weiner, D; Sexual function in people with disability and chronic illness

1997, P85

- (247) Wernicke, J; Psychopharmacol Bull 1987, V23, P164 MEDLINE
- (248) Wheadon, D; Presented at the American Congress of Neuropharmacology 1993
- (249) Wing, Y; Psychopharmacology (Berl) 1996, V124, P377 CAPLUS
- (250) Wise, T; J Clin Psychiatry 1994, V55, P417 MEDLINE
- (251) Wise, T; J Clin Psychiatry Monogr 1994, V1, P19
- (252) Zajecka, J; J Clin Psychiatry 1991, V52, P66 MEDLINE
- (253) Zajecka, J; Psychopharmacol Bull 1997, V33, P755 CAPLUS
- (254) Zohar, J; Arch Gen Psychiatry 1988, V45, P167 MEDLINE
- (255) Zubieta, J; J Clin Psychopharmacol 1991, V11, P327 MEDLINE

=>

AN 1998:510509 CAPLUS
 DN 129:270469
 TI Effect of SSRI antidepressants on **ejaculation**: A double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline
 AU Waldinger, Marcel D.; Hengeveld, Michiel W.; Zwinderman, Aeilko H.; Olivier, Berend
 CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, The Hague, Neth.
 SO Journal of Clinical Psychopharmacology (1998), 18(4), 274-281
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Depression is a common cause of sexual dysfunction, but also antidepressant medication is often assocd. with sexual side effects. This article includes two related studies. The first double-blind, placebo-controlled study was conducted in men with lifelong rapid **ejaculation** and aimed to assess putative differences between the major selective **serotonin** reuptake inhibitors (SSRIs) (fluoxetine, fluvoxamine, paroxetine, and sertraline) with regard to their **ejaculation**-delaying effect. Sixty men with an intravaginal **ejaculation** latency time (IELT) of 1 min or less were randomly assigned to receive fluoxetine 20 mg/day, fluvoxamine 100 mg/day, paroxetine 20 mg/day, sertraline 50 mg/day, or placebo for 6 wk. During the 1-mo baseline and 6-wk treatment periods, the men measured their IELT at home using a stopwatch. The trial was completed by 51 men. During the 6-wk treatment period, the geometric mean IELT in the placebo group was const. at approx. 20 s. Anal. of variance revealed a between-groups difference in the evolution of IELT delay ($p = 0.0004$); in the paroxetine, fluoxetine, and sertraline groups there was a gradual increase to about 110 s, whereas in the fluvoxamine group, IELT was increased to only approx. 40 s. The paroxetine, fluoxetine, and sertraline groups differed significantly ($p < 0.001$, $p < 0.001$, $p = 0.017$, resp.) from placebo but the fluvoxamine group did not ($p = 0.38$). Compared with baseline, paroxetine exerted the strongest delay in **ejaculation**, followed by fluoxetine and sertraline. There was no clin. relevant delay in **ejaculation** with fluvoxamine. In men with lifelong rapid **ejaculation**, paroxetine delayed **ejaculation** most strongly, whereas fluvoxamine delayed **ejaculation** the least. The second double-blind, placebo-controlled study was carried out in men with lifelong rapid **ejaculation** (IELT \leq 1 min) and in men with lifelong less-rapid **ejaculation** (IELT > 1 min) to investigate whether data about SSRI-induced delayed **ejaculation** in men with rapid **ejaculation** may be extrapolated to men with less-rapid **ejaculation**. After measurement of IELT at home (using a stopwatch) during a 1-mo baseline assessment, 32 men with an IELT of 1 min or less (group 1) or more than 1 min (group 2) were randomly assigned to receive paroxetine 20 mg/day or placebo for 6 wk in a double-blind manner. Patients continued to measure their IELTs at home during the 6 wk of the study. At baseline, 24 patients consistently had IELTs of one minute or less (group 1), and eight patients had IELTs of more than 1 min (group 2). The geometric mean IELT was 14 s in group 1 and 83 s in group 2. Twelve patients in group 1 and five in group 2 were randomized to the paroxetine 20 mg/day. The percentage increase in the geometric mean IELT compared with baseline in patients treated with paroxetine was 420% (95% confidence interval [CI], 216-758%) in group 1 and 480% (95% CI, 177-1,118%) in group 2 ($p = 0.81$). After 6 wk of treatment with paroxetine, the geometric mean IELT was 92 s in group 1 and 602 s in group 2. Therefore, the paroxetine-induced percentage increase in IELT seems to be independent of the baseline IELT. This suggests that

ejaculation-delaying side effects of some SSRIs investigated in men with lifelong rapid **ejaculation** may be generalized to men with less-rapid **ejaculation**.

ST SSRI antidepressant **ejaculation** fluoxetine fluvoxamine paroxetine; sertraline SSRI antidepressant **ejaculation** fluoxetine fluvoxamine

IT Sexual behavior

(**ejaculation**; vSSRIs antidepressants fluoxetine, fluvoxamine paroxetine, and sertraline effects on **ejaculation** latency in men)

IT Sexual behavior

(premature **ejaculation**; SSRIs antidepressants fluoxetine, fluvoxamine paroxetine, and sertraline effects on **ejaculation** latency in men)

IT Antidepressants

(selective **serotonin** reuptake inhibitors; SSRIs antidepressants fluoxetine, fluvoxamine paroxetine, and sertraline effects on **ejaculation** latency in men)

IT 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine 61869-08-7, Paroxetine 79617-96-2, Sertraline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(SSRIs antidepressants fluoxetine, fluvoxamine paroxetine, and sertraline effects on **ejaculation** latency in men)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Ahlenius, S; Pharmacol Biochem Behav 1981, V15, P758
- (2) Anon; Informatorium Medicamentorum 1996 1996
- (3) Casper, R; Arch Gen Psychiatry 1985, V42, P1098 MEDLINE
- (4) Derogatis, L; SCL-90, Handleiding bij een Multidimensionale Psychopathologie-indicator 1986
- (5) Dunner, D; J Clin Psychiatry 1992, V53(2 suppl), P21
- (6) Fabre, L; Biol Psychiatry 1995, V38, P592 CAPLUS
- (7) Gommans, J; Psychopharmacology (Berl), in press
- (8) Kara, H; J Urol 1996, V156, P1631 CAPLUS
- (9) Kennedy, S; Eur Neuropsychopharmacol 1996, V6, P177 CAPLUS
- (10) Kowalski, A; Br J Psychiatry 1985, V147, P413 MEDLINE
- (11) Lemberger, L; J Clin Psychiatry 1985, V46, P14 CAPLUS
- (12) Lingjaerde, O; Acta Psychiatr Scand 1987, V76(suppl 334), P1
- (13) Marsden, C; Psychopharmacology 1987, V1, P244 CAPLUS
- (14) Marson, R; Brain Res 1990, V515, P303 MEDLINE
- (15) Mathew, R; Arch Sex Behav 1982, V11, P323 MEDLINE
- (16) Mendels, J; J Clin Psychopharmacol 1995, V15, P341 MEDLINE
- (17) Meston, C; J Psychoactive Drugs 1992, V24, P1 MEDLINE
- (18) Mos, J; Eur Neuropsychopharmacol, in press
- (19) Olivier, B; Pharmacopsychiatry 1993, V26(suppl 1), P2
- (20) Preskorn, S; Int Clin Psychopharmacol 1995, V10, P129 MEDLINE
- (21) Simpson, G; Dis Nerv Syst 1965, V26, P787 MEDLINE
- (22) Steiger, A; J Clin Psychopharmacol 1988, V8, P349 MEDLINE
- (23) Thase, M; Biol Psychiatry 1992, V31, P1136 MEDLINE
- (24) Walczak, D; Ann Clin Psychiatry 1996, V8, P139 MEDLINE
- (25) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (26) Waldinger, M; Behav Brain Res 1998, V92, P111 MEDLINE
- (27) Waldinger, M; Br J Urol 1997, V79, P592 CAPLUS
- (28) Waldinger, M; CNS Drugs 1996, V6, P204 CAPLUS
- (29) Waldinger, M; PhD thesis, University of Utrecht 1997, P127
- (30) Waldinger, M; Psychiatr Genet 1998, V8, P37 MEDLINE
- (31) Wernicke, J; Psychopharmacol Bull 1987, V23, P164 MEDLINE
- (32) Yells, D; Pharmacol Biochem Behav 1994, V49, P121 CAPLUS

=>

AN 1998:264650 CAPLUS
 DN 129:103665
 TI Premature **ejaculation** and serotonergic antidepressants-induced delayed **ejaculation**. The involvement of the serotonergic system
 AU Waldingeri, Marcel D.; Berendsen, Hemmie H. G.; Blok, Bertil F. M.; Olivier, Berend; Holstege, Gert
 CS Department of Psychiatry and Neurosexology, Leyenburg Hospital, Leyweg 275, The Hague, 2545 CH, Neth.
 SO Behavioural Brain Research (1998), 92(2), 111-118
 CODEN: BBREDI; ISSN: 0166-4328
 PB Elsevier Science B.V.
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 Section cross-reference(s): 14
 AB A review with 58 refs. Premature **ejaculation** has generally been considered a psychosexual disorder with psychogenic etiol. Although still mainly treated by behavioral therapy, in recent years double-blind studies have indicated the beneficial effects of some of the serotonergic antidepressants (SSRIs) in delaying **ejaculation**. We describe here the neurophysiol. and the peripheral neuroanatomy of **ejaculation** and provide a review of the involvement of **serotonin** in the central nervous system in relation to serotonergic nuclei and their projections. A hypothesis of the role of 5-HT1A and 5-HT2C receptors in premature **ejaculation** is postulated.
 ST review antidepressant premature **ejaculation** serotonergic system
 IT 5-HT receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (5-HT1A; serotonergic system in antidepressants-induced delayed **ejaculation**)
 IT 5-HT receptors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (5-HT2C; serotonergic system in antidepressants-induced delayed **ejaculation**)
 IT Sexual behavior
 Sexual behavior
 (premature **ejaculation**; serotonergic system in antidepressants-induced delayed **ejaculation**)
 IT Antidepressants
 (serotonergic system in antidepressants-induced delayed **ejaculation**)
 IT Nerve
 (serotonergic; serotonergic system in antidepressants-induced delayed **ejaculation**)
 IT 50-67-9, **Serotonin**, biological studies
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (serotonergic system in antidepressants-induced delayed **ejaculation**)
 RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Abraham, K; Psychoanalyse 1917, VIV, PI71
 (2) Ahlenius, S; Pharmacol Biochem Behav 1981, V15, P785 CAPLUS
 (3) Althof, S; J Clin Psychiatry 1995, V56, P402 MEDLINE
 (4) American Psychiatric Association; Diagnostic and Statistical Manual of Mental Disorders, 4th ed 1994
 (5) Aycok, L; J Urol 1949, V62, P361
 (6) Bennett, D; Lancet 1961, VII, P1309

- (7) Benson, G; The Physiology of Reproduction 1988
- (8) Berendsen, H; Br J Pharmacol 1990, V101, P667 CAPLUS
- (9) Berendsen, H; Eur J Pharmacol 1987, V338, P191
- (10) Berendsen, H; Eur J Pharmacol 1994, V253, P83 CAPLUS
- (11) Berendsen, H; Pharmacol Biochem Behav 1989, V33, P821 CAPLUS
- (12) Berendsen, H; Psychopharmacology 1990, V101, P57 CAPLUS
- (13) Berkovitch, M; J Urol 1995, V154, P1360 MEDLINE
- (14) Bertacinni, G; Lancet 1960, V1, P881
- (15) Crenshaw, R; Annual Meeting of the American Association of Sex Educators, Counselors and Therapists 1992
- (16) Damrau, F; J Urol 1963, V89, P936 MEDLINE
- (17) de Groat, W; Central Regulation of Autonomic Functions 1990, P310
- (18) Deamicis, L; Arch Sexual Behav 1985, V14, P467 MEDLINE
- (19) Erspamer, V; Arch f Exp Path Pharmacol 1940, V196, P336
- (20) Erspamer, V; Nature 1952, V169, P800 CAPLUS
- (21) Farthing, M; Scand J Gastroenterol 1991, V26, P92 CAPLUS
- (22) Foreman, M; Life Sci 1989, V45, P1263 CAPLUS
- (23) Girgis, S; Andrologia 1982, V29, P364
- (24) Goodman, R; J Int Med Res 1980, V8(S3), P53
- (25) Grahame-Smith, D; Q J Med 1988, V67, P459 MEDLINE
- (26) Haensel, S; J Urol 1996, V156, P1310 CAPLUS
- (27) Hawton, K; Behav Res Ther 1986, V24, P665 MEDLINE
- (28) Holstege, G; Progr Brain Res 1991, V87, P307 MEDLINE
- (29) Holstege, J; The Emotional Motor System Progr Brain Res 1996, V107, P159 CAPLUS
- (30) Hoyer, D; Pharmacol Rev 1994, V46, P157 CAPLUS
- (31) Jacobs, B; Physiol Rev 1992, V72, P165 CAPLUS
- (32) Lawrence, J; Int J Psychiatry Med 1992, V22, P77
- (33) Marberger, H; Physiology and Genetics of Reproduction; Basic Life Sciences 1974, V4 MEDLINE
- (34) Masters, W; Human Sexual Inadequacy 1970, P92
- (35) Mendels, J; J Clin Psychopharmacol 1995, V15, P341 MEDLINE
- (36) Meston, C; J Psychoactive Drugs 1992, V24, P1 MEDLINE
- (37) Molewijk, H; Eur J Neurosci 1989, V214(2), P121
- (38) Molliver, M; Ann NY Acad Sci 1990, V600, P640
- (39) Peroutka, S; Mol Pharmacol 1979, V16, P687 CAPLUS
- (40) Rapport, M; J Biol Chem 1949, V180, P961 CAPLUS
- (41) Retief, P; S Afr Med J 1950, V24, P509
- (42) Ruff, G; Clin Psychol Rev 1985, V5, P627
- (43) Segraves, R; Am J Psychiatry 1987, V144, P1240 MEDLINE
- (44) Segraves, R; J Sex Marital Ther 1993, V19, P198 MEDLINE
- (45) Semans, J; J Urol 1938, V40, P836
- (46) Semans, J; S Afr Med J 1956, V49, P353
- (47) Singer, C; Sexual Dysfunction, a Neuro-Medical Approach 1994, P30
- (48) Steinbush, H; Neuroscience 1981, V4, P557
- (49) Szele, F; Life Sci 1988, V43, P1297 CAPLUS
- (50) Tork, I; Ann NY Acad Sci 1990, V600, P6
- (51) Twarag, B; Am J Physiol 1953, V174, P157
- (52) Waldinger, M; Am J Psychiatry 1994, V151, P1377 MEDLINE
- (53) Waldinger, M; Br J Urol 1997, V79, P592 CAPLUS
- (54) Waldinger, M; Diagnostic Criteria for Premature Ejaculation, submitted 1997
- (55) Waldinger, M; J Clin Psychopharmacol, in press 1997
- (56) Waldinger, M; Psychiatr Genet, in press 1997
- (57) Woolley, D; Proc Natl Acad Sci 1954, V40, P228 CAPLUS
- (58) Yap, C; Neuropharmacology 1983, V22, P801 CAPLUS

=>

AN 1997:672097 CAPLUS
 DN 127:326407
 TI The treatment of comorbid premature **ejaculation** and panic disorder with fluoxetine
 AU Kindler, S.; Dolberg, O.T.; Cohen, H.; Hirschmann, S.; Kotler, M.
 CS Anxiety Clinic, Psychiatric Division, Sheba Medical Center, Ranmat-Gan, and Sackler School of Medicine, Tel Aviv University, Tel-Aviv, 52621, Israel
 SO Clinical Neuropharmacology (1997), 20(5), 466-471
 CODEN: CLNEDB; ISSN: 0362-5664
 PB Lippincott-Raven
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Premature **ejaculation** is a common sexual disturbance among men. Both open-label and double-blind studies have demonstrated the effectiveness of serotonergic medications for this disorder. These studies support the hypothesis that the serotonergic system has an important role in the modulation of sexual response, esp. attainment of orgasm. Serotonergic dysfunction also has been linked to the pathogenesis of panic disorder. Several studies have demonstrated the efficacy of serotonergic drugs in this disorder. The purpose of the present study was to examine the efficacy of fluoxetine, a **serotonin** selective reuptake inhibitor for the treatment of comorbid premature **ejaculation** and panic disorder, in 10 men in an open-label design. The patients were given 20 mg of fluoxetine for 8 wk of the study. Parameters pertaining to sexual function and measures of anxiety were examd. Improvement of premature **ejaculation** was noted as of week 2 of the study, whereas measures of panic and sexual satisfaction became statistically significant only as of week 4. Further studies with larger samples and longer periods of follow-up are needed in order to det. the usefulness of fluoxetine for the treatment of comorbid premature **ejaculation** and panic disorder.
 ST fluoxetine premature **ejaculation** panic disorder antipsychotic
 IT Anxiety
 (panic disorder; treatment of comorbid premature **ejaculation** and panic disorder with fluoxetine in humans)
 IT Sexual behavior
 Sexual behavior
 (premature **ejaculation**; treatment of comorbid premature **ejaculation** and panic disorder with fluoxetine in humans)
 IT Antipsychotics
 (treatment of comorbid premature **ejaculation** and panic disorder with fluoxetine in humans)
 IT 54910-89-3, Fluoxetine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment of comorbid premature **ejaculation** and panic disorder with fluoxetine in humans)

=>

AN 1996:657688 CAPLUS
 DN 125:317071
 TI The efficacy of fluoxetine in the treatment of premature
ejaculation: A double-blind placebo controlled study
 AU Kara, Hayrettin; Aydin, Sabahattin; Agargun, M. Yucel; Odabas, Oner;
 Yilmaz, Yuksel
 CS Medical School Yuzuncu, Yil University, Van, Turk.
 SO Journal of Urology (Baltimore) (1996), 156(5), 1631-1632
 CODEN: JOURAA; ISSN: 0022-5347
 PB Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB The efficacy of the selective **serotonin** re-uptake inhibitor
 fluoxetine in the treatment of premature **ejaculation** was examd.
 The study comprized 17 patients with premature **ejaculation** who
 presented to the urol. clinic of the authors' medical school. In this
 double-blind study the patients were randomized into treatment groups
 receiving 20 mg. fluoxetine daily for 1 wk and 40 mg. daily afterward
 (group (1)) or 1 capsule placebo daily for 1 wk and 2 capsules daily
 afterward (group (2)). The groups were evaluated according to the latent
 period of intravaginal **ejaculation**. The latent period of
 intravaginal **ejaculation** in group 1 was significantly longer
 than that in group 2. Nausea, headache and insomnia were reported side
 effects. Fluoxetine may be regarded as a safe and effective alternative
 in the treatment of premature **ejaculation**.
 ST fluoxetine premature **ejaculation**
 IT Sexual behavior
 (disorder, premature **ejaculation**, efficacy of fluoxetine in
 treatment of premature **ejaculation** dealing with a
 double-blind placebo controlled study in humans)
 IT 54910-89-3, Fluoxetine
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (efficacy of fluoxetine in treatment of premature **ejaculation**
 dealing with a double-blind placebo controlled study in humans)

=>

AN 1996:614257 CAPLUS
 DN 125:264724
 TI Use of psychoactive agents in the treatment of sexual dysfunction
 AU Waldinger, Marcel D.
 CS Department Psychiatry and Neurosexology, Leyenburg Hospital, The Hague, Neth.
 SO CNS Drugs (1996), 6(3), 204-216
 CODEN: CNDREF; ISSN: 1172-7047
 PB Adis
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 AB A review with 86 refs. Sexual function can be subdivided into phases of sexual desire, penile erection, **ejaculation** and orgasm. Dysfunction of these processes is manifest as disorders that include hypoactive sexual desire, male erectile dysfunction, premature and retarded **ejaculation**, and anorgasmia. These disorders can be primary in etiol. or can be caused by a no. of psychoactive drugs including, commonly, antidepressants. At present, sexual dysfunction is rarely treated with pharmacol. agents. The usual approach consists of psychotherapy. However, in recent years, more interest has arisen in treating disorders of sexual function with psychopharmacol. drugs, particularly sexual dysfunction that is the adverse effect of antidepressants. Clin. reports suggest that primary premature **ejaculation** can be successfully treated with clomipramine and selective **serotonin** (5-hydroxytryptamine; 5-HT) reuptake inhibitors. At present, only a few oral medications have been shown to be useful in the treatment of erectile dysfunction (including yohimbine and trazodone), although these have not been developed specifically for this indication. The pharmacol. treatment of primary retarded **ejaculation** and female primary anorgasmia still offers no efficacy. There are, on the other hand,.
 ST psychotropic sexual dysfunction review
 IT Psychotropics
 (use of psychoactive agents in the treatment of sexual dysfunction in humans)
 IT Sexual behavior
 (disorder, use of psychoactive agents in the treatment of sexual dysfunction in humans)


=>

AN 1997:702829 CAPLUS
 DN 127:341724
 TI Fluvoxamine maleate in the treatment of depression: a single-center,
 double-blind, placebo-controlled comparison with imipramine in outpatients
 AU Claghorn, James L.; Earl, Craig Q.; Walczak, Donna D.; Stoner, Kim A.;
 Wong, Lung Fai; Kanter, Donald; Houser, Vincent P.
 CS Clin. Res. Assocs., Houston, TX, USA
 SO Journal of Clinical Psychopharmacology (1996), 16(2), 113-120
 CODEN: JCPYDR; ISSN: 0271-0749
 PB Williams & Wilkins
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB The efficacy and safety of fluvoxamine maleate, a **selective
 serotonin reuptake inhibitor**, was compared
 with placebo and imipramine in patients with major depression disorder.
 Previous literature has cited a dose range of 100 to 300 mg/day of
 fluvoxamine maleate for the treatment of major depression; however, this
 study demonstrates that a dose range of 50 to 150 mg/day is as effective
 as imipramine (80-240 mg/day). After a 1- to 2-wk, single-blind, placebo
 washout phase, 150 depressed outpatients were randomized to double-blind
 treatment with fluvoxamine maleate (50-150 mg/day), imipramine (80-240
 mg/day), or placebo for 6 wk. Flovoxamine produced a significant
 therapeutic benefit over placebo (p .ltoreq. 0.05) as assessed by the
 total score on the Hamilton Rating Scale for Depression; imipramine
 (80-240 mg/day) produced similar results. The secondary outcome variables
 (i.e., Clin. Global Impression severity of illness item of 56-Item Hopkins
 Symptom Checklist depression factor) also showed significant differences
 between fluvoxamine maleate and placebo during three of the four final
 weeks of the study. Both fluvoxamine maleate and imipramine appeared to
 be safe and well tolerated by the majority of patients. As expected from
 the pharmacol. of these agents, the imipramine groups reported more
 anticholinergic effects (dry mouth, dizziness, and urinary retention) and
 electrocardiog. effects, whereas the fluvoxamine group reported more
 nausea, somnolence, and abnormal **ejaculation**. The majority of
 these adverse events were mild to moderate and, with the exception of dry
 mouth (imipramine) and abnormal **ejaculation** (fluvoxamine), were
 transient. The data clearly demonstrate the antidepressant activity and
 tolerability of fluvoxamine maleate (50-150 mg/day) was compared with
 placebo; it is also as effective as the tricyclic antidepressant
 imipramine (80-240 mg/day) in patients with major depressive disorder.
 ST fluvoxamine imipramine antidepressant
 IT Antidepressants
 (selective serotonin reuptake inhibitors; Comparison of fluvoxamine and
 imipramine in treatment of depression in humans)
 IT 54739-18-3, Fluvoxamine
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); THU
 (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Comparison of fluvoxamine and imipramine in treatment of depression in
 humans)
 IT 50-49-7, Imipramine
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Comparison of fluvoxamine and imipramine in treatment of depression in
 humans)

=>

RN 129938-20-1 REGISTRY
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
hydrochloride, (.alpha.S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
hydrochloride, (S)-
OTHER NAMES:
CN **Dapoxetine hydrochloride**
CN LY 210448 hydrochloride
FS STEREOSEARCH
MF C21 H23 N O . Cl H
SR US Adopted Names Council
LC STN Files: CA, CAPLUS, IPA, SYNTHLINE, USAN, USPATFULL
Other Sources: WHO
CRN (119356-77-3)

Absolute stereochemistry.




● HCl

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2003 ACS on STN
RN 119356-77-3 REGISTRY
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
(.alpha.S)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenemethanamine, N,N-dimethyl-.alpha.-[2-(1-naphthalenyloxy)ethyl]-,
(S)-
OTHER NAMES:
CN **Dapoxetine**
CN LY 210448
FS STEREOSEARCH
MF C21 H23 N O
CI COM
SR CA
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB,
CIN, DDFU, DRUGNL, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, PHAR, PROMT,
RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

12 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=>

L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:79863 CAPLUS
 DN 126:180636
 TI Tolerability and safety of citalopram
 AU Baldwin, David; Johnson, F. Neil
 CS Royal South Hants Hospital, University Department of Psychiatry,
 Southampton, SO14 0YG, UK
 SO Reviews in Contemporary Pharmacotherapy (1995), 6(6), 315-325
 CODEN: RCPHFW; ISSN: 0954-8602
 PB Marius Press
 DT Journal; General Review
 LA English
 CC 1-0 (Pharmacology)
 AB A review with .apprx.45 refs. The **selective serotonin
 reuptake inhibitor** citalopram has proven efficacy in the
 treatment of acute episodes of depression, and in continuation treatment
 following symptomatic resoln. The tolerability profile of citalopram is
 markedly different from that seen with older tricyclic antidepressant
 drugs, and is similar to that of the other SSRIs. Adverse events which
 occur more frequently with citalopram than with placebo in controlled
 trials are nausea, dry mouth, somnolence, increased sweating, tremor,
 diarrhea, and **ejaculation** failure. When compared with a range
 of tricyclic and related drugs in controlled trials, citalopram showed
 more nausea and **ejaculation** failure events than the comparator
 drugs, but on ten other categories of adverse event the tricyclics and
 related drugs were significantly worse than citalopram. The tolerability
 profile among elderly patients was broadly similar to that seen amongst
 younger patients. When compared with established drugs citalopram may
 have certain advantages in the treatment of elderly patients if the daily
 dosage is adjusted appropriately. Citalopram was, on the evidence
 currently available, well tolerated in chronic use. It appears to be
 relatively safe in overdose when taken alone, and may be esp. useful in
 depressed patients with suicidal thoughts or a history of suicidal
 behavior.
 ST review citalopram antidepressant
 IT Antidepressants
 (tolerability and safety of citalopram in humans)
 IT 59729-33-8, Citalopram
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (tolerability and safety of citalopram in humans)

=>